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ABSTRACT 
 
 
 
 
 
 
 
AIDS is one of the most important pandemics currently taking place on Hearth. Unfor-
tunately the high mutation rate of the virus is preventing immunologist to find an effec-
tive vaccine against its etiological agent: HIV. Therefore new biological targets needs to 
be identified to develop new approaches to prevent and treat HIV infection. 
Antimicrobial peptides are important molecules involved in natural immune response 
characterized by both antimicrobial and antiviral activity and, given their role as a first 
defense barrier against pathogens, probably play a relevant function in HIV-1 transmis-
sion and infection. They probably interact on infection site to give a first defense barrier 
against virus ingression. Many studies reported anti-HIV-1 effects of different antimi-
crobial peptides; nonetheless none of those studies took into account the fact that differ-
ent classes of antimicrobial peptides, being contemporarily present at the site of infec-
tion, are likely to cooperate synergistically. 
 
In our work we were able to investigate the role of single nucleotide polymorphisms 
(SNPs) in a number of genes related to the innate immunity on HIV-1 infection and ver-
tical transmission in a group of Brazilian children coming from impoverished areas of 
Recife and its surroundings. 
The groups we studied were: healthy controls of same ethnic origin of the patients (eth-
nic origin has been verified by D-loop mitochondrial DNA sequencing), infected patient 
born from HIV-1 infected mothers and exposed uninfected children that were born from 
HIV-1 positive mothers but didn’t contract the infection. In no case mothers underwent 
caesarian section or antiretroviral therapy before delivery to reduce infection risk. 
We were able to demonstrate that two SNPs in the 5’UTR of the DEFB1 gene, namely -
20(G/A) and -52(G/A), are able to influence susceptibility to HIV-1 infection. 
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Furthermore we evidenced, with in vitro studies that these two SNPs together with a 
third SNP located in the same region -44(C/G), do possess a functional activity on gene 
transcription. 
We were also able to show that one of two studied SNPs in the LTF gene, encoding for 
lactoferrin, is strongly correlated with protection from HIV-1 infection. The SNP: R29K 
does confer a stronger antimicrobial activity to lactoferrin and it also modifies the pep-
tide sequence of the N-terminal antimicrobial portion of lactoferrin: lactoferricin. 
Studies on the sequence of the hCAP18 gene, coding for the only known human 
cathelicidin, LL37, lacked of significant results. We failed to evidence the presence of 
any coding non-synonymous polymorphism in the studied patients. We, however, were 
able to identify some novel mutations that, unfortunately, are too rare to possess any 
statistical significance in our study. 
 
The defensin locus 8p23 is known to be subjected to high recombination rate. As a 
consequence many of the defensin genes are present in the human genome in a variable 
number of copies that could influence protein expression. 
We therefore employed the MLPA technique to study the influence of copy-number 
polymorphism of the following genes: DEFA4, DEFA5, DEFA6, DEFB1, DEFB4, 
DEFB107B, DEFB108, DEFA3, DEFA7, DEFB4, DEFB103A, DEFB104, DEFB105, 
DEFB106, and DEFB107B. 
We were able to find that low copy-number polymorphisms of the DEFB104 gene sig-
nificantly increase susceptibility to HIV-1 transmission. 
Functional studies showed that mRNA expression is linearly dependant on the number 
of present copies of the DEFB104 gene. 
There was no correlation between the other studied genes and HIV-1 infection or verti-
cal transmission. 
 
Moreover, to strengthen our study, we performed further analysis on other innate im-
munity genes, other than defensins, namely MBL2 and it’s associated serine protease 
(MASP2). 
We were able to evidence how MBL2 haplotypes characterized by high MBL produc-
tion are protective towards HIV-1 infection. The studied SNPs were 52 Arg-Cys, 54 
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Glu-Asp and 57 Glu-Gly in the first exon of MBL2 and -550(G/C) and -221(G/C) in the 
gene promoter. 
We also genotyped our groups for SNPs in the MASP2 gene, that is functionally com-
plementary to MBL. We find no risk genotype or haplotype for the D105G and the 
R99K polymorphisms.  
 
In conclusion we were able to demonstrate that polymorphisms in many innate immu-
nity genes could influence HIV-1 infection and vertical transmission, thereby providing 
a target for designing new strategies to fight HIV-1 spreading. 
It should be noted, however, that no general rule could be inferred from the obtained 
data, as it seems that, at least in the HIV-1 case, the innate immunity could play a dual 
role, as a reduced gene expression sometimes inhibit HIV-1 activity and sometimes 
promotes it 
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INTRODUCTION 
 
 
 
 
 
 
 
 
The AIDS pandemic 
Promising developments have been seen in recent years in global efforts to address the 
AIDS (acquired immunodeficiency syndrome) spreading, including increased access to 
effective treatment and prevention programs.  
However, the number of people living with HIV-1, the etiologic agent of AIDS, contin-
ues to grow, as does the number of deaths due to AIDS. 
According to the World Health Organization, about 40 million people were living with 
HIV-1 in 2006, meaning that, if we accept the estimate of 6.6 billions of people in the 
world, almost one every 160 people in the world is infected with the HIV-1 virus. 
Reporting UNAIDS (www.unaids.org) data on HIV-1 epidemiology, Sub-Saharan Af-
rica continues to bear the brunt of the global epidemic, with two thirds (63%) of all 
adults and children with HIV, globally living in sub-Saharan Africa, with its epicenter 
in southern Africa. One third (32%) of all people with HIV-1 live in southern Africa 
and 34% of all deaths due to AIDS in 2006 occurred there.  
Declines in national HIV-1 prevalence are being observed in some sub-Saharan African 
countries, but such trends are currently neither strong nor widespread enough to reduce 
the epidemics’ overall impact in the cited regions. Almost three quarters (72%) of all 
adult and child deaths due to AIDS in 2006 occurred in sub- Saharan Africa. Overall 
sub-Saharan Africa is home to an estimated 25 million adults and children infected by 
HIV-1. In the past two years, the number of people living with HIV-1 increased in 
every region of the world. The most striking increment did occur in East Asia, Eastern 
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Europe and Central Asia, where the number of people living with HIV-1 in 2006 was 
over one fifth (21%) higher than in 2004.  
 
The 270000 adults and children newly infected with HIV-1 in Eastern Europe and Cen-
tral Asia in 2006 showed an increase of almost 70% over the 160000 people who were 
estimated to have acquired HIV-1 in 2004. In South and South-East Asia, the number of 
new HIV-1 infections rose by 15% in 2004–2006, while in the Middle East and North 
Africa it grew by 12%. In Latin America, the Caribbean and North America, new infec-
tions in 2006 remained roughly the same as in 2004.  
 
 
 
Figure 1 Number of adults and children estimated to be living with AIDS in 2006 
according to UNAIDS/World Health Organization 
 
The 270000 adults and children newly infected with HIV-1 in Eastern Europe and Cen-
tral Asia in 2006 showed an increase of almost 70% over the 160000 people who ac-
quired HIV-1 in 2004. In South and South-East Asia, the number of new HIV-1 infec-
tions rose by 15% in 2004–2006, while in the Middle East and North Africa it grew by 
12%. In Latin America, the Caribbean and North America, new infections in 2006 re-
mained roughly the same as in 2004.  
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Access to treatment and care has greatly increased in recent years, albeit from a very 
low starting level in many countries. Through the expanded provision of antiretroviral 
treatment, an estimated two million life years were gained since 2002 in low- and mid-
dle-income countries. In sub-Saharan Africa alone, some 790000 life-years have been 
gained, the vast majority of which in the past two years of antiretroviral treatment scale-
up. In Latin America, where wide-scale treatment provision began earlier, some 834000 
life-years have been gained since 2002. Unfortunately, while the benefits of increased 
diffusion of cares are clear, accession to healthcare is still difficult in many regions of 
the world. 
 
 
Figure 2 estimated number of adults and children newly infected with HIV during 
2006 (according to UNAIDS/ World Health Organization data) 
 
Moreover, a complication that's still present in underdeveloped countries, and in which 
we focused our attention in the present study, is vertical transmission of the HIV-1 virus 
from mother to child at the moment of delivery. 
The use of highly active antiretroviral therapy leads to maximal virological suppression, 
thus minimizing the risk of drug resistance, but it is only available in developed coun-
tries. On the other hand, in developing countries, the use of short-course regimens is 
becoming more widespread.  
HIV-1 infected women do present higher risk for complications during pregnancy, in-
cluding ectopic pregnancy, early abortions, bacterial pneumonia, urinary tract infection, 
  
15 
oral and recurrent vaginal thrush, malaria, and tuberculosis. Regional anesthesia is often 
the treatment of choice when administering anesthesia in an HIV-infected pregnant 
woman. Infected children present decreased survival rates, while uninfected children 
born to infected mothers present a higher incidence of poor weight gain, short stature, 
and wasting than would be expected for the general population (Rigopoulos et al., 
2007). 
 
As said before, those problems have virtually disappeared in modern countries because 
of the strict control on pregnant women, the use of antiretroviral drugs that keep the vi-
ral charge low, and, perhaps most importantly, because of the routine practice of caesar-
ian section when managing HIV-1 positive mothers. 
In fact, HIV-1 is not normally able to diffuse across undamaged placental membrane 
and infection can only happens if the newborn is exposed to his mother's infected blood: 
an occurrence that's much more likely to take place during natural delivery. Moreover 
HIV-1 transmission can occur via breast-feeding. 
Unfortunately, in poor areas it's not easy to follow HIV-infected pregnant as they often 
arrive at the hospital to receive medical treatment only after the delivery took place and 
they seldom did receive some medical advice on their disease before. 
This is the case, in particular, for mothers coming from the poorest quarters of Brazilian 
cities, the so-called favelas, from which the groups we studied came from. 
Notwithstanding the fact that cures are becoming more and more widespread the great 
problem of the AIDS pandemic is long from being solved. 
Actually, despite more than 20 years passed from the identification of HIV-1 as the 
etiologic agent of AIDS, no great results have been achieved so far in the research of a 
reliable vaccine. In fact, as the knowledge on the virus is progressing, vaccinologists 
have learned that the biological properties of the virus hamper themselves the discovery 
of an effective vaccine; therefore new targets are urgently needed to control HIV-1 
spreading in human populations and AIDS morbidity and mortality over the world.  
 
New antiretroviral therapies are now available that allow to treat AIDS almost as a 
chronic disease, and lifespan of HIV-1 positive people has considerably extended in the 
last 10 years. 
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Unfortunately those therapies are mostly limited to patients living in developed coun-
tries, leaving the areas of the planet with the highest risk without a reliable and afford-
able treatment. New approaches, using autologous dendritic cells (Lu et al., 2004) did 
show some interesting results, but still have the drawbacks of the difficulty of the proto-
col and the need of a patient-tailored treatment. 
 
Clearly the actual array of molecular targets toward HIV-1 has revealed to be insuffi-
cient to effectively fight the virus, and new targets are needed. 
One of the routes that researchers worldwide took to discover new targets has been to 
study the genetic susceptibility to HIV-1 infection and progression, in order to pinpoint 
genes that can modulate the steps of viral infection and replication. In this way we are 
trying to explain the inter-personal variability to be infected by the HIV-1 virus. 
In fact, the clinical consequences of viral exposure are variable. Some individuals can 
be repeatedly exposed to the virus but remain free from infection. Others can be in-
fected but remain free from clinical disease.  
 
Susceptibility to HIV-1 is a complex phenomenon that result from the interaction of en-
vironmental factors and the host's genetic background; however, differences between 
individuals in disease-free survival and resistance to infection have mostly been attrib-
uted to viral variability rather than to genetic difference (Deacon et al., 1995). 
 
Genetic factors involved in HIV-1 susceptibility 
Two main families of host's genes, namely major histocompatibility complex (MHC) 
(Pareja et al., 1997) and chemokine receptors (Murphy, 1996), were demonstrated to 
control HIV-1 transmission, thus limiting the spread of the epidemic. 
Many different groups showed that a number of chemokine receptors also act as HIV-1 
coreceptors and are therefore required for HIV-1 entry in cells (Alkhatib et al., 1996; 
Deng et al., 1996; Dragic et al., 1996). Among these receptors, the most important is 
likely CCR5: a highly polymorphic gene, with several structural variants specific for 
different ethnic groups. Among these variants, the mutant CCR5 !32 allele bears a 32 
base pairs deletion in its coding region, leading to the production of a truncated protein 
that is not expressed on cell surface. This polymorphic variant is quite frequent in Cau-
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casians, where 1% of healthy individuals are homozygous for the variant (Stephens et 
al., 1998). Homozygous carriers of the CCR5 !32 variant display a strong (Samson et 
al., 1996), although incomplete (Theodorou et al., 1997), resistance to HIV-1 infection, 
since the absence of CCR5 from the cell surface impairs the virus’ entrance to the cell.  
 
It has been shown that most of the HIV-resistant individuals bear an A2/A28 human 
leukocyte antigen (HLA)-A and the authors suggested that enhanced presentation of 
HIV-1 peptides by HLA A2/A28 to CD8+ lymphocytes, that eliminate HIV-infected 
cells before the establishment of a productive infection (Kaul et al., 2000), is responsi-
ble for this phenomenon (MacDonald et al., 2000). Furthermore, also HLA concordance 
between mother and fetus has been suggested to influences mother to child transmission 
(MacDonald et al., 1998; Polycarpou et al., 2002). 
Taken together, these data suggest that HLA molecules play a significant role in differ-
ential susceptibility to HIV-1 infection. 
HLA genes have also been studied as candidate genes able to modify host's genetic 
background on disease progression. The rationale for these studies is that HLA genes 
are extremely polymorphic and that the host's HLA genotype is an important factor in 
determining the gravity of other infectious diseases (Hill, 1996). The molecular basis 
for these differences is that each allelic variant of a class I or class II HLA molecule 
presents a restrained and specific repertoire of peptides to CD8+ or CD4+ T lympho-
cytes, which in turn mount a specific response against the pathogen. In other words, an-
tigen-presenting cells can be differently able of present a specific antigenic peptide to T 
lymphocytes, depending on the HLA type exhibit on their surface. Therefore, patients 
carrying HLA variants that more efficiently present peptides critical for the survival of 
the virus also mount a better immune response against the virus. This concept has usu-
ally been accepted by people working on the genetics of infectious disease, but only re-
cently proved, in a study that demonstrated that viral sequences evolve during HIV-1 
infection and that this evolution is under the control of the host's HLA genotype (Moore 
et al., 2002). 
 
HLA class I molecules can be classified in two major categories, depending on the 
presence of isoleucine or threonine (Bw4 subtype) versus asparagine (Bw6 subtype) at 
position 80. Patients with isoleucine at position 80 and bearing also a KIR3DS1 natural 
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killer activator receptor in their genomes progressed less rapidly to clinical AIDS than 
the others. The most plausible explanation for this finding is that patients bearing this 
compound genotype use one more cell-mediated cytotoxic pathway to eliminate HIV-
infected cells. Indeed, HLA isoleucine-80 molecules present on the surface of HIV-
infected cells are recognized by the KIR3DS1 activator receptor, giving thus a positive 
signal for killing by natural killer or natural killer T cells, which usually express this 
receptor on cell surface. (Martin et al., 2002). 
Furthermore, gene variants could directly influence disease-free survival times. Indeed, 
many studies showed that patients heterozygous for CCR5 !32 have a delayed progres-
sion towards clinical AIDS and that they develop a symptomatic primary infection less 
frequently than patients with two functional alleles of CCR5 (Dean et al., 1996; Meyer 
et al., 1997; Zimmerman et al., 1997). 
Moreover, the HIV-1 viral load at early stages of disease is lower in the CCR5 !32 het-
erozygous patients. The protective genetic effect of CCR5 !32 is now openly recog-
nized, as shown by a recent meta-analysis of different seroconverter cohorts assembled 
in different countries (Ioannidis et al., 2001). The same protective effect has been also 
found in pediatric cohorts (Misrahi et al., 1998). 
Comparable data have been obtained for many different variants in the promoter of 
CCR5 that seem to influence progression of HIV-1 disease, probably through modula-
tion of CCR5 mRNA production (Martin et al., 1998; McDermott et al., 1998). 
There is also increased evidence that genetic variations in the promoter of the RANTES 
(regulated upon activation, normal T cell expressed and secreted) gene, one of the 
ligands of CCR5, could also be relevant for both susceptibility and disease progression 
in HIV-1 disease (An et al., 2002; Liu et al., 1999; McDermott et al., 2000). This effect 
is likely due to an effect on RANTES mRNA transcription efficiency that, in turn, can 
modulate RANTES production. Variations in the production of the RANTES protein 
influences the availability of CCR5 free molecules for HIV-1 binding and cell entry, 
since RANTES inhibits CCR5-mediated HIV-1 entry by competitive binding and down-
modulation of CCR5. 
Moreover, the protective effect of CCR5 !32 polymorphism is reported to be SDF-1 
genotype’s restricted (Sei et al., 2001). 
SDF-1 is a molecule that belongs to the chemokine family and shows a great chemotac-
tic activity on T- lymphocytes and macrophages. It presents two isoform (" and #) sub-
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sequently to alternative splicing. And it has been shown to bind the HIV-1 coreceptor 
CXCR4 and block, at least in vitro, HIV-1 infection of T CD4+ cells (Bleul et al., 
1996). 
A polymorphism in the 3’UTR region of the gene coding for SDF-1 has been associated 
to HIV-1 infection and disease progression. (Brambilla et al., 2000; John et al., 2000; 
Mummidi et al., 1998). 
 
Another polymorphic chemokine receptor gene that is also a minor coreceptor for HIV-
1 is CX3CR1, for which three structural variants exist in Caucasians. All three have dif-
ferent binding affinities for the natural ligand of the receptor and patients homozygous 
for the I249M280 variant show a very rapid disease progression towards AIDS (Faure 
et al., 2000). However, the deleterious effect of the I249M280 variant was not found in 
several cohorts analyzed after the initial report (McDermott et al., 2000). 
Of course it is possible that differences between the reports are a consequence of the 
selection process of the patients enrolled in these cohorts. A typical example concerns 
studies of disease-free survival in cohorts enrolling patients with a known date of infec-
tion (or seroconversion). The date of infection is usually defined as the midpoint be-
tween a negative and a positive HIV-1 test; however, the distance allowed between 
these two points to enroll a patient as a seroconverter is variable from one cohort to an-
other (from one to several years), leading an approximation of the infection date and 
disease-free survival with little precision 
Cytokine gene polymorphisms and particularly single nucleotide polymorphisms in the 
promoters of interleukin-4 (IL-4) and IL-10 have also been shown to influence HIV-1 
disease progression in seroconverter cohorts. The molecular basis of this difference is 
thought to be modulation of mRNA production of IL-4 and IL-10, two T helper (Th) 2-
type cytokines with pleiotropic effects on the immune system. However, both studies 
are single-cohort studies and confirmation in other cohorts is necessary to really appre-
ciate the impact of these findings (Nakayama et al., 2000; Shin et al., 2000). 
Interleukin-18 (IL-18) is a very important cytokine in both innate and acquired immuni-
ties and IL-18 production seems to be an integral part of the host’s innate response to 
viral pathogens (Pirhonen et al., 1999; Tanaka-Kataoka et al., 1999). The role of IL-18 
in HIV-1 infection is not totally clarified yet, albeit a more than fourfold increase of 
plasma IL-18 concentration has been found in HIV-1-infected subjects compared to 
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healthy individuals as well as a positive correlation between plasma IL-18 concentration 
and HIV-1 viral load. (Wiercinska-Drapalo et al., 2004) and similar results have been 
obtained by other research groups (Ahmad et al., 2002; Stylianou et al., 2003). A poly-
morphism (C607A) in the promoter region of the IL-18 gene has been correlated to 
HIV-1 infection in a pediatric Brazilian population (Segat et al., 2006). 
 
Gene Genotypes related to disease progression Consistency of the findings 
across different studies 
CCR5 CCR5 !32 heterozygosity delays disease 
progression in children and adults. 
Yes (confirmed by meta-
analysis) 
 Promoter variants influence disease progres-
sion 
Several studies without possi-
bility for cross-validation 
CCR2 CCR2 64I delays disease progression in 
adults 
No 
RANTES Promoter variants influence disease progres-
sion 
Several studies without possi-
bility for cross-validation 
SDF1 Homozygous for SDF1-3A show a delayed 
disease progression 
No 
CX3CR1 Patients homozygous for the I349 M280 
haplotype progress rapidly to AIDS 
No 
HLA Several alleles or allelic groups inluence 
disease progression 
Yes 
 Homozygosity for HLA A,B or C molecules 
influence disease progression 
Single study 
 Combined genotype of the Bw4 supertype 
with KIR haplotype influences disease pro-
gression 
Single study 
IL-4 Promoter variants influence disease progres-
sion 
Single study 
IL-10 Promoter variants influence disease progres-
sion 
Single study 
 MBL Structural variants influence disease pro-
gression 
No 
Table 1 Summary of genes that influence HIV-1 progression to AIDS 
 
Although the presented genes are probably the ones that have the most striking effect on 
HIV-1 infection and progression, there is no doubt that a plethora of other genes do play 
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a role in modulating and modifying host’s susceptibility to infection and therefore are 
good candidate genes to design novel approaches to develop anti-HIV-1 drugs. 
Genetic variability is a very important factor to assess the susceptibility of the newborn 
to be infected at delivery, and we think that polymorphisms in innate immunity gene 
could be significant in modifying liability to be infected by HIV-1. 
 
Innate immunity as source of targets for HIV-1 research 
The human body is permanently exposed to thousands of potentially pathogenic micro-
organisms, including bacteria, viruses and fungi. 
Therefore it's not surprising that the human body developed, during millennia of evolu-
tion, a system to face such a bewildering array of infectious agents and to prevent dam-
ages due to infections. 
The role of the immune system is far from being simple: pathogens could present them-
selves in a great variety of forms. Moreover, microorganisms, due to their short life cy-
cle, evolve much more rapidly than the immune system itself. Lastly, many microorgan-
isms behave like opportunistic pathogens, meaning that they are constantly present on 
the epidermis, mucosae or intestinal tract and only gave problems when the body ho-
meostasis is impaired, while being generally harmless when normal physiology occur. 
Only to name a few of them we can recall Escherichia coli, useful in favoring digestion 
and potentially lethal if enters the blood stream, Staphyilococcus aureus, which often 
infects the relatively vulnerable hair follicle and glands, or Candida albicans, a normal 
component of the vaginal flora that causes candidiasis. 
 
Many immunology textbooks classify the immune system in two distinct classes: the 
innate immunity and the acquired immunity; the first responsible for an early action of 
defense against pathogens and the latter accountable for a subsequent, more precise and 
strong response. 
Advancements in immunology have clearly demonstrated that this classification is be-
coming more and more didactic and it is now generally accepted that innate and ac-
quired immunity share a strong interplay. In addition, innate immunity, whose role has 
been neglected for almost a century, is gaining the importance it deserves in the field of 
immunology. 
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Innate immunity, in fact, forms an efficient first line of defense against infection by mi-
croorganisms, often providing an adequate protection of the body without the need of 
any acquired immune response. The main advantage of the innate immunity when con-
fronted with the acquired immunity is the fact that the proteins and peptides of the for-
mer are generally already presents, formed and available at the site of infection, while 
maturation of the acquired immunity requires a long time. 
 
Proteins belonging to the innate immune system have a great potential for being ideal 
molecular targets to study host’s susceptibility to HIV-1 infection, since they are the 
first part of the immune system to actually get in touch with the virions. Innate immu-
nity proteins are expressed in a wide array of tissues and especially on the most vulner-
able areas of the human body, like the oral cavity or the reproductive tract. 
It is then plausible to assume that inter-individual differences in HIV-1 infection and 
AIDS progression are partly explainable with variations in the genetic background of 
innate immunity. 
 
Mannose binding lectin and its related proteases 
The existence of mammalian serum lectins was first predicted in 1975 by Robinson et 
al. (1975), and the human protein was first isolated by Wild et al. (1983) in liver tissues. 
More recently, extra-hepatic transcription of MBL has been reported and this may have 
implications regarding its role in localized host defense (Seyfarth et al., 2006). 
MBL structure has been studied extensively and consists of multimers of an identical 
polypeptide chain of 32 kDa. Each chain comprises four distinct regions encoded by 
different exons of the MBL2 gene. 
Each chain has a C-terminal, calcium-dependent carbohydrate-recognition domain 
(CRD); a short, "-helical, hydrophobic neck region (in the so-called coiled-coil con-
figuration); a collagene-like region and a cysteine-rich N-terminal region. Three poly-
peptide chains form a triple helix within the collagenous region, stabilized by hydro-
phobic interactions and interchain disulphide bonds within the N-terminal cysteine-rich 
region. In serum, MBL consists of oligomers ranging from dimers to hexamers, and X-
ray crystallographic studies demonstrated that in this form the oligomers show a bou-
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quet-like structure due to an interruption in the collagenous region, giving rise to a 
slight bending of the triple helix structure. 
 
Clustering of the structural subunits provides a flat platform, permitting binding of 
MBL to the arrays of repeating sugar groups on microbial surfaces. Although the bind-
ing affinity of each individual interaction between the carbohydrate-recognition domain 
and the sugar is relatively low at 103 M (Iobst et al., 1994), the formation of higher or-
der oligomers provides a way for MBL to bind to the bacterial sugars with high avidity. 
 
 
 
Figure 3 MBL2 gene structure, MBL polypeptide structure and MBL oligomeric 
structure. Upper panel shows the exon structure of the human MBL2 gene. Exon 0 
(Ex0) is not translated into protein. Middle panel shows the organization of the 
MBL polypeptide. The MBL polypeptide consists of four domains, including an N-
terminal cysteine-rich region cross linking the polypeptides, a collagen-like stalk re-
gion, an -helic neck region and a C-type carbohydrate recognition domain. The 
lower panel illustrates one of the predominant forms of MBL found in serum, which 
consists of four subunits of triple helices of MBL polypeptides 
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MBL is a major pattern-recognition molecule of the innate immune system that primar-
ily recognizes specific sugar groups on the surface of a wide range of bacteria, viruses, 
fungi and protozoa. 
The understanding of MBL function has grown rapidly over the past three decades. It is 
now recognized to have a role in different processes, as complement activation, promo-
tion of complement-independent opsonophagocytosis, modulation of inflammation, 
recognition of altered self-structures and apoptotic cell clearance. 
A role for MBL in host defense was first proposed in 1987 when Ikeda et al. observed 
that the protein was able to trigger the classical pathway of complement (Ikeda et al., 
1987). However, it is now clear that MBL activates a novel third pathway of comple-
ment, often termed the MBL o lectin pathway, in an antibody- and C1-independent way. 
Similar to the C1 complex of the classical pathway, the initiating complexes of the 
lectin pathway comprise separate recognition and enzyme components. The recognition 
components, MBL and serum ficolins, bind directly to sugars or N-acetyl groups on 
pathogenic cells and activate three different enzymes, called MBL-associated serine 
proteases (MASPs-1 to -3), to activate complement (Schwaeble et al., 2002; Turner, 
1996). 
MASPs are homologues of C1r and C1s of the classical pathway. They all have the 
same modular organization consisting of two domains found in complement component 
Clr/Cls, Uegf and bone morphogenic protein 1 (CUB domains), separated by a Ca2+-
binding epidermal growth factor (EGF)-like domain and followed by two complement 
control protein (CCP) modules and a C-terminal serine protease domain (Schwaeble et 
al., 2002) .  
 
MASPs-1 and -3 are encoded by a common gene through alternative splicing and have 
identical N-terminal domains but different linker regions and serine protease domains. 
By screening a liver cDNA library, Stover et al. (Stover et al., 1999) identified a cDNA 
encoding a shorter variant of MASP2, which they termed MAP19 (MBL-associated 
plasma protein of 19 kD) that is an alternatively spliced product of the MASP-2 gene 
(Takahashi et al., 1999). 
 
The deduced 185-amino acid MAP19 protein retains the signal peptide, the N-terminal 
CUB1 domain, and the EGF-like domain of full-length MASP2, but it has a unique C-
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terminal sequence (EQSL) and lacks the serine protease catalytic domain. Northern blot 
analysis revealed higher expression of the 1.0-kb MAP19 transcript than of the 2.6-kb 
transcript encoding the serine protease domain of MASP2. Immunoblot analysis indi-
cated that un-cleaved MASP2 is expressed as a 76-kD protein, while the A chain has a 
molecular mass of 52 kD and the B chain has a mass of 31 kD. Stover et al. (Stover et 
al., 1999) proposed o role for MAP19 in modulating the activation of complement via 
the MBL pathway. 
MASPs normally circulate as zymogens. However, when lectin–MASP complexes bind 
to target epitopes on pathogens, MASP-1 and -2 activate through autolysis at a single 
site within the short linker region between the CCP-2 module and serine protease do-
main. The active protease domain remains attached to the N-terminal fragment through 
a single disulphide bond. MASP-3 is also activated through cleavage of the linker re-
gion. However, the zymogen cannot autoactivate, so is probably activated through the 
action of an unidentified serum (Zundel et al., 2004). 
Currently, only MASP-2 has a clearly defined role in complement activation (Thiel et 
al., 1997). It initially cleaves C4 to produce the peptide anaphylatoxin C4a and the C4b 
fragment, which attaches to the activating surface of the pathogen upon exposure of the 
highly reactive thioester group. C2 then binds to the immobilized C4b molecule and is 
also cleaved by MASP-2 to generate C2b and C2a. C2a remains attached to C4b to be-
come the catalytic component of the C3 convertase, the enzyme that catalyse the next 
step in the reaction pathway (Kerr, 1980). The roles of MASP-1 and MASP- 3 are not  
yet known. MASP-1 cleaves C2 but not C4, so it might enhance complement activation 
triggered by lectin–MASP-2 complexes, but cannot initiate activation itself (Chen and 
Wallis, 2004). No natural substrate for MASP-3 has been identified.  
 
In addition to its role in complement activation, in a study by Kulhman et. al (1989) it’s 
shown how MBL is able to directly interact with cell surface receptors to promote op-
sonophagocytosis. Subsequently, a number of putative MBL-binding receptors have 
been proposed including C1qR/calreticulin (Malhotra et al., 1990), C1qRp (Tenner et 
al., 1995) and CR1 (Klickstein et al., 1997). However, it is still uncertain if MBL is act-
ing as a direct opsonin or is merely enhancing other complement pathways and/or anti-
body-mediated phagocytosis. 
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The role of MBL as a modulator of inflammation appears to be complex and, accord-
ingly, its mechanism of action remains unexplained. One possible explanation is that 
MBL is able to trigger proinflammatory cytokine release from monocytes (Chaka et al., 
1997; Soell et al., 1995).  
 
 
Figure 4 schematic representation of complement activation pathways (Nature Re-
views Immunology) 
 
A role for MBL in the clearance of apoptotic cells was first proposed by Ogden et al. in 
2001 (Ogden et al., 2001). MBL was found to bind directly to apoptotic cells that ex-
pose terminal sugars of cytoskeletal proteins, thereby permitting their recognition and 
directly facilitating their phagocytosis by macrophages. Defects in the clearance of 
apoptotic cells have been implicated in the pathogenesis of certain autoimmune condi-
tions, although the precise role of MBL, if any, remains elusive.  
Changes in cell surface structures during oncogenic transformation appear to promote 
binding of MBL to cancer cells (Hakomori, 2001) where the protein can mediate cyto-
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toxic effects including MBL-dependent cell mediated cytotoxicity (Ma et al., 1999; Na-
kagawa et al., 2003).  
There are two human MBL genes, but only MBL2 encodes for the functional protein, 
while MBL1 is a pseudogene. The functional MBL2 gene is located on chromosome 10 
(q11.2-q21) and comprises four exons.  
 
Exon 1 encodes the signal peptide, a cysteine-rich region and part of the glycine-rich 
collagenous region. Exon 2 encodes the remainder of the collagenous region and exon 3 
encodes an "-helical coiled-coil structure. Finally, exon 4 encodes the carbohydrate-
binding domain. The promoter region of the MBL2 gene contains a number of regula-
tory elements, which affect transcription of the protein. 
 
Polymorphisms in MBL2 gene and MBL deficiencies 
MBL deficiency has been reported and is largely explained by three single point muta-
tions in codons 52, 54 and 57 of exon 1 in the MBL2 gene (Turner, 1996). These muta-
tions are frequently referred to as variants D, B and C, respectively, with A indicating 
wild-type. The B variant mutation occurs in 22–28% of Eurasian populations, whereas 
the C variant mutation is characteristic of sub-Saharan African populations in whom it 
reaches frequencies of 50–60%. The D mutation reaches frequencies of 14% in Euro-
pean populations but can be much lower elsewhere.  
The exon 1 mutations in the MBL2 gene are believed to impair oligomerization and lead 
to a functional deficiency. In the case of the B and C mutations, critical axial glycines of 
the triple collagenous helix are replaced by dicarboxylic acids which would be expected 
to distort the helix (Sumiya et al., 1991) In the case of the D variant, the effect of the 
mutation is to replace an arginine residue by a cysteine (Madsen et al., 1994) and it has 
been claimed by Wallis and Cheng (1999) that the presence of this extra cysteine resi-
due causes the formation of adventitious disulphide bonds, dramatically reducing the 
formation of higher order oligomers.  
In addition to the above structural gene mutations, several polymorphisms have been 
described in the promoter region of the MBL2 gene (Madsen et al., 1995). These are the 
H/L, X/Y and P/Q allele at positions $550, $221 and +4 of the MBL2 gene.  
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These promoter polymorphisms combine to form haplotypes that are in strong linkage 
disequilibrium with the exon 1 mutations, resulting in seven common extended haplo-
types, namely HYPA, LYPA, LYQA, LXPA, HYPD, LYPB and LYQC. Other rare 
haplotypes have also been described (Boldt and Petzl-Erler, 2002).  
 
 
 
Figure 5 MBL2 polymorphisms. Two promoters, promoter 1 and promoter 0 regu-
late the transcription of the human MBL2 gene. Similar to promoter 1 promoter 0 
also includes a TATA box for transcription initiation, and transcription factor bind-
ing DNA sequences. Six DNA polymorphisms in the MBL2 gene are known to be 
associated with variation in quantity and/or function of MBL in serum. Three vari-
ants affect the expression of the MBL2 gene. They are localized in the promoter 1 
(position -550, H/L variant and –221, X/Y variant) and in the 5'-untranslated region 
(position +4, P/Q variant) of the MBL2 gene. Three base substitutions in exon 1 in 
codons 52 (D), 54 (B) and 57 (C) result in amino-acid changes (arginine to cysteine, 
glycine to aspartic acid and glycine to glutamic acid, respectively) and decreased 
level and function of MBL. The normal allele is named A. 
 
The combination of structural gene and promoter polymorphisms results in a dramatic 
variation in MBL concentration in apparently healthy individuals of up to 1000-fold 
(Caucasian: range <20–10,000 ng/ml). In addition, Ezekowitz and colleagues (1988) 
presented evidence that MBL was an acute-phase reactant. The authors found that MBL 
messenger RNA transcripts were barely detectable in normal liver but that induction 
was seen in liver exposed to acute stress. Subsequent studies have shown that MBL lev-
els can increase between 1.5 and threefold during the acute phase, but this response is 
variable between individuals (Thiel et al., 1992). It should also be noted that even dur-
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ing an acute-phase response, individuals heterozygous or homozygous for MBL2 muta-
tions appear unable to achieve the protein levels of those possessing a wild-type geno-
type. Approximately one-third of the Caucasian population possesses genotypes confer-
ring low levels of MBL, with approximately 5% having very low levels. 
 
The high frequency of variant alleles observed in certain populations was initially puz-
zling since it suggests that functional MBL deficiency may as well be advantageous. 
Similarities have been proposed between the MBL genetic system and the role of the 
hemoglobin mutation that leads to sickle cell anemia gene in protection against malaria 
as occurs in carriers of the sickle cell hemoglobin allele (Allison 1954). The argument 
runs as follows: certain intracellular parasites use C3 opsonization and C3 receptors on 
monocytes/macrophages to enter their host. Therefore, any reduction in complement-
activating function of the host may reduce the probability of parasitization. In support of 
this notion is a study on patients with visceral leishmaniosis, which revealed that such 
patients are more likely to have high MBL levels than uninfected controls (Santos et al., 
2001). A small study of Ethiopian patients with lepromatous or borderline lepromatous 
leprosy also found that their MBL levels were significantly higher than those of healthy 
blood donors (Garred et al., 1994). An alternative explanation of the unexpectedly high 
frequency of low MBL phenotype individuals found in many tropical regions is that ex-
cessive complement activation can result in immunopathologically mediated host dam-
age; therefore, any mechanism that reduces complement activation may be beneficial 
(Lipscombe et al., 1992). 
The identification of MBL deficiency as the cause of the so-called common opsonic de-
fect has been followed by a plethora of disease association studies aimed at defining the 
precise role of this protein. A number of the early studies concentrated on paediatric 
populations and MBL was suggested to provide substitute 'antibody-like' activity during 
the 'window of vulnerability' (approximately 6–24 months), when maternal immuno-
globulin G (IgG) antibody levels have waned but the infant's own adaptive immune re-
sponse is still immature (Super et al., 1989). Nevertheless, studies in adults suggested 
that there might be a role for MBL throughout life (Summerfield et al., 1995). Notwith-
standing these reports, the majority of individuals possessing a variant MBL allele ap-
parently suffers no adverse effects and remains essentially healthy. Nevertheless, MBL 
deficiency has been shown to be associated with increased susceptibility to many infec-
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tious diseases such as bacterial diseases in neutropenic patients, meningococcal menin-
gitis, invasive fungal infections, and viral infections (Eisen and Minchinton, 2003; 
Turner, 2003). Several reports suggest that MBL can also modulate the disease severity 
and can be used as a marker to predict the therapeutic efficacy in some disorders, e.g. 
the response to interferon treatment in patients with type C chronic hepatitis (Matsushita 
et al., 1998). Interestingly, it has been shown that individuals with mutations in the 
MBL2 gene are at increased risk of having autoimmune diseases such as systemic lupus 
erythematosus, celiac disease and rheumatoid arthritis (Boniotto et al., 2005; Davies et 
al., 1997; Garred et al., 2000; Huang et al., 2003).  
 
Polymorphisms in MASPs genes and MASP deficiencies 
Inherited MASP-2 deficiency has been described as the result of a mutation causing the 
exchange of aspartic acid with a glycine at position 105, located in the first domain of 
the protein, CUB1, involved in calcium binding. This mutation abolishes MASP-2 bind-
ing to MBL and ficolins, and deprives it of functional activity. The index case suffered 
from recurrent severe infections and autoimmune reactions. The gene frequency of the 
mutation among Caucasians is 3.6% albeit it is not found in Chinese, who present a dif-
ferent mutation also associated with MASP-2 deficiency (Sorensen et al., 2005). 
The same mutation, and more generally MASP dysfunction, is suspected to be a major 
modifier gene in cystic fibrosis (Olesen et al., 2006). 
In their work, Thiel et al (2007) examined human populations for MASP-2 levels, 
MASP-2 function and for the presence of mutations in coding exons of MASP2. The 
MASP-2 levels differed between populations, being lowest in Africans from Zambia 
(median, 196 ng/ml) followed by Hong Kong Chinese (262 ng/ml), Brazilian Amerindi-
ans (290 ng/ml) and Danish Caucasians (416 ng/ml). In the Chinese population, a novel 
four amino-acid tandem duplication was associated with low levels of MASP-2. This 
new SNP was only found in Chinese (gene frequency 0.26%) while D105G was found 
only in Caucasians and Inuits from West-Greenland. The P126L and R99Q were pre-
sent in Africans and Amerindians only, except for R99Q in one Caucasian. MASP-2 
levels were reduced in individuals who presented the V377A mutation. The MASP-2 
present in individuals homozygous for p.377A or p.99Q had a normal enzyme activity 
whereas MASP-2 in individuals homozygous for p.126L was non-functional. 
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To date, no MASP-1/MASP-3 deficiencies are known, however a polymorphism result-
ing in the amino acid substitution of a glycine with a glutamic acid residue in the 
MASP-1/ 3 gene, which may influence the function of the gene product, has recently 
been decribed. (Weiss et al., 2007). 
 
MBL and human immunodeficiency virus 
While numerous viral factors will determine the fate of an individual exposed to HIV, 
there are data to indicate that MBL can influence both susceptibility and severity of 
HIV-1 infection. 
Thanks to its ability to bind to carbohydrate moieties, the likely target for HIV-1 bind-
ing is the gp120 glycoprotein, that is heavily glycosilated. While MBL can be readily 
demonstrated to bind to purified gp120 (Ezekowitz et al., 1989), the capacity of MBL to 
neutralize primary HIV-1 isolates is less convincing. Recent data indicate the MBL can 
opsonize HIV-1 but does not induce neutralization at the levels at which it is normally 
present in serum. However, binding and opsonization of HIV-1 by MBL may alter virus 
trafficking and viral antigen presentation during HIV-1 infection. MBL may influence 
uptake by dendritic cells (DC), which express a cell surface lectin called 'DC-specific 
intracellular adhesion molecule 3-grabbing non-integrin' (DC-SIGN). DC-SIGN has 
been shown to mediate a type of infection called 'trans'-infection, where DC bind HIV-1 
and efficiently transfer the virus to T cells. Preincubation of HIV-1 strains with MBL 
prevents DC-SIGN-mediated trans-infection of T cells and indicates that at least in vi-
tro, MBL may inhibit DC-SIGN-mediated uptake and spread of HIV-1 (Ying et al., 
2004). 
Whatever the mechanism of MBL interactions with HIV, a number of clinical studies 
have suggested that deficiency of MBL is a risk factor for acquiring HIV-1 infection. 
MBL deficiency appears to increase the acquisition of HIV-1 infection by between 
three- and eightfold (Garred et al., 1997; Garred et al., 1997; Nielsen et al., 1995; Pro-
haszka et al., 1997). There is also an increased risk of vertical transmission from in-
fected mothers to their offspring (Boniotto et al., 2000). However, these findings have 
not been replicated in all populations, with some studies failing to demonstrate a role 
for MBL in HIV-1 infection (Malik et al., 2003; McBride et al., 1998; Senaldi et al., 
1995).  
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There is even less clarity with regard to the role of MBL in HIV-1 disease progression. 
Garred et al. (1997) demonstrated that men with MBL variant alleles had a shorter sur-
vival time following the onset of AIDS than did patients with wild-type MBL alleles. 
However, in a well-characterized cohort of homosexual men, variant MBL alleles had 
an insignificant effect on survival following the diagnosis of AIDS (Maas et al., 1998). 
In this latter study, there appeared to be a protective effect of MBL variant alleles, with 
a delay in the development of AIDS from the time of HIV-1 seroconversion. Patients 
with MBL variant alleles had lower CD4 counts at the time of developing AIDS, indi-
cating that MBL deficiency may influence the onset of AIDS for any given CD4 count. 
Furthermore, MBL mutations appeared to protect against the development of Kaposi 
sarcoma (Maas et al., 1998). In another study, Prohaszka et al. (1997) found that MBL 
levels were lower in asymptomatic HIV-positive individuals compared with HIV-
negative controls, whereas in the AIDS patients they were not; patients with high MBL 
levels had significantly lower numbers of CD4 cells. A possible explanation is that en-
hanced proinflammatory cytokine production in advanced HIV-1 disease acts to in-
crease MBL synthesis (Arai et al., 1993), elevating levels in patients with late-stage dis-
ease. Indeed, a recent study has shown in vitro that MBL can enhance proinflammatory 
cytokine production and viral replication (Heggelund et al., 2005). In the light of studies 
indicating a role for MBL in inflammatory modulation, it is tempting to suggest that 
under some circumstances, MBL may act to promote inflammatory cells activation, 
thereby accelerating the rate of CD4+ T-cell depletion. 
Few studies have assessed the impact of MBL in the context of effective antiviral ther-
apy. However, one study has attempted to relate MBL status and HIV-infected long-
term non-progressors (LTNPs) (Hundt et al., 2000). MBL levels were consistent with a 
wild-type genotype in the six LTNPs studied. Amoroso and colleagues had also sug-
gested such an effect in a study showing that children with rapidly progressing disease 
were more likely to have MBL variant alleles (codon 54) than slower progressors 
(Amoroso et al., 1999). 
 
Lactoferrin 
Lactoferrin is an avid iron-binding glycoprotein that (with transferrin and melanoma 
tumor antigen p97) belongs to a family of iron-binding proteins that modulate iron me-
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tabolism, hematopoiesis, and immunologic reactions that are all evolutionary products 
of gene duplication. 
The gene transcript is assembled from 17 exons, like the bovine (bLf) and murine lac-
toferrin (mLf) genes, which are separated by introns ranging in size from about 300 bp 
to 3.3 kb. The total length of the gene is about 24.5 kb,. In situ fluorescence hybridiza-
tion indicated that the human Lactoferrin gene (LTF) was mapped in the region 3p21.3 
(Kim et al., 1998). 
 
 
Figure 6 Localization of LTF gene 
 
Lactoferrin is found on mucosal surfaces, within the specific granules of polymor-
phonuclear leukocytes, and in biological fluids, like milk, seminal fluid and saliva, sug-
gesting a protective role in the innate immune response. 
Milk is by far the most abundant source of lactoferrin with human colostrum, the early 
milk, containing up to 7 g/l (Masson and Heremans, 1971). There is a great variation in 
the concentration of lactoferrin in other human body fluids. The concentration in tears is 
as high as 2 mg/ml whereas that in blood is normally only as high as 1 %g/ml, although 
it can rise to 200 %g/ml during inflammatory processes (Masson and Heremans, 1971). 
Lactoferrin is a monomeric glycoprotein with a molecular mass of about 80 kDa. The 
protein comprises two homologous lobes corresponding to its amino- (residues 1–333) 
and carboxyl- (residues 345–692) terminal halves, connected by a three-turn "-helix at 
residues 334–344. Each lobe is further subdivided into two domains, with a single iron-
binding site situated between the inner faces of the inter-domain cleft. Each iron (Fe3+) 
atom is coordinated to four protein ligands, namely, 2 tyrosines, 1 aspartate, and 1 his-
tidine, and also to a synergistic anion that, in vivo, is normally carbonate.  
The two lobes have 125 amino acids in common (37% homology) and exhibit very 
similar tertiary structures, consistent with the hypothesis that the two lobes arose as a 
product of gene duplication (Metz-Boutigue et al., 1984). 
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Many roles have been proposed for lactoferrin, and although some of these are clearly 
related to its iron-binding properties, for example its ability to provide bacteria with a 
source of iron, others appear to be independent of iron binding. 
The antimicrobial activity of lactoferrin is well established. This activity has been for a 
long time ascribed to the ability of lactoferrin to sequester iron, thus depriving potential 
pathogens of this essential nutrient. However, lactoferrin is now known to possess a 
second type of antimicrobial activity as a result of a direct interaction between the pro-
tein and the bacteria.  
It has been well established that iron is an essential nutrient for the growth of almost all 
bacteria that have developed mechanisms for obtaining iron as they are often exposed to 
iron-limited conditions. In the normal situation, iron in the body is protein-bound, rather 
than “free”, in order to minimize the generation of unwanted free radicals as a result of 
iron-catalyzed cascades. The siderophores produced by bacteria to obtain iron for their 
metabolism frequently have a higher affinity for iron than lactoferrin and therefore can 
acquire iron at the host’s expense. The iron–siderophore complex is then taken up into 
bacteria by siderophore-specific receptors. Since this mechanism for iron intake does 
not require a direct interaction between the bacteria and the host’s iron-binding protein, 
it is not host-specific. 
In recent years it has become apparent that, under iron-restricted conditions, some bac-
teria can express membrane-bound proteins for their host’s iron-containing proteins and 
exploit an iron-uptake mechanism that requires the direct interaction of the protein with 
a specific bacterial receptor. Bacterial species such as Haemophilus influenzae, Actino-
bacillus pleuropneumonie, and Bordetella pertussis are able to use transferrin- and lac-
toferrin-bound iron directly without the involvement of siderophores (Gonzalez et al., 
1990; Herrington and Sparling, 1985).  
The anti-bacterial activity of lactoferrin was initially ascribed to its ability to bind and 
sequester environmental iron, thereby depriving potential pathogens of this essential 
nutrient (Arnold et al., 1977). The ability of lactoferrin to inhibit bacterial growth in vi-
tro was indeed one of the earliest functions described for the protein. The antimicrobial 
activity of lactoferrin was demonstrated against a number of bacteria (Arnold et al., 
1977). Further studies have shown that lactoferrin was bactericidal only when in its 
iron-free state and that iron-saturated lactoferrin has a reduced antimicrobial activity 
(Arnold et al., 1980; Kalmar and Arnold, 1988; Yamauchi et al., 1993). 
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However, Arnold and co-workers demonstrated iron-independent killing by lactoferrin 
in 1982. Previous work in 1981, had shown that lactoferrin was bactericidal for Strepto-
coccus mutans even when exogenous iron was added to the experimental media (Arnold 
et al., 1981) and it has been proposed that this iron-independent lactoferrin killing could 
be a result of a direct interaction of lactoferrin with the bacterial surface (Bortner et al., 
1986). Lactoferrin was shown to interact with lipopolysaccharide (LPS) of the Gram-
negative bacterial membrane of E. coli (Appelmelk et al., 1994), with the release of the 
LPS from the membrane. However, this release was blocked by addition of Ca2+ and 
Mg2+ ions. The presence of Ca2+ ions also inhibited the ability of lactoferrin to in-
crease the susceptibility of E. coli to the antibiotic rifampicin (Ellison et al., 1990).  
Many studies suggested that lactoferrin could bind to the isolated lipid A portion of 
LPS; in fact the addition of lipid A inhibited lactoferrin binding to LPS, as did the addi-
tion of polymyxin B (Appelmelk et al., 1994).  
In a study by Naidu et al. lactoferrin has been demonstrated to interact reversibly with 
E. coli’s membrane porins, even if the porins may be protected from attack by the poly-
saccharide portion of the LPS and thus antibacterial activity may be decreased in vivo 
(Naidu et al., 1993). Binding of lactoferrin to moieties on the bacterial membrane sur-
face such as LPS and its killing effects have been shown to be correlated, with the pep-
tide concentration being crucial for cell death (Naidu et al., 1993). 
Lactoferrin has been shown to modulate the activity of known antibacterial agents such 
as lysozyme and antibiotics, so may work synergistically (Ellison and Giehl, 1991; Elli-
son et al., 1988).  
 
Polymorphisms in the LTF gene 
Because of the biological functions of lactoferrin, polymorphisms in the LTF gene 
could be an important factor in genetic susceptibility to environmental insults and dis-
eases.  
More than 60 SNPs have been identified in the lactoferrin gene, either in the promoter 
region, exons or introns (Teng and Gladwell, 2006). 
Recently a single-nucleotide polymorphism in the lactoferrin gene has been associated 
with susceptibility to diarrhea in North American travelers to Mexico, underlying the 
antimicrobial role of this protein against enteric pathogens (Mohamed et al., 2007). A 
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single-point A/G nucleotide mutation causing a non-conservative threonine/alanine sub-
stitution at position 11 (T11A) of the secreted lactoferrin protein has been associated 
with aggressive periodontitis (Jordan et al., 2005). 
A Lys/Arg polymorphism at position 29 in the N-terminal region of human lactoferrin 
that results from a single nucleotide polymorphism in exon 1 of the human lactoferrin 
gene has been identified. When tested against different bacterial species lactoferrin con-
taining lisine at position 29 exhibited significantly greater bactericidal activity against 
the gram-positive species Streptococcus mutans and Streptococcus mitis than did lac-
toferrin containing arginine. In addition, the lysine-containing lactoferrin stimulated bo-
vine tracheal epithelial cells to synthesize much higher levels of tracheal antimicrobial 
peptide mRNA than did the arginine-containing variant. The lysine and arginine alleles 
show different frequencies among healthy human subjects, and patients with localized 
juvenile periodontitis, suggesting that these two lactoferrin variants are functionally dif-
ferent and that these differences may contribute to the pathogenesis of localized juvenile 
periodontitis (Velliyagounder et al., 2003). 
 
Antiviral activity of lactoferrin 
Besides being characterized by a broad spectrum antimicrobial activity against bacteria 
and fungi, lactoferrin is able to inhibit replication of a wide range of viruses. Most stud-
ies indicate that lactoferrin prevents infection of the host cell, rather than inhibiting vi-
rus replication after the target cell has become infected. Infection of the target cell is 
prevented by direct binding to virus particles for hepatitis C virus (HCV), herpes sim-
plex virus (HSV), polio- and rotavirus. Studies on HCV demonstrated that human lac-
toferrin is able to bind to E1 and E2 envelope proteins in vitro, with interaction with the 
E2 protein also taking place in vivo (Yi et al., 1997).  
Another mechanism by which lactoferrin exert its antiviral activity is binding to host 
cell molecules that the virus uses as a receptor to entry the cell such as heparin sulphate 
proteoglycans (HSPGs). Many viruses tend to dock on HSPGs of target cells; after this 
initial contact, the virus particles roll to their specific viral receptor and subsequently 
enter the host cell, for instance by fusing with the host cell membrane (Laquerre et al., 
1998). Binding of lactoferrin to membrane’s HSPGs at some extents prevents this first 
contact and therefore subsequent infection of the host cell.  
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For some viruses, it was found that Apolactoferrin (that is the iron-depleted form of lac-
toferrin) was more effective than the metal-saturated complexes of lactoferrin in block-
ing infection, although the reason is still unknown. Nevertheless, it is speculated that 
binding to target cell may lead to an increased uptake of metal ions like Zn2+, which has 
been shown to be effective against poliovirus (Esposito and Obljeski, 1976). Another 
reason for the increased activity of apolactoferrin could be that many enzymes, includ-
ing viral enzymes, require metal ions as a co-factor for their function. 
Other researches demonstrated that an indirect antiviral mode of action of lactoferrin 
takes place through the upregulation of the antiviral response of the immune system. 
Administration of lactoferrin to cell cultures in vitro, or animals and healthy volunteers 
led to an upregulation of cell types that play an important role during the early phases of 
viral infection, such as natural killer (NK) cells, monocyte/macrophages and granulo-
cytes (Crouch et al., 1992; Levay and Viljoen, 1995).  
 
Lactoferrin and human immunodeficiency virus 
Lactoferrin has also been reported to be active against HIV-1, (Harmsen et al., 1995) 
while it does not inhibit HIV-2 replication.  
It has been reported that lactoferrin exerts its effect in the early phase of infection, at the 
level of virus adsorption and penetration 
Human lactoferrin contain a cluster of negative charges between residues 210-240. This 
peptide sequence contributes to two beta-sheets, with a net negatively charged loop 
(residues 231-245). This loop is relatively easily accessible and may interact with the 
positively charged domains in the V3 loop of the viral envelope protein gp120. These 
data also confirm that lactoferrin inhibits viral replication at an early stage, probably 
during virus-cell fusion and binding, by binding to the gp120 molecule, thus inhibiting 
subsequent interaction with the CD4 receptor and possibly with the CXCR4 and CCR5 
co-receptors. 
The antiviral activity of lactoferrin in HIV-1 infection has been tested (Berkhout et al., 
2002). Bovine lactoferrin was capable to completely impede the infection spreading at a 
concentration of 10 µM and considerable inhibition of virus replication was observed at 
concentration as low as 0.1 µM. Since it was suggested that lactoferrin, apart from its 
interaction with the V3 loop, could possibly inhibit virus-cell interaction through com-
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petitive binding to the CXCR4 and CCR5 coreceptors, the antiviral activity of lactofer-
rin against HIV-1 variants with different V3 domains and co-receptor usage was tested. 
Bovine lactoferrin was able to inhibit various HIV-1 strains that use the CXCR4 and 
CCR5 co-receptor, confirming the broad activity spectrum of lactoferrin (Moriuchi and 
Moriuchi, 2001). This result suggests that it is possible for lactoferrin to bind to both the 
V3 loop of gp120 and the co-receptor CXCR-4 or CCR5.  
There are also indications that lactoferrin is able to inhibit viral processes within the 
host cell. Lactoferrin was shown to inhibit the reverse transcriptase, protease and inte-
grase enzymes (Ng et al., 2001; Wang et al., 2000,). Interestingly, it was also found that 
lactoferrin resistance coincided with a loss of viral replication capacity or fitness (Berk-
hout et al., 2002). 
In a preliminary study, 6 months' lactoferrin administration (3 g/day, orally) was evalu-
ated in 22 human immunodeficiency virus type 1 (HIV-1) vertically infected children, 
showing how this protein was effective in increasing CD4+ cell count and  useful in ad-
dition to antiretroviral therapy (Zuccotti et al., 2006).  
 
Antimicrobial peptides 
A relevant part of the innate immunity is formed by peptides with direct antimicrobial 
activity, able to directly kill pathogens or impair their activity. Initial reports of plant 
peptides with antibacterial or antifungal properties date from the early 1970s (Fernan-
dez de Caleya et al., 1972). Over the past 30 years, a hundreds of peptide antibiotics and 
antimicrobial peptides from animals and plants have been discovered, therefore requir-
ing databases as http://www.bbcm.univ.trieste.it/~tossi/amsdb.html, to be established 
updated and maintained by professor A. Tossi, and http://aps.unmc.edu/AP/main.html, 
(Wang and Wang, 2004) . 
Most of the progresses that have been done in studying and understanding antimicrobial 
peptides are due to the serious problem of resistance of bacteria and fungi to the com-
monly used antibiotics, a fact that generated a growing interest in the field of peptide 
antibiotics. The effect of this is that there's an increasing awareness that antimicrobial 
peptides or their synthetic analogues could be used to design and product novel thera-
peutic agents (Reddy et al., 2004). 
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Antimicrobial peptides take their name and classification from their principal character-
istic: their antibacterial and antifungal activity. It should however be noted and never 
forgotten that many of these peptides do have a much broader range of biological prop-
erties: some of them, for example, possess antiviral as well as anticancer properties; fur-
thermore, they can influence inflammation, proliferation, wound healing, release of cy-
tokines, homeostasis, chemotaxis and the preservation of a balance between proteases 
and protease inhibitors (Bals, 2000). Those effects have only recently been discovered 
and clearly show how strong could be the interplay between innate and acquired immu-
nity and how relevantly the former can influence the latter in vivo. 
Notably, antimicrobial peptides markedly differ in their biochemical properties (amino 
acid composition, length and secondary structure). However, they all play essential 
roles in non-specific host defenses by preventing or limiting infections by their ability 
to selectively recognize potential pathogens. 
Most peptides exert their antifungal or antibacterial effects by taking advantage of their 
high surface electrostatic charge to destabilize the microbial membrane, leading to cell 
death. This mechanism could also account for antiviral activity versus coated viruses 
like HIV-1, and different works have shown that defensins directly interact with the 
HIV-1 capside (Quinones-Mateu et al., 2003). 
However, many different mechanisms of action are proposed for several peptides, in-
cluding inhibiting synthesis of specific membrane proteins (Axen et al., 1997; Engstrom 
et al., 1984) or stress proteins (Groisman, 1996), arrest of DNA synthesis (Boman et al., 
1993), breakage of single-strand DNA (Bateman et al., 1991), interaction with DNA 
(Park et al., 1998), and production of hydrogen peroxide (Leem et al., 1996). Antimi-
crobial peptides can also act by triggering apoptosis in eukaryotic cells (Velasco et al., 
1997; Yoo et al., 1997) or autolysis in bacterial targets (Chitnis et al., 1993). In many 
cases probably more than one mechanism is employed by antimicrobial peptides to per-
form their task, making the comprehension of this peptides' role even more complex. 
Many works published so far showed that antimicrobial peptides also exhibit a direct 
antiviral activity (Leikina et al., 2005; Oppenheim et al., 2003; Yang et al., 2004). 
While this effect is not easily explainable for uncoated viruses it's quite reasonable that 
antimicrobial peptides could interact with coated viruses' membranes and interfere with 
infection. 
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It has been demonstrated, for example, that the "-defensin retrocyclin 2 (RC2) inhibited 
influenza virus infection by blocking membrane fusion mediated by the viral hemagglu-
tinin. RC2 was effective even after hemagglutinin attained a fusogenic conformation or 
had induced membrane hemifusion. RC2, that is a multivalent lectin, prevented hemag-
glutinin-mediated fusion by erecting a network of crosslinked and immobilized surface 
glycoproteins (Leikina et al., 2005). In the same study it has been shown that this effect 
is not restricted to influenza virus, as RC2 also inhibited fusion mediated by Sindbis vi-
rus and baculovirus. 
Human ß-defensin 3 and MBL were also able to block viral fusion by creating a protec-
tive barricade of immobilized surface proteins. The authors proposed that this general 
mechanism might explain the broad-spectrum antiviral activity of many multivalent 
lectins of the innate immune system. 
Many antimicrobial peptides, in particular, have been demonstrated, beside other, to di-
rectly interact with HIV-1 viral particles (Quinones-Mateu et al., 2003) and interfere 
with the normal viral transmission, either by disgregation of the viral membrane or by 
binding to viruses’ surface thus acting as an obstacle to the mechanism of infection at 
the point that some of them have been demonstrated to inhibit HIV-1 replication in vitro 
(Nakashima et al., 1993). 
Antimicrobial peptides are able to directly bind to the viral membrane, destabilizing it 
and maybe destroying it, eventually generating a naked virion unable to infect CD4+ 
cells. Obviously, in order to take full advantages from antimicrobial peptides ability to 
interfere with HIV-1 the peptides should be able to interact with viral membranes and 
have to be present at the site of infection in such a concentration to inactivate the initial 
viral charge. 
Genetic polymorphisms that are able to mutate the primary sequence of antimicrobial 
peptides can straightly determine the peptide’s affinity to viral membrane, while single 
nucleotide polymorphisms in the promoter can modify peptide’s expression in the infec-
tion site. 
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Defensins 
Defensins represent one of the most important classes of antimicrobial peptides. They 
have a typical length of 30-40 amino acid residues with a molecular weight that falls in 
the 3-4 kD range (Ganz and Lehrer, 1994; Huttner and Bevins, 1999) 
All human defensins are characterized by the presence, in their sequence, of six cysteine 
residues that give them the ability to form three intramolecular disulfide bridges in a 
peculiar pattern (Ganz, 2005; Lehrer, 2004).  According to the distinctive spacing be-
tween their six cysteine residues and their disulfide bond pattern, defensins can be clas-
sified as #- and $- forms  (Huttner and Bevins, 1999) that, regardless of their differ-
ences in secondary structure, share an analogous three-dimensional structure in solution 
(Bauer et al., 2001; Hill et al., 1991; Zimmermann et al., 1995). 
Genomic organization of the defensin locus does present some interesting properties. 
 In fact all "- and most #-defensins genes map in a cluster in 8p23.1, a region that is 
known to be a frequent site of chromosomal rearrangements mediated by two olfactory 
repeat regions (ORRs) 5 cM apart. For example, an inversion polymorphism between 
these two ORRs can be found in normal population (Giglio et al., 2001; Giglio et al., 
2002; Shimokawa et al., 2004; Sugawara et al., 2003). Within this cluster, two different 
defensins gene sub-clusters can be distinguished: one that contains the genes DEFB1, 
DEFA6, DEFA4, DEFA1, DEFT1, DEFA3 and DEFA5; the other one that comprises 
the genes DEFB109p, DEFB108, DEFB4, DEFB103, SPAG11, DEFB104, DEFB106, 
DEFB105, and DEFB107. The latter cluster is also duplicated in reverse complemen-
tary (Taudien et al., 2004) and even a high copy number variation in this locus can oc-
cur, originating an euchromatic variant (EV) (Barber et al., 1998; Hollox et al., 2005; 
O'Malley and Storto, 1999). 
 Moreover, genes of both sub-clusters can vary inter-individually in their copy numbers. 
(Hollox et al., 2003; Mars et al., 1995). 
 
!-defensins 
The human #-defensins that have been discovered so far are 29-35 amino acids long 
and are characterized by a disulfide bridges pattern in which cysteine 1 is bound to cys-
teine 6, cysteine 2 to cysteine 4 and the third disulfide bond links cysteine 3 and 5, re-
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sulting in peptides forming a triple-stranded b-sheet structure with a $-hairpin loop con-
taining cationic charged molecules. 
In humans, six #-defensins (HNP-1 to 6) have been discovered and are either expressed 
in neutrophils or present in the granules of Paneth cells of the small intestine and in the 
epithelial cells of the female urogenital tract (Jones and Bevins, 1993). The finding of 
an abundant defensin mRNA expression in human Paneth cells supports the notion that 
these epithelial cells may play a key role in host defense of the human bowel and 
strengthen the hypothesis that peptide-based host defenses are prevalent at mucosal sur-
faces in mammals. 
HNP-1 to 4 can be found in the azurophilic granules of granulocytes. Half of the azuro-
philic protein content is composed of HNP-1, 2 and 3, whereas HNP-4 is present at 
lower concentrations (Ganz et al., 1990). Expression of HNP-1 to 3 is also detectable in 
B cells and natural killer cells. In neutrophils, the #-defensins play a role in the oxygen-
independent killing of phagocytosed microorganisms.  
The two other #-defensins, HD-5 and 6, are referred to as enteric defensins, and are 
found in the granules of Paneth cells, that provide host defence against microbes in the 
small intestine. 
Paneth cells are functionally similar to neutrophils and secrete a number of antimicro-
bial molecules into the lumen of the crypt when exposed to bacteria or bacterial anti-
gens, thus contributing to the maintenance of the gastrointestinal barrier (Ganz, 2000). 
All the six genes of the #-defensins are found in the same region of chromosome 8 and 
are located in the cluster present in the band 8p23.  
 
Figure 7 Schematic representation of the #-defensin cluster. 
 
The genes DEFA1, from which both HNP-1 and HNP-3 are derived, and DEFA5, en-
coding the HD-5 peptide, present a copy number polymorphism, while the other #-
defensin genes are present in single copy per aploid genome. 
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#-Defensins, which are expressed as prepropeptides with no antimicrobial activity, are 
activated by proteolitic  cleavage that releases the C-terminal part of the peptide, re-
sponsible for the antimicrobial properties of the peptide. In the case of the enteric de-
fensins, a single metalloproteinase is responsible for the release of the active peptide. 
The three-dimensional fold of #-defensins give raise to a highly amphiphilic molecule. 
Therefore, microbicidal and cytotoxic properties of defensins are most likely a conse-
quence of their ability to insert into biological membranes and to generate pores. 
 
"- defensins 
The second class of human defensins are $-defensins, that are larger than #-defensins. 
Although there is little primary sequence homology between #- and $- defensin fami-
lies, their tertiary structures are very similar because of the presence of three disulfide 
bonds. In $-defensins the three disulfide bridges are between residues 1 and 5, 2 and 4, 
and 3 and 6, also resulting in peptides with a triple-stranded $-sheet structure and a $-
hairpin loop containing cationic charged molecules (Lehrer, 2004).  
The first human $-defensin (hBD-1) was isolated from hemofiltrate of patients undergo-
ing dialysis treatment. hBD-1, a short basic peptide of 36 amino acid residues, has been 
found to be expressed in epithelia that are directly exposed to the environment or mi-
crobial flora (e.g. in the lung, mammary gland, salivary gland, kidney, pancreas and 
prostate) (Bensch et al., 1995). 
A second member of the family, hBD-2, was first characterized in psoriatic skin. hBD-2 
is widely expressed in epithelia (lung, gut, urogenital system, pancreas and skin), leuko-
cytes and the bone marrow. In contrast to hBD-1, exposure of epithelial tissue to LPS or 
pro-inflammatory agents (TNF-a or IL-1b) up-regulates the expression of hBD-2 
(Harder et al., 1997).  
Another defensin (hBD-3) was isolated from human lesional psoriatic scales and cloned 
from keratinocytes. While hBD-1 and 2 show microbicidal activity predominantly 
against Gram-negative bacteria, and only low, if any, microbicidal activity against 
Gram-positive bacteria, hBD-3 demonstrated a salt-insensitive broad spectrum of potent 
antimicrobial activity against many potentially pathogenic microbes including multire-
sistant S. aureus and vancomycin-resistant Enterococcus faecium. Ultrastructural analy-
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ses of hBD-3-treated S. aureus revealed signs of cell wall perforation, thus providing 
more evidence about defensins mode of action. 
Investigation of different tissues revealed skin and tonsils to be major hBD-3 mRNA-
expressing tissues. Molecular cloning and biochemical analyses of antimicrobial pep-
tides in cell culture supernatants revealed keratinocytes and airway epithelial cells as 
cellular sources of hBD-3.  Like hBD-2, hBD-3 is also induced by inflammatory stim-
uli, such as Tumor Necrosis Factor-# and contact with bacteria (Harder et al., 2001). 
These first three human $-defensins were discovered through the identification of an-
timicrobial substances in large amounts of biological material. The genes of these three 
$-defensins are located in a single cluster at chromosomal region 8p23.  
 
 
Figure 8 Schematic representation of the #-defensins cluster. 
 
In this gene cluster, three other $-defensin genes were discovered. The predicted pep-
tides conserve the six-cysteine motif identical with hBD-1, and were named hBD-4, 
hBD-5 and hBD-6 (Garcia et al., 2001; Yamaguchi et al., 2002). Yamaguchi et al. 
(2002) showed that hBD-4, hBD-5 and hBD-6 are expressed in the human epididymis; 
hBD-4 was found to be expressed in the testis but this data have not been confirmed. 
The low basal expression of hBD-4 in lung epithelial cells could be upregulated by con-
tact with bacteria or by phorbol 12-myristate 13-acetate (PMA), an activator of protein 
kinase C. However, expression of hBD-4 was not induced by exposure to IL-1a, IL-6, 
IFNc or TNF-a. hBD-4 inhibited the growth of Gram-positive and Gram-negative bacte-
ria and of the yeast, Saccharomyces cerevisiae (Garcia et al., 2001,).  
Yamaguchi et al. (2002) proposed the division of the $-defensins in two groups: the 
epididymis-specific isoforms and the other isoforms. The epididymis-specific isoforms 
include hBD-4, hBD-5, and hBD-6. The other isoforms include hBD-1, hBD-2 and 
hBD-3.  
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Recently, more #-defensin-like genes have been discovered with a computational search 
tool based on hidden Markov models, in combination with the BLAST research imple-
mentation (Schutte and McCray, 2002). Using this strategy 28 new human $-defensin 
genes were discovered in five syntenic chromosomal regions. 
 
 
Figure 9 Schematic representation of the localization of #-defensins genes (indi-
cated in red) on human chromosomes. 
 
Within each syntenic cluster, the gene sequences and organization were similar, sug-
gesting each cluster pair arose from a common ancestor and was retained because of 
conserved functions. Reported preliminary analysis indicates that at least 26 of the pre-
dicted genes are actually transcribed.  
Human $-defensin 118 is one of these recently characterized defensin and appears to be 
an epididymis-specific peptide that has potent antibacterial activity that is dose, time, 
and structure dependent.  
Incubation of Escherichia coli for 60 min with 10 µg/ml DEFB118 reduced bacterial 
survival to 20% of the control, and 25 %g/ml reduced survival to 5% of the control. 
DEFB118 concentrations of 50 and 100 µg/ml further reduced survival to less than 2 
and 1%, respectively. It should be noted that complete reduction of disulfide bonds and 
alkylation of cysteines resulted in the complete loss of antibacterial activity, providing 
strong evidence about the importance of a correct folding disulfide bonds formation on 
defensins physiological effect. DEFB118 has been shown to cause rapid permeabiliza-
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tion of both outer and inner membranes of E. coli and striking morphological alterations 
in the bacterial surfaces visible by scanning electron microscopy consistent with a 
membrane-disruptive mechanism of bacterial killing. In contrast, eukaryotic cell mem-
branes were not permeabilized by DEFB118, as indicated by using a rat erythrocyte 
hemolytic assay. Again, studies on DEFB118 inhibition of macromolecular synthesis 
and membrane permeability in E. coli were consistent with a primary effect at the cell 
membrane level, similarly to the case of other studied defensins. DEFB118 may con-
tribute to epididymal innate immunity and protect the sperm against attack by microor-
ganisms in the male and female reproductive tracts (Yenugu et al., 2004).  
 
Defensins activities 
Besides their direct antimicrobial activity that likely relies on membrane disruption by 
generation of pores, defensins also show additional properties (Kamysz et al., 2003; 
Oppenheim et al., 2003). 
Lichtenstein et al. (1986), for example, examined the activity of defensins against vari-
ous tumor targets. The three human #-defensins, HNP-1, HNP-2, and HNP-3 were able 
to lyse human and murine targets when tested with chromium release and dye exclusion 
assays. Defensin-mediated tumor cell lysis was concentration-dependent, inhibited by 
serum, and dependent on temperature-sensitive events. Lysis was first detected by three 
hours of incubation and it reached a plateau between eight and 14 hours. Moreover, in 
vitro exposure of murine teratocarcinoma cells to HNP 1-3 abrogated their in vivo on-
cogenicity. Nonmalignant target cells were also susceptible to defensin-mediated lysis. 
When tumor cells were incubated with human defensins in combination with hydrogen 
peroxide, synergistic cytotoxicity was detected.  
Defensins are also effective mitogens in vitro when used at the same concentration 
range in which they display effective antimicrobial activity in in vitro experiments. The 
concentrations that induce the mitogenic process are in the same range as those ex-
pected to be present in vivo during the wound healing process (Murphy et al., 1993). 
Charp et al. (1988) tested the three major alpha-defensins, showing that HNP-2 ap-
peared to be more potent than HNP-1 and HNP-3. Kinetic studies indicated that defens-
ins inhibited protein kinase C (PKC) noncompetitively with respect to phosphatidylser-
ine (a phospholipid cofactor), Ca2+ (an activator), ATP (a phosphoryl donor) and his-
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tone H1 (a substrate protein) with Ki values ranging from 1.2 to 1.7 µM. Defensins did 
not inhibit the binding of (3H) phorbol 12,13-dibutyrate to PKC; however they inhibited 
the PKC activity stimulated by 12-O-tetradecanoylphorbol-13-acetate. Defensins had 
little or no effect on myosin light chain kinase (a calmodulin/Ca2+-dependent protein 
kinase) and the holoenzyme or catalytic subunit of cyclic AMP-dependent protein 
kinase, indicating a specificity of action of defensins. The authors concluded that de-
fensins might have profound effects on functions of neutrophils and other mammalian 
cells, in addition to their well-recognized antimicrobial activities. 
Another recognized function of defensins is their monocyte-chemotactic activity, which 
was found predominantly in the defensin-containing fraction of the neutrophil granules 
(Territo et al., 1989). Purified preparations of each of the three human defensins (HNP-
1, HNP-2, HNP-3) were tested showing a significant chemotactic activity of HNP-1 at 
the nanomolar range. HNP-2 was less active, while HNP-3 failed to exhibit chemotactic 
activity. Further analysis of monocyte response to HNP-1 and HNP-2 confirmed that 
their activity was chemotactic rather than chemokinetic. Neutrophils demonstrated a 
low level of response to defensins but this reaction was primarily chemokinetic, sug-
gesting that defensins may play a role in the recruitment of monocytes by neutrophils 
into inflammatory sites, strengthening the relationship between innate and acquired 
immunity. 
Finally, it was shown that HNP-1 could stimulate cytokine and adhesion molecule ex-
pression (Chaly et al., 2000). In fact HNP-1 up-regulated the expression of TNF-# and 
IL-1 $ in monocytes activated with Staphylococcus aureus or PMA, while expression of 
IL-10 mRNA was down-regulated while production of IL-8 was not affected. HNP-1 
alone was unable to induce TNF-# or IL-1 $ expression in resting monocytes. It was 
also demonstrated that HNP-1 could attenuate the inhibitory action of dexamethasone 
on TNF-# production. HNP-1 also caused about 5-fold suppression of VCAM-1 ex-
pression in TNF-#-activated human umbilical vein endothelial cells, while the ICAM-1 
expression was not affected; suggesting that neutrophil defensins have the potential to 
modulate the inflammatory responses through regulation of cytokine production and 
adhesion molecule expression. 
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Antiviral activity of defensins 
Defensins do possess a dual role in antiviral activity: the first aspect of antiviral activity 
involves direct interaction with viral envelopes, probably in a way comparable to their 
antibacterial activity, and the other involves indirect antiviral activity through interac-
tions with possible target cells. These defensin–cell interactions are complex and possi-
bly mediated by interacting with cell-surface glycoproteins and/or interfering with cell-
signalling pathways that are required for viral replication. 
Direct effect on the virion has been shown, for example, for HNP-1, that was originally 
reported to have a direct effect on several enveloped viruses but not on non-enveloped 
viruses (Daher et al., 1986). Among those enveloped viruses tested, HNP-1 has a potent 
direct inhibitory effect on herpes simplex virus-1 (HSV-1) and HSV-2, while his direct 
effect was moderate on vesicular stomatitis virus (VSV) and influenza virus, and much 
smaller on cytomegalovirus (CMV). The shown differential inhibitory effect of HNP-1 
against different enveloped viruses could be due to variability in viral envelopes’ lipid 
composition of different viruses, as the lipid composition of bacterial membranes has 
been shown to influence membrane permeabilization by rabbit neutrophil defensins 
(Hristova et al., 1997).  
The exact mechanism of direct inactivation of the virion by defensins is not totally un-
derstood yet, and current models, including viral membrane disruption or binding to vi-
ral glycoproteins, need to be further investigated. Factors such as serum and salt are 
known to alter the functions of defensins in vitro; therefore, the different antiviral 
mechanisms of defensins might be operative in mucosal surfaces rather than blood, de-
pending on the salt concentration or the presence of serum. This seems to be the case 
with the direct antiviral effect. Serum has been shown to diminish the direct effect of 
defensins on the virion (Chang et al., 2005; Daher et al., 1986).  
High concentrations of defensins are known to cause cytotoxicity in the absence of se-
rum, and this is associated with changes in cell-membrane permeability in a similar way 
to the antibacterial activity of the defensins. This cytotoxicity can be abolished by the 
presence of serum (Okrent et al., 1990; Van Wetering et al., 1997) and defensin-
mediated cytotoxicity might partially account for the antiviral effect (Mackewicz et al., 
2003). In addition, most defensins have potent direct antibacterial activities in condi-
tions of low salt concentration (Lehrer et al., 1993). However, the required conditions 
for optimum activity vary depending on the specific function of defensins. For example, 
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neither a low concentration of salt nor the absence of serum is required for the chemo-
tactic effects of defensins (Chertov et al., 1996; Yang et al., 1999).  
The anti-HIV-1 activity of HNP-1, HNP-2 and HNP-3 has recently been investigated 
(Chang et al., 2003; Mackewicz et al., 2003; Zhang et al., 2002). HNP-1, HNP-2 and 
HNP-3 all have similar activities against HIV-1 primary isolates (Wu et al., 2005), in 
contrast to their differential chemotactic activities on monocytes, which HNP-3 does not 
effect (Territo et al., 1989). HNP-1, HNP-2 and HNP-3 have at least two mechanisms of 
anti-HIV-1 activity. They can inhibit HIV-1 replication by a direct interaction with the 
virus as well by affecting the target cells (Chang et al., 2003; Chang et al., 2005; 
Mackewicz et al., 2003). In the absence of serum, HNP-1 can directly inactivate the vi-
rus before it infects a cell (Chang et al., 2005). In the presence of serum and at non-
cytotoxic concentrations (low dose), HNP-1 acts on infected cells and blocks HIV-1 in-
fection at the steps of nuclear import and transcription. Furthermore, in primary CD4+ 
T cells, HNP-1 interference with PKC signalling is associated with the ability of HNP-1 
to inhibit infection after HIV-1 enters the cell, although other signalling pathways might 
also be involved (Chang et al., 2005). For example, in macrophages, HNP-1 and HNP-2 
upregulate the expression of CC-chemokines, which could contribute to inhibition of 
HIV-1 through competition for receptors (Guo et al., 2004). CC-chemokines can also 
induce the release of HNPs from neutrophils by degranulation (Jan et al., 2006). Both 
effects could have a role in vivo in an innate immune response to HIV. At the mucosal 
surface, HNPs might work to directly inactivate the virions in the absence of serum; 
however, in the presence of serum, their inhibitory effect would largely be on the in-
fected cell. HNPs are positively charged, so direct binding to HIV-1 virions through 
charge interactions might account for some of their direct inhibition of HIV-1 virions, 
as well as for their sensitivity to serum through competing inter- actions with serum 
proteins. HNP-1, HNP-2 and HNP-3 have been reported to function as lectins, by bind-
ing to the HIV-1 envelope glycoprotein gp120 and CD4 with high affinity, although 
their interference with the interaction between HIV-1 gp120 and CD4 has not been well 
defined (Wang et al., 2004). HNP binding to gp120 is strongly attenuated by serum, 
therefore accounting for the loss of the direct effect on the virion in the presence of se-
rum. Interestingly, in contrast to HNP-1, HNP-2 and HNP-3, HNP-4 acts in a lectin- 
independent manner and does not bind to CD4 or HIV-1 gp120 (Wang et al., 2004; Wu 
et al., 2005). However, HNP-4 inhibits HIV-1 replication more effectively than HNP-1, 
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HNP-2 and HNP-3 (Wu et al., 2005), although it is not clear whether the antiviral activ-
ity of HNP-4 is mediated through a direct effect on virions or on the infected cells. 
Other #-defensins, including HD5, mouse cryptdin-3 and cryptdin-4, and rhesus ma-
caque myeloid have been tested for their ability to block HIV-1 infection (Tanabe et al., 
2004). At the high concentrations associated with cytotoxicity, RMAD4 blocks HIV-1 
replication, whereas cryptdin-3 enhances viral replication. The other peptides tested do 
not have anti-HIV-1 activity in the assay systems reported. The mechanism of enhanced 
HIV-1 replication by cryptdin-3 and the effect of these peptides on HIV-1 replication 
following viral entry are not clear. Because experiments carried out with these defensins 
used a transformed cell line, alternative assay systems including primary cells will help 
to better define the anti-HIV-1 activity of these defensins. For example, HNP-1 causes 
post-entry inhibition of HIV-1 in primary CD4+ T cells and macrophages but not in 
several transformed T-cell lines (Chang et al., 2003; Chang et al., 2005). The anti-HIV-
1 activities of HBD2 and HBD3 have been shown under different conditions (Quinones-
Mateu et al., 2003; Sun et al., 2005). One condition used mimics the oral mucosal envi-
ron- ment, with low salt concentrations and the absence of serum (Quinones-Mateu et 
al., 2003), and another condition used has high salt concentrations and the presence of 
serum (Sun et al., 2005). Similar to HNP-1 (Chang et al., 2005), HBD2 and HBD3 have 
dual anti- HIV-1 activities through direct interactions with the virus and indirectly by 
altering the target cell. HBD2 and HBD3 have been shown, by electron microscopy, to 
interact with cellular membranes as well as HIV-1 virions, although membrane disrup-
tion is not apparent. HBD2 does not affect cell–cell fusion but instead inhibits the for-
mation of early reverse-transcribed HIV-1 DNA products (Sun et al., 2005). There are 
conflicting reports on the downregulation of expression of HIV-1 co-receptors by 
HBD1 and HBD2 did not modulate cell-surface HIV-1 co-receptor expression by pri-
mary CD4+ T cells. By contrast, Quinones-Mateu et al. (Quinones-Mateu et al., 2003) 
showed HBD2- and HBD3-mediated downregulation of surface CXCR4 but not CCR5 
expression by peripheral-blood mono- nuclear cells (PBMCs) at high salt conditions 
and in the absence of serum. These conflicting reports might be due to differences in the 
source of the defensin and/or experimental conditions used (that is, the presence or ab-
sence of serum). Interestingly, HBD2 is constitutively expressed in healthy adult oral 
mucosa but the level seems to be diminished in HIV-infected individuals (Sun et al., 
2005). 
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In response to viral infection, target cells can produce cytokines, chemokines and other 
antiviral factors to control viral replication. In a similar way to the cytokine induction 
that occurs as an early innate immune response to viral infection, HIV-1 induces mRNA 
expression of HBD2 and HBD3, but not HBD1, in normal human oral epithelial cells, 
even in the absence of HIV-1 replication (Quinones-Mateu et al., 2003). These cells 
lack cell-surface expression of the HIV-1 entry receptors CD4, CC-chemokine receptor 
5 (CCR5) and CXC-chemokine receptor 4 (CXCR4), or galactosylceramide, so it is un-
clear what inter actions between the virus and the cell are responsible for this induction 
of expression.  
Defensins could also act as chemotactic agents for T cells, monocytes and immature 
dendritic cells, and can induce cytokine production by monocytes and epithelial cells 
(Yang et al., 2004). Therefore, defensins might control viral replication by modulating 
the immune system, in addition to acting as direct effectors. Increasing evidence indi-
cates that some activities of defensins are receptor mediated, resulting in activation of 
downstream signaling events. For example, the chemotatic activity of HBD1, HBD2 
and HBD3 for memory T cells and immature dendritic cells is mediated through bind-
ing to CCR6, which is the receptor for CC-chemokine ligand 20 (CCL20; also known as 
MIP3) (Yang et al., 1999; Zlotnik and Yoshie, 2000). In addition, HBD2 has multiple 
activities on mast cells, including induction of mast-cell migration, degranulation and 
prostaglandin D2 production. These activities can be blocked by pertussis toxin and by 
phospholipase C inhibitor, indicating that Gi-protein-coupled receptors and phospholi-
pase C signaling pathways are involved (Niyonsaba et al., 2003).  
Murine $-defensin 2 can recruit bone-marrow-derived immature DCs through CCR6 
and can induce DC maturation through TLR4 (Biragyn et al., 2002). Although the spe-
cific receptors responsible for the chemotactic activity of HNP-1, HNP-2 and HNP-3 
have not been identified, their chemotactic activity can also be blocked by pertussis 
toxin, indicating the involvement of a G-protein-coupled receptor (Chertov et al., 1996; 
Yang et al., 2000). Several studies have implicated a role for specific receptors in other 
biological functions of HNPs (Higazi et al., 1996; Higazi et al., 2000; Kougias et al., 
2005; Singh et al., 1988). For example, HNPs bind to low-density-lipoprotein-receptor-
related proteins and interact with protein kinase C leading to decreased smooth-muscle 
contraction in response to phenylephrine (Nassar et al., 2002). HNPs also interact with 
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adrenocorticotropic hormone receptors and heparan sulphate proteoglycans (HSPGs) to 
modulate other bio- logical activities (Higazi et al., 1996; Higazi et al., 2000). HNP-1 
has been shown to inhibit the activity of conventional PKC isoforms in a cell-free sys-
tem (Charp et al., 1988). This PKC inhibitory activity seems to be important for the 
HNP-1-mediated inhibition of HIV-1 replication in primary CD4+ T cells (Chang et al., 
2005). Taken together, these studies indicate that several biological functions involved 
human receptors with subsequent regulation of cell-signaling pathways. However, the 
role of these receptor interactions and signaling pathways in defensin-mediated antiviral 
activities remains to be determined.  
 
Polymorphisms in defensins genes 
Polymorphisms of human defensin genes clearly influence susceptibility to viral infec-
tion and disease progression, as has been shown for HIV-1 infection (Gonzalez et al., 
2005; Gonzalez et al., 2002; Hogan and Hammer, 2001; Kaslow et al., 2005). The hu-
man #-defensins genes DEFA1 (encoding HNP-1) and DEFA3 (encoding HNP-3) have 
polymorphisms in both copy number and the location of 19-kilobase (kb) tandem re-
peats on chromosome 8p23.1 (Aldred et al., 2005; Mars et al., 1995). Gene expression 
of HNP-1 and HNP-3 at the RNA level in leukocytes correlates with the number of cop-
ies of the corresponding gene (Mars et al., 1995). Similarly, DEFB4 (encoding HBD2), 
DEFB103 (encoding HBD3) and DEFB104 (encoding HBD4), is polymorphic in copy 
number, with a repeat size of at least 240 kb (Hollox et al., 2003). The DEFB104 copy 
number correlates with the level of transcription. Although correlation between the pro-
tein levels of defensins and their gene-copy numbers has not been reported, it is tempt-
ing to speculate that variable expression levels of these defensins could lead to differen-
tial susceptibility to infection with or progression of infectious diseases. Polymorphisms 
in the DEFB1 gene (encoding HBD1) have been associated with susceptibility to dis-
eases, including chronic obstructive pulmonary disease (COPD) and asthma, and are 
associated with the severity of cystic-fibrosis-associated pulmonary disease (Dork and 
Stuhrmann, 1998; Levy et al., 2005; Matsushita et al., 2002; Salvatore et al., 2002; 
Vankeerberghen et al., 2005). Although viral infections are one of the main triggers of 
exacerbations of obstructive airway diseases such as asthma and COPD (Message and 
Johnston, 2004), the association of polymorphisms in DEFB1 with susceptibility to vi-
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ral respiratory infections is not known. Interestingly, a single-nucleotide polymorphism 
in the 5 reported to be associated with perinatal transmission of HIV-1 in a cohort of 
Italian children (Braida et al., 2004). However, the significance of this mutation in the 
control of HIV-1 infection remains to be explored. 
 
Cathelicidins: LL37 
Cathelicidins are a family of antimicrobial peptides derived from proteolitic cleavage of 
bigger polypeptides, that contain a very well conserved signal sequence and a pro-
region that is highly homologus to cathelin, a cathepsin L inhibitor. On the other hand, 
the cathelicidin C-terminal domain shows substantial heterogeneity (Hancock and Dia-
mond, 2000).  
So far only one cathelicidin has been characterized in humans: LL37. This peptide is 
derived by proteolysis from the C-terminal end of the CAP18 protein (hCAP18)  
Larrick et al. (1996) cloned the human CAP18 gene from a human genomic phage li-
brary. Sequence analysis revealed that, like several other genes expressed late in poly-
morphonuclear leukocyte development, the hCAP18 gene does not contain typical 
TATA box or CCAAT sequences. The gene is located on chromosome band 3p21.3, it 
is 1963 base pairs long, and consist in 4 exons: exons 1-3 encode for a signal sequence 
and the cathelin region while exon 4 contains the information for the mature antibacte-
rial peptide. Potential binding sites for acute-phase-response factors were identified in 
the promoter and in intron 2. It is mainly expressed in leukocytes such as neutrophils, 
monocytes, NK cells, T cells and B cells, and in epithelial cells of the testis, skin, and 
the gastrointestinal and respiratory tracts (Agerberth et al., 2000; Bals et al., 1998; Cow-
land et al., 1995; Frohm et al., 1997).  
 
 
Figure 10 Localization of the LL37 gene. 
 
LL37 is induced by inflammatory or infectious stimuli (Frohm et al., 1997) and has 
been shown to have antimicrobial activity against both Gram-positive and Gram-
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negative bacteria (Turner et al., 1998). Besides its antimicrobial activity, the peptide 
binds and neutralizes LPS and protects against endotoxic shock in a murine model of 
septicemia (Bals et al., 1999). Furthermore, it is chemotactic for neutrophils, mono-
cytes, mast cells and T cells, induces degranulation of mast cells, alters transcriptional 
responses in macrophages, stimulates wound vascularization and re-epithelialization of 
healing skin (Zanetti, 2004), and has antitumor activity (Okumura et al., 2004). The 
LL37 peptide is 37 amino acid residues long, and, contrarily to defensins, has a linear 
structure because it does not contain any cysteine residue that permits the formation of 
disulfide bonds. The peptide adopts a largely random coil conformation in a hydrophilic 
environment, and an "-helical structure in a hydrophobic environment (Turner et al., 
1998). That accounts for the antimicrobial effect of LL37; in fact the amphipathic " -
helical conformation is adopted when LL37 interacts with biological membranes. Be-
sides, LL37 is believed to multimerize, generating channels in the membrane, from 
which endoplasm can easily flow through (Henzler Wildman et al., 2003). LL37 is also 
able to trigger the p38 kinase pathway in monocytes and it's also chemotactic for T cells 
(Bowdish et al., 2004). 
 
Antiviral effects of LL37 
Antiviral activity of LL37 has been evidenced by several studies. LL37, for example, 
shown a direct antiviral activity against orhopox and has been described to inhibit vac-
cinia virus replication in a concentration-independent manner (Howell et al., 2004). 
Vaccinia virus treated with LL37 showed altered morphology, suggesting that LL37 
might have a direct effect on the virion. Importantly, the physiological role of 
cathelicidin has been shown with a strain of mice that were know-out for the murine 
homologue of LL37: CRAMP. These mice have enhanced morbidity or mortality fol-
lowing exposure to vaccinia virus compared with control wild-type mice. 
Notably, LL37, similar to defensins, has chemotactic activity and other activities that 
are mediated through alterations in receptor-mediated cells signaling. Moreover it is ex-
pressed also in testis (Agerberth et al., 1995) and could protect semen from pathogenic 
microorganisms. 
So far no studies have been performed on the relationship between LL37 and HIV-1 
infection and susceptibility in humans but the cathelicidin LL37 has been shown to spe-
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cifically inhibit lentiviral vector infectivity (Steinstraesser et al., 2005). The strongest 
inhibition was seen if the lentiviral vectors were preincubated with LL37, suggesting a 
direct interaction with the vector particles. Since, in the same study, lentiviral vectors 
and retroviral vectors were inhibited to a similar degree even if not sharing any viral 
protein, the authors suggest that the target for LL37 on the particles is probably cell-
derived. This could either be the lipid membrane derived from the cell, which surrounds 
the vector particles or cellular membrane proteins that are frequently incorporated in 
lentiviral and retroviral particles during budding (Gould et al., 2003). LL37 inhibited 
HIV-1 to lesser degree then the lentiviral vectors in vitro, and due an IC50 of 88 %g/ml 
against wild type HIV-1, the authors debated whether LL37 concentrations are suffi-
ciently high at mucosal membranes to play a role in host defense against HIV-1.  In 
their recent work, Bergman et al. (Bergman et al., 2007) have evaluated the capacity of 
LL37 to inhibit HIV-1 infection in vitro. They demonstrated that LL37 inhibits HIV-1 
replication in PBMC, including primary CD4+ T cells. This inhibition was readily re-
produced using various HIV-1 isolates without detectable changes in the target cell ex-
pression of HIV-1 chemokine receptors. Given the epithelial expression of LL37, it may 
contribute to the local protection against HIV-1 infection. 
 
Lactoferricin 
The presence of stable antimicrobial peptides resulting from proteolytic cleavage of lac-
toferrin was demonstrated by experiments that shown that limited acid proteolysis of 
bovine lactoferrin yielded a hydrolysate that had greater antibacterial activity than lac-
toferrin (Saito et al., 1991). 
Bellamy and co-workers described the generation, after pepsin hydrolysis, of fragments 
from human and bovine lactoferrins that showed enhanced antimicrobial activity but 
lacked any iron-binding capacity. The fragments were characterized and named human 
(H) and bovine (B) lactoferricin. Both peptides are derived from the N-terminal region 
of the N-lobe and have greater antibacterial activity than their parent proteins (Bellamy 
et al., 1992; Bellamy et al., 1992). Lactoferricin H corresponds to amino acid residues 
1–47 from the N-terminal region of the lactoferrin protein and includes an 18-residue 
loop formed by an internal disulphide bridge. Residues 1–11 constitute a separate frag-
ment, which remains bound to the main loop by a disulfide bridge. 
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Lactoferricin H is similar to lactoferricin B in that it has a loop region held together by a 
disulphide bridge. It has been suggested that antimicrobial activity was independent of 
the presence of this bridge (Bellamy et al., 1992; Bellamy et al., 1992), but other studies 
pointed toward the importance of the disulfide bridge in antimicrobial activity by con-
ferring rigidity and stability to the peptide as observed with cyclic peptides. Notwith-
standing the fact that the total and net positive charges carried by the lactoferricin H are 
higher than those carried by lactoferricin B, the proportion of basic amino acid residues 
is greater in the bovine peptide. The lower cationicity within the 18-residue loop might 
be at the heart of the difference in antimicrobial activity exhibited by human lactoferrin-
derived peptides. 
To date little is known about the mechanism by which lactoferricins exerts their activ-
ity, even if it has been shown that they causes damage by generating blisters on the 
outer membrane of Gram-negative bacteria (Yamauchi et al., 1993), and that regions 
within lactoferricin bind to the LPS (Elass-Rochard et al., 1995). Interaction between 
LPS and both lactoferricins have been investigated, using a synthetic octadecapeptide 
corresponding to residues 20–37 in lactoferricin H, concluding that the 28–34 loop re-
gion of the peptide were found to be involved in LPS binding (Elass-Rochard et al., 
1995). 
There is no clear evidence of specific receptors linked to the killing mechanism. The 
only direct interaction experiments have been against Candida albicans, which is killed 
by lactoferricin B, where 14C-labelled lactoferricin B bound to C. albicans and the rate 
of binding appeared to be consistent with the rate of killing induced by the peptide. 
Again, as with gram-negative bacteria, cells exhibited profound ultrastructural damage, 
which appeared to reflect the induction of an autolytic response (Bellamy et al., 1993). 
Activity studies against E. coli in the pH range 5.5 and 7.5, showed that the peptide was 
most effective in slightly alkaline conditions, and that bacterial effectiveness was re-
duced in the presence of Na+, K+, Mg2+ or Ca2+ ions. 
The sequence for human lactoferricin forms a surface-exposed "-helix with a hydro-
phobic tail within the native proteins (Odell et al., 1996). However, the peptides may 
adopt a different conformation when released from the parent protein, and/or when in 
contact with their target. The 3D structure of synthetic bovine lactoferricin has been 
solved by NMR spectroscopy and it was shown to adopt an anti-parallel #-sheet in wa-
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ter, with a hydrophobic core surrounded by hydrophilic and charged amino acids 
(Hwang et al., 1998; Schibli et al., 1999).  
Lactoferricins also exhibit moderate antiviral activity, and bovine lactoferricin does 
peresent antiviral activity at 100 µM (Berkhout et al., 1997). However, this peptide 
shows little anti-HIV-1 activity when compared to intact lactoferrin, indicating that 
other parts of the lactoferrin molecule are important. To date there are no studies on the 
relation between human lactoferricin and HIV-1 infection. 
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AIMS OF THE STUDY 
 
 
 
 
 
 
With our study we wanted to clarify the effect that antimicrobial peptides exert, both 
alone or synergistically, in HIV infection and in AIDS progression in humans. At pre-
sent, in fact, no studies have been performed on this subject that, in virtue of its poten-
tial effect on public health, deserves great attention. 
In particular there is a lack of knowledge on the synergistical effect that different types 
of antimicrobial peptides could elicit in the site of infection. 
Since genetic association studies proved to be very effective in identifying polymorphic 
proteins associated to resistance to host pathogens or differential progression of infec-
tion and thus it will be the primary tool used in the research. 
Since recent scientific studies and interesting experiments demonstrated the importance 
of several peptides in preventing HIV infection by blocking virus–host cells interac-
tions, we focusedthis project on the classes of peptides that were already described in 
the first part of this thesis, namely alpha and beta defensins, cathelicidin (LL-37/hCAP-
18) and lactoferrin. 
 
We believe that the results of our work will be beneficial to a better understanding both 
of antimicrobial peptides’ and HIV-1’s physiology and could be a starting point to de-
velop better treatments for AIDS.  
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MATHERIALS AND METHODS 
 
 
 
 
 
 
 
Enrollment of patients 
Two distinct groups of subjects have been enrolled for this study. 
The first DNA bank was collected in 2002 and incuded genomic DNA extracted from 
303 Brazilian newborns, further subdivided in three groups: 128 infected children, 60 
exposed-uninfected children and 115 healthy controls.  
 
Figure 11 First DNA collection (2002) 
 
The infected group consisted of samples of DNA extracted from children born from 
HIV-1 positive mothers and that contracted the infection during delivery. 
The exposed-uninfected group was the most valuable and comprised children that, de-
spite being born from HIV-1 infected mothers, weren’t infected during delivery. 
The healthy controls group was formed by samples extracted from newborns of HIV-1 
negative mothers. 
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All mothers came from the impoverished areas of Recife and were admitted at the gy-
necological service of the IMIP. In no case the HIV-1 positive mothers did underwent 
antiretroviral therapy prior to delivery and parturition was not aided by caesarian sec-
tion in order to prevent mother’s blood contact to the children. 
The aims of the study were explained and written consent was obtained. 
 
Figure 12 Figure 14: Second DNA collection (2006) 
 
In 2006 a new sample collection took place at the IMIP. The new DNA bank counted 
360 DNA samples and, compared to the previous DNA bank, was enriched in HIV-1 
positive children, and, more importantly, in exposed uninfected children. Globally, in 
the new DNA bank we had 96 healthy controls, 192 HIV-1 infected children and 72 ex-
posed-uninfected children. For the collection of the samples we continued to enroll the 
same kind of patients that were admitted at the gynecological service of the IMIP.  
Written informed consent was obtained and the study has been approved by IMIP’s 
ethical committee. 
 
DNA extraction 
Blood samples collected in 2002 were frozen to -20°C after collection in EDTA con-
taining tubes and was extracted with phenol/chloroform procedure as follows. 
Sample was thawed and 0.8 ml of SSC buffer (3M sodium cloride, 0.3M sodium citrate, 
pH 7.0) were added to 1 ml of blood. The sample was then microcentrifuged for 1 min-
ute at 12000 rpm 
  
61 
One ml of the supernatant was then discarded and 1ml of SSC buffer was added before 
another centrifugation for 1 minute at 12000 rpm. Then all the supernatant was dis-
carded and 375µl of a 0.2M solution of sodium acetate was added to the pellet and vor-
texed. 
Then 25µl of 10% SDS and 5µl of proteinase K solution (20mg/ml) were added and the 
mix was incubated for 1 hour at 55°C. 
After the incubation 120 µl of phenol/chlorophorm/isoamyl alcohol were added and the 
sample was vortexed for 30 second and then centrifuged for 2 minutes at 12000 rpm. 
The aqueous supernatant was then put in a new 1.5ml tube and 1 ml of 100% ethanol, 
stored in ice, was added. The mix was then incubated at -20°C for 15 minutes. After a 
centrifugation for 2 minutes at 12000 rpm the supernatant was decanted and drained. 
Then 180µl of 10:1 TE buffer were added and put at 55°C for 10 minutes before adding 
20µl of a 2M sodium acetate solution. Then 500µl of cold 100% ethanol were added 
and centrifuged at maximum speed for one minute. 
The resulting pellet was washed with 1 ml of 80% ethanol and centrifuged again before 
being dried to the air. 
The DNA pellet was resuspended with 100µl of TE buffer overnight. 
The samples collected in 2006 were characterized by a higher quality of the DNA, 
which was extracted with the Wizard Genomic DNA Purification Kit from Promega 
according to manufacturer’s instructions. 
 
Mitochondrial D-loop sequencing 
Direct sequencing of the hypervariable D-loop sequence has been performed on the 
DNA collected in 2006 as previously described (Alves-Silva et al., 2000) in order to 
assess genetic homogeneity among the three different groups. 
PCR amplification of the mtDNA control region (nucleotide position 16060-16362) was 
performed in a 25µl reaction volume using primer forward 5’-
TCAAAGCTTACACCAGTCTTGTAAAAC-3’ and primer reverse 5’-
CTGAAGTAGGAACCAGATG-3’, both at a 0.8µM concentration and 1X PCR Master 
Mix (Applied Biosystems). 
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 Thermal cycler conditions where 10 minutes of preincubation at 95°C, then 30 cycles 
of 95°C for 60 seconds, 55°C for 30 seconds and 72°C for 60 seconds. A final extension 
step was done holding at 72°C for 4 minutes. 
PCR products obtained this way usually contain excess primers and dNTP that are not 
compatible with the direct sequencing procedure. Samples were then digested with the 
two enzymes exonuclease I (Exo), that destroys every single-stranded template or 
primer, and Shrimp Alcaline Phosphatase (Sap), that degrades nucleotides. 
The digestion reaction consisted of 1 unit of Sap (United States Biochemical, Harvard) 
and 5 units of Exo (United States Biochemical, Harvard) in a total volume of 7µl with a 
DNA quantity ranging from 60 to 80ng as estimated by agarose gel electrophoresis. The 
mixture was kept for 15 minutes at 37°C and then the enzymes were inactivated by 15 
minutes at 85°C. 
DNA sequencing of PCR products was performed using the BigDye Terminator Cycle 
Sequencing Ready Reaction Kit 2.0 (Applied Biosystems, Foster City, CA): that briefly 
consist in a labeling reaction of the PCR product with fluorescent nucleotides to allow 
detection of the fragments by the automatic sequencer. 1.88µl of water, 0.8µl of BigDye 
terminator kit and 0.32µl of 10pM primer were added to the digested PCR products and 
the mix were then put in a thermal-cycler with the following thermal profile: 1 minute 
at 96°C followed by 26 cycles composed by10 seconds at 96°C, 5 seconds at 50°C and 
4 minutes at 60°C. 
After a DNA precipitation and purification step, the labeled mixture was then added 
with 20µl of formammide to proceed with automatic sequencing in an ABI 3730XL se-
quencer (Applied Biosystems) with a 36 cm capillary filled with POP-6 polymer. Se-
quences were handled using SeqScape 1.0 Software. 
 
Analysis of polymorphism in the DEFB1 gene 
SNP genotyping 
We analyzed three SNPs located in the 5’UTR of the DEFB1 gene: -52(G/A), -44(C/G) 
and -20(G/A) (NCBI SNPs database id: rs1799946, rs1800972 and rs11362, respec-
tively). 
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The studied SNPs have been firstly described by Dork and Stuhrmann (1998) and 
successively have been associated with increased susceptibility to vertical transmission 
in an Italian cohort by Braida et al. (2004). 
Analysis of the frequencies of the three 5’ UTR polymorphisms have been performed 
with direct sequencing using primers (5’-GAAGTTCACCCTTGACTGTGGC-3’ and 
5’-CATCCGAGACTCACATCAGCC-3’.) designed using the software Primer Express 
2.0 (Applied Biosystems, Foster City, CA) according to the human sequences available 
in GenBank. Reactions took place in a final volume of 25µl and were conducted with 
1X PCR Buffer II (Applied Biosystems), 2 mM MgCl2, 50 %M each dNTPs, 0.2 %M 
forward primer, 0.2µM reverse primers, 0.5 U of AmpliTaq Gold Polymerase (Applied 
Biosystems).  
Thermal-cycler conditions consisted of a pre-cycling period of 10 minutes at 95°C fol-
lowed by 40 cycles of 30 seconds at 95°C, 30 seconds at 57°C and an elongation step at 
72°C for 30 seconds. PCR reaction was terminated by a final elongation step at 72°C 
for 4 minutes. 
PCR products were then processed in the same way as for the mitochondrial D-loop re-
gion sequencing. 
 
Functional characterization of DEFB1 SNPs   
Further analysis involved investigation over the functional effect of the studied poly-
morphisms. 
With the aim of verifying an eventual transcriptional functional effect of the SNPs in 
the 5’UTR region of DEFB1 gene we employed a Dual Luciferase assay. 
Starting from the wild type DEFB1 5’UTR region we generated three mutated inserts 
using primers designed to introduce the desired mutation into the wild type sequence. 
The four different fragments (wild type, -52A, -44G and -20A) have been cloned into 
pGL3 promoter vector (Promega) and Caco2 cells were transfected in 24-well plates 
(Costar, Corning NY) while at 70-80% confluence. Caco2 cells were transfected for 48 
h with 1µg of the reporter plasmids and 20 ng of control renilla luciferase expression 
plasmid (phRG-TK, Promega) using 5µl of GenePORTER transfection reagent (Gene 
Therapy Systems) according to manufacturers instruction. After transfection cells were 
harvested with 100µl of Passive Lysis Buffer (Promega) and firefly luciferase activity 
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from hBD-1-pGL3 reporter vector and Renilla luciferase activity from the control vec-
tor were measured using the Dual Luciferase assay system (Promega) on a TD-20/20 
luminometer (Turner Design, CA). Promoter activity was calculated as the ratio be-
tween firefly and Renilla luciferase activities measured in each sample. 
 
Analysis of polymorphisms in the lactoferrin gene 
In our study we focused our attention on polymorphisms located in the second and 
fourth exon of the LTF gene. This way, with only 2 direct sequences, we were able to 
genotype a total of 7 coding non-synonymous single nucleotide polymorphisms out of 
the 11 reported by the NCBI database, namely rs1126477, rs17855464, rs17855496 and 
rs1126478 (in exon 2) and rs17851346, rs17851991 and rs1126479 (in exon 4). Primers 
used to amplify exon 2 where 5’- AGCAAGATGCCTCCACTTGT-3’ and 5’-
TCTCCCTTCCATTCAGCTTG-3’, while to amplify exon 4 the primers used where  
5’-TCAATTCTGTCTGCCCCTTT-3’ and 5’-CACTATCCCCCAGCCATCT-3’.  
Successively we focused on the two most promising SNPs, namely rs1126477 and 
rs1126478, both located in exon 2 and we developed two allele specific PCRs in order 
to genotype a larger number of subjects with a faster and cheaper technology. 
To genotype rs1126477 polymorphism, also reported in the literature as T11A, we em-
ployed the two allele specific primers 5’-CTCGGGTTGGGATACGGC-3’ and 5’-
CTCGGGTTGGGATACGGT-3’ while using 5’-TTGTGGAGAATGGCTGGACA-3’ 
as a common reverse primer. 
Reactions, in a final volume of 25µl, were conducted with 1X PCR Buffer II (Applied 
Biosystems), 2 mM MgCl2, 50 %M each dNTPs, 0.2 %M of C or T allele-specific and 
reverse primers, 0.5 U of AmpliTaq Gold Polymerase (Applied Biosystems) and 1X 
SYBR Green I (Molecular Probes). Thermal-cycler conditions were as follows: a pre-
cycling period of 10 minutes at 95°C followed by 40 cycles composed by 30 seconds at 
95°C, 30 seconds at 57°C and an elongation step at 72°C for 30 seconds. 
Genotyping of the rs1126478 has been performed by using 5’- CAATGGCAAAG-
GAATATGAGAAA-3’ and 5’- CAATGGCAAAGGAATATGAGAAG-3’ as forward, 
allele-specific primers and 5’-AGCACAGTTCCCTGTGAGAGA-3’ as reverse primer. 
Reactions, similarly to the T11A case, were conducted at 25µl total volume using 1X 
PCR Buffer II (Applied Biosystems), 2 mM MgCl2, 50 %M each dNTPs, 0.2 %M of A or 
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G allele-specific and reverse primers, 0.5 U of AmpliTaq Gold Polymerase (Applied 
Biosystems) and 1X SYBR Green I (Molecular Probes). Thermal-cycling conditions 
were as follows: initial hold at 95°C for 10 minutes followed by 40 cycles at 95°C for 
30 seconds, 58°C for 30 seconds and 72°C for 30 seconds. 
Runs were conducted on an ABI 7900 real-time instrument and genotyping was per-
formed on the evaluating the Ct values of the two allele-specific reactions. 
 
 
Analysis of polymorphism in the MBL2 gene 
Three single nucleotide polymorphisms: 52 Arg-Cys, 54 Glu-Asp and 57 Glu-Gly, 
(rs5030737, rs1800450, and rs1800451, respectively) in the first exon of the MBL2 
gene, encoding for the MBL protein, are linked to decreased protein expression levels 
and correlated with impaired immune response in a number of different diseases (Eisen 
and Minchinton, 2003; Turner and Hamvas, 2000). 
As suggested by Garred et al. (1997) the three variant alleles found in the first exon of 
the MBL2 gene were grouped in the same category of allele 0, since they have a similar 
functional effect on MBL, impeding a correct formation of oligomers, as indicated by 
Larsen et al (2004). 
PCR reactions were performed in a total volume of 25µl containing 1X PCR Buffer II 
(Applied Biosystems, Foster City, CA), 2 mM MgCl2, 50 µM each dNTPs, 0.5 µM of 
forward primer (5'-GGCTTCCCAGGCAAAGATG-3'), 0.5µM of reverse primer (5'-
AGCCCAACACGTACCTGGTT-3'), 1X SYBR green (Molecular Bioprobes, Eugene, 
OR) and 0.5 U of AmpliTaq Gold Polymerase (Applied Biosystems). Thermal-cycling 
conditions were as follows: initial hold at 95°C for 10 minutes  followed by 40 cycles at 
95°C for 15 seconds and 60°C for 1 minute. After the amplification step a melting tem-
perature analysis (MTA) was performed, from 60°C to 95°C in an ABI 7900 instru-
ment. The first derivative of the raw data curves was automatically calculated by the 
instrument's software and the resulting curves were visually analyzed to perform the 
genotyping.   
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Figure 13 a) Example MTA profiles obtained for different genotypes with our tech-
nique 
b) Example curve of a double heterozygous sample with the characteristic two peaks 
 
Genotypes discrimination was performed on the basis of samples’ melting profile, since 
the shape of the resulting curves allowed to discern samples with different genotypes: 
the wild-type genotype gave a peak at 80.4ºC±0.2ºC while the heterozygous samples 
gave a peak that has a maximum at about the same temperature as the wild-type 
(80.0ºC±0.4ºC) but presents a markedly different shape in the left part of the curve that 
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permits to clearly discriminate between samples with different genotypes. The mutated 
samples gave a sharp peak at 79.5ºC±0.3ºC and thus could be distinguished from the 
wild-type samples simply observing the experimental Tm (see figure 13a). 
We also genotyped composite heterozygous samples (successively considered as 0/0 
subject in the statistical analysis and whose experimental MTA curve is reported on fig-
ure 13b) that had one allele mutated at the codon 52 and one allele mutated at the codon 
54. The resultant MTA profile was quite peculiar, with two peaks at 76.1ºC±0.3ºC and 
79.6ºC±0.2ºC; the resulting profile makes the determination of the genotype very easy. 
Moreover we developed two allele-specific PCRs for the two most important promoter 
polymorphisms: G-550C (rs11003125, known as H/L variant) and G-221C (rs7096206, 
known as X/Y variant).  
To genotype the H/L polymorphic variant we used 5’-
TGCTTCCCCTTGGTGTTTTTAC-3’ and 5’-TGCTTCCCCTTGGTGTTTTTAG-3’ as 
the two allele-specific reverse primers and 5’-GCCAGGGCCAACGTAGTAAG-3’ as a 
common forward primer. 
For the X/Y polymorphisms the reverse allele-specific primer used were 5’-
CTGGAAGACTATAAACATGCTTTC-3’ and 5’-
CTGGAAGACTATAAACATGCTTTG-3’, and 5’-CCGAAGAGGACATGGAGAGA-
3’, as a common forward  primer  
Both genotyping reactions took advantage of the same experimental parameters: reac-
tions were performed in a final volume of 12.5µl, were conducted with 1X PCR Buffer 
II (Applied Biosystems), 2 mM MgCl2, 50 %M each dNTPs, 0.2 %M of allele-specific 
and reverse primers, 0.5 U of AmpliTaq Gold Polymerase (Applied Biosystems) and 1X 
SYBR Green I (Molecular Probes). Thermal-cycler conditions were as follows: a pre-
cycling period of 10 minutes at 95°C followed by 40 cycles composed by 30 seconds at 
95°C, 30 seconds at 57°C and an elongation step at 72°C for 30 seconds. 
 
Analysis of polymorphism in the MASP2 gene 
The genotyping of MASP rs12711521 SNP was performed by using TAQman pre-
designed SNPs Genotyping Assays (assay id. C__22271950_20; Applied Biosystems) 
according to manufacturer’s instructions. This assay is based on the allelic discrimina-
tion using VIC and FAM fluorophores for each SNP-specific labeled probe. The PCR 
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was carried out in a final volume of 10 µl, in a 96–well PCR plate and the amplified re-
sults was analyzed at the end point by using the ABI 7900HT Sequence Detection Sys-
tem (Applied Biosystems). 
MASP D105G genotyping was performed by direct sequencing by using primers 
(Primer Reverse 5’-CCCAAGGAGTAGCCAGGGTT-3’ Primer Forward 5’-
TGTGGATGATGTCAGGCCAG-3’) designed using the software Primer Express 2.0 
(Applied Biosystems, Foster City, CA) according to the human sequences available in 
GenBank. 
PCR reactions were carried out in a GeneAmp 9700 Thermal cycler (Applied Biosys-
tems, Foster City, CA) using PCR buffer 1X, 1 unit of Taq Gold, 0.2mM dNTPs and 
MgCl2  2 mM). The cycling was performed with an initial denaturation for 10 minutes 
at 95°C, followed by 40 cycles at 95°C for 20 seconds, at the annealing temperature of 
55°C for 30 seconds and 72°C for 30 seconds with a final extension to 72°C for 7 min-
utes.  
DNA sequencing of PCR products was performed using the BigDye Terminator as pre-
viously described. 
 
Analysis of the sequence of the LL37 gene 
Since no coding non-synonymous polymorphisms are described in the NCBI database 
so far we analyzed the entire gene coding sequence to look for novel polymorphisms. 
Analysis of the coding sequence of the hCAMP-18 gene was performed by direct se-
quencing of 3 distinct amplicons that, together, spanned all the 4 exons that compose 
the gene. 
The first exon was amplified using the following primers: 5’-
CTAGAGGGAGGCAGACATGG-3’ and 5’-AGCAGAATGTCCCCCAAAG-3’. The 
second and the third exons were amplified together with the following couple of prim-
ers: 5’-CCCCATTTCCTCCTCTGACT-3’ and 5’-ACACTCTATGCCCCCATCAG-3’ 
while the fourth exon was amplified with the primers 5’-
CCTGTTTCTTCCTGTACACAACC-3’ and 5’-GAGGCAAAACAAGTGAGACTGA-
3’. 
All reactions took place in a final volume of 25µl and were performed with 1X PCR 
Buffer II (Applied Biosystems), 2 mM MgCl2, 50 %M each dNTPs, 0.2 %M forward 
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primer, 0.2µM reverse primers, 0.5 U of AmpliTaq Gold Polymerase (Applied Biosys-
tems). Thermal-cycler conditions were a pre-cycling period of 10 minutes at 95°C fol-
lowed by 40 cycles of 30 seconds at 95°C, 30 seconds at 58°C while the elongation step 
was set at 72°C for 30 seconds. PCR reaction was terminated by a final elongation step 
at 72°C for 4 minutes. 
We then analyzed the sequence of the 5’UTR and promoter region of the hCAMP-18 
gene. 
Do to this two couples of primers were designed on the NM_004345 reference sequence 
whose amplicons overlapped covering the entire coding sequence. 
The first couple of primers was 5’-TGGGTCCAGAGAGCATGTGGTAT-3’ and 5’-
GGAAGAGAGCCAGGTGCCTAT-3’ while the second couple was 5’-
GAACTCCTTATCTCAGGTGATCC-3’ and 5’-TCTTCATGGTCCCCATGTCTG-3’. 
Reactions took place in a final volume of 25µl and were conducted with 1X PCR Buffer 
II (Applied Biosystems), 2 mM MgCl2, 50 %M each dNTPs, 0.2 %M forward primer, 
0.2µM reverse primers, 0.5 U of AmpliTaq Gold Polymerase (Applied Biosystems).  
Thermal-cycler conditions consisted of a pre-cycling period of 10 minutes at 95°C fol-
lowed by 40 cycles of 30 seconds at 95°C, 30 seconds at 57°C and an elongation step at 
72°C for 30 seconds. PCR reaction was terminated by a final elongation step at 72°C 
for 4 minutes. PCR products were then processed in the same way as for the mitochon-
drial D-loop region sequencing. 
 
Analysis of defensins gene copy number polymorphism  
Multiple Ligation-dependent Probe Amplification 
Multiple Ligation-dependent Probe Amplification (MLPA) relies on the use of progres-
sively longer oligonucleotide probes in order to generate locus-specific amplicons of 
increasing size that can be resolved electrophoretically. In the original description of the 
method (Schouten et al., 2002,), these long oligonucleotides were generated using a se-
ries of proprietary M13-based vectors, since their size is beyond that attainable by stan-
dard chemical synthesis.  
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MLPA protocol consists of five steps: hybridization of the probes, a ligation reaction, a 
PCR reaction, followed by separation of amplification products by electrophoresis and 
data analysis. 
The probes designed to be used in MLPA reactions consists of two different oligonu-
cleotides, each of which containing one of the common PCR primer sequences. It is 
only when these two probe parts are both hybridised to their target sequence that they 
can be ligated to each other. Only ligated probes will be amplified exponentially in a 
PCR reaction. The number of probe ligation products depends on the number of target 
sequences in the sample. 
Multiplexing is made possible by stuffer sequences that are inserted in the probes in or-
der to make them all different in size. This way up to 45 unique MLPA probes can be 
multiplexed in a single reaction. The Salsa defensin kit p139 that we used to perform 
our experiments contained 19 MLPA probes specific for 13 different defensin genes, as 
well as 2 MLPA probes specific for the defensin-like gene SPAG11. In addition, 13 
probes for other genes present at the same locus of the defensin genes, at 8p23, are pre-
sent. To ensure a proper copy number quantification, 9 MLPA probes specific for genes 
located on other chromosomes were included as controls. 
In the first step, hybridization of the specific probes, specific probes are allowed to hy-
bridize overnight at 60°C after a rapid denaturation of the DNA sample at 95°C. 
After hybridisation with the target, the two components of the probe will be ligated by a 
specific ligase enzyme, but only when they are both hybridised at adjacent sites. It must 
be noted that the ligation reaction is specific enough to allow the possibility to distin-
guish sequences differing in a single nucleotide. 
The resulting ligation product contains both PCR primer sequences in one fragment, 
and hence will be amplified exponentially during the PCR reaction. In contrast, probe 
oligonucleotides that are not ligated will contain only a single primer sequence. As a 
consequence, non-ligated probe sequences will not be amplified exponentially and will 
not generate a signal. The removal of unbound probes is thus not necessary in MLPA. 
The amplified amplicons were then separated with an ABI 3730XL automatic sequencer 
(Applied Biosystems). Following the PCR reaction 1 to 3 %l of the PCR reaction were 
mixed with 0.3 %l internal size standard and 9 %l of HiDi formamide (ABI nr.4311320). 
The mix was then incubated for 2 minutes at 94°C, and hold at 4°C for 5 min.  
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Sequencer parameters were as follows: internal standard: 600LIZ filter set 500ROX 
(ABI nr. 401734) filter set D; Capillaries were 36 cm long, filled with POP-7 polyemer. 
Temperature of run was set at 60°C while capillary fill volume was 184 steps; Pre run 
voltage was set at 15 kV with a pre run time of 3 minutes. Voltage ad injection was 3.0 
kV; injection time was: 30 sec; run voltage was 15 kV.  
Data analysis was performed with the Coffalyser software, downloadable at the 
www.mlpa.com web site following manufacturer’s instructions and suggestions. 
 
Generation of MLPA control 
Due to the difficulties in obtaining a “standard” sample that contained all the genes 
studied with MLPA in two copies per diploid genome (four copies for the genes that are 
normally duplicated) we decided to create artificially a standard control that had certain 
amounts of each gene. Therefore we created 44 different plasmids, each containing one 
kind of target sequence. To do so we employed specially designed primers, with whom 
we were able to amplify, for each target sequence, a fragment of about 150 base pairs, 
flanked on each side by an XhoI restriction site. We then inserted this fragment in a 
common pGL3 and selected the plasmids with only one inserted target sequence. Inser-
tion and ligation were performed with standard molecular biology methods as already 
described in the third edition of “Molecular Cloning” (Sambrook and Russel, 2001)  
Sequence determination has been done with an ABI 3130XL automatic sequencer as 
described above. 
An E. Coli strain has been transfected with the different plasmids and, after one night of 
growth at 37°C, amplified plasmid has been purified with a Millipore Plasmid Miniprep 
and the resulting DNA has been spectrophotometrically quantified. 
Then, equals amounts of DNA for each different plasmid have been quantified with a 
NanoDrop spectrphotometer and then adequate amounts of each plasmid has been 
added to a pool to generate the standard DNA mix. 
In silico analysis of the pGL3 plasmid sequence, performed with BLAST, showed that 
none of the target sequences were present before recombination. 
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Statistical analysis 
Data analysis has been performed using the most relevant statistical test. 
Allele and genotype frequencies were calculated by direct gene counting;  Hardy-
Weinberg equilibrium was calculated by expected genotype frequencies. 
Assessment for differences in genotypic and allelic frequencies to do association studies 
have been done using Chi-square test or exact Fisher test. 
Choice of one of the two methods was not relevant in most cases: in fact the Chi-square 
test is just a simplification of the exact Fisher test and gives similar results if the number 
of samples is large enough. The use of Chi-square test in spite of Fisher test is generally 
accepted when none of the tested subgroups is composed by less than five units. 
The employed test is clearly specified in the text in a case-by-case manner. 
Haplotypes and linkage disequilibrium have been estimated with the Arlequin software 
3.01 (http://cmpg.unibe.ch/software/arlequin3/) . 
To test for differences in the copy number distributions of MLPA experiments the use 
of a parametrical test was not suitable and therefore we opted for the Wilcoxon-Mann 
non-parametric test. 
When relevant we executed correction of p-values for multiple observation. This tech-
nique is greatly useful when computing a large number of p-values during an experi-
ment in order to reduce the probability to obtain false-positive results. 
To do multiple comparison correction we take advantage of two different methods: the 
classical one proposed by Bonferroni and another proposed by Benjamini and Hochberg 
(1995). Choice of one method in the different cases has been done on the basis of the 
achieved results and taking into account the different peculiarities of the different meth-
ods. The Bonferroni method, in fact, is way more restrictive than the Benjamini and 
Hochberg one, the latter being especially designed to minimize false negative errors in 
biological experiments. We have generally preferred to use the Benjamini and 
Hochberg during association studies for polymorphisms and the Bonferroni method in 
the MLPA experiments in order to avoid the higher risk of false positive that’s implied 
in the analysis when computing a large number of p-values. When referring to a cor-
rected p-value the method that was used to obtain it is clearly stated, however, for all 
experiments p-values have been calculated with both methods. 
Statistical analyses have been performed with the open-source R package, available at 
the www.r-project.org site. 
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RESULTS AND DISCUSSION 
 
 
 
 
 
 
 
General Remarks 
Samples  
Both the 2002 and the 2006 sample collects took place at the Instituto Materno Infantil 
do Pernambuco (IMIP) with the collaboration of the Laboratorio de Imunopatologia 
Keizo Azami (LIKA). 
It should be noted that Brazilian health system exists on two different levels: public 
assistance that’s free for everyone and private assistance that’s only available to a 
smaller part of population, characterized by medium or high social level, scholarity and 
economical conditions. Mothers that are cured in private hospitals belong to the smaller 
part of population mentioned above, are more informed and undergo a proper follow-
up, with all relevant clinical analysis.  
The IMIP is a hospital that’s really peculiar in the Brazilian scene. In fact it’s neither a 
public nor a private hospital; it was founded and constructed with money coming from 
donations, without government’s founding, with the aim of give Recife’s poor people 
free medical assistance. It’s located in the center of one of Recife’s biggest favela in 
order to be near to the people it wants to help. 
Since getting money is a great problem all hospital’s doctors work for free and the en-
tirety of the funding are employed to ameliorate the center and to pay for drugs. 
Because of the lack of a monetary fee, most doctors that work at the IMIP are volun-
teers that offer their free time or doctors that came from abroad thanks to co-operational 
project. As a consequence all personnel is greatly motivated and was happy to partici-
pate to the sample collection, despite the extra work required for this. 
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All the mothers whose children had their DNA extracted were selected to come from 
poor areas of the Recife metropolitan region. To assure maximum homogeneity, none of 
the enrolled subjects underwent antiretroviral therapy or caesarian section before deliv-
ery, due to the discussed limitations. 
During the 2002 collection a problem arose that persisted also in the 2006 subsequent 
collection. In fact it has been difficult to obtain mothers’ biological samples, a fact that 
impaired the efforts to perform statistical analysis on mothers’ genetic background and 
forced us to perform our analysis only on children’s DNA.  
As a matter of fact this problem is a direct consequence of the choice of reducing our 
cohort only to children born from impoverished mothers, since we had to face the diffi-
cult situation of Brazilian health system. It appeared clear that due to our study finalities 
the sample collection must take place among the poor people, but it was equally clear 
that public hospitals didn’t had the means, both in terms of monetary founds and avail-
able personnel, to provide an adequate way to systematically collect samples. 
Still we had to face the problems correlated with the population we studied. Medical 
conditions in the favelas are dramatic, with an elevated HIV-1 incidence and little or no 
medical advice on AIDS prevention and treatment. Mothers often came to the hospital 
after the parturition or in such advanced labor conditions that caesarian section was im-
possible. A rightly done medical follow up is usually impossible because mothers fail to 
return for clinical tests. 
The lack of data on mothers should be seen as the major drawback of the entire thesis 
work. In fact, it’s plausible that vertical transmission could be also influenced by 
mother’s genetical background: a genetic defect that induces high viral load in the 
mother could, for example, increase the risk of mother to son infection. 
We paid the unique opportunity to work on large cohorts with the fact that we could not 
get the entire picture of the phenomenon and we are forced to obtain our result solely on 
the basis of the analysis we can do on children’s DNA. 
 
First sample collection  
In order to evaluate the role of antimicrobial peptides in HIV-1 vertical transmission we 
have started to study the DNA bank that was already present at the Burlo Garofolo 
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Children Hospital and that has been collected in 2002 at the Instituto Materno Infantil 
do Pernambuco (IMIP). 
The DNA bank consisted of DNA extracted from 303 Brazilian newborns and classified 
as healthy controls, HIV-1 positive subjects and exposed non-infected subjects. Healthy 
controls subjects were children born from uninfected mothers and that therefore didn’t 
incur in any exposition to HIV-1 virus, while both the HIV-1 infected children and the 
exposed uninfected subjects were born form HIV-1 positive mothers and were differ-
enced on the presence of the absence of HIV-1 transmission during delivery.  
These DNA samples were used to assess the role of polymorphisms in the 5’UTR of 
DEFB1 gene and defensin gene copy number polymorphisms on HIV-1 vertical 
transmission.  
 
Second sample collection 
A second collection of samples was performed in 2006 with similar procedures to the 
ones employed for the first round of sample accumulation. The second DNA bank, that 
was gathered, as in the previous case, at the IMIP, had some qualitative advantages over 
the first DNA bank, though. 
In fact we were able to take advantages of the new facilities of the virology service at 
the LIKA. The virology department has been renewed in 2004 and now is more closely 
bound to IMIP’s clinical service. As a consequence of this we were able to detect viral 
presence by Real-time PCR methods that weren’t available during the first collection, 
making the diagnosis much more precise. 
Furthermore we changed the methodology used to extract DNA, abandoning the phe-
nol-chloroform method for a more modern and rapid method based on the Wizard Ge-
nomic DNA Purification Kit from Promega. This way we could ensure maximum qual-
ity constancy for the extracted DNA. 
The new DNA bank we were able to gather was composed of 360 DNA samples and 
was enriched in HIV-1 positive children whose percentage rose by more than 10 per-
centages point compared to the previous bank, and, more importantly, in exposed unin-
fected children, probably the most valuable group, whose percentage was taken to 20%, 
compared to 16.67% in the previous group. The new DNA bank comprised globally 192 
HIV-1 infected children, 72 exposed-uninfected children and 96 healthy controls. For 
  
76 
samples collection we continued to enroll patients that were admitted at the gynecologi-
cal service of the IMIP, as for the previous collection. 
Due to the higher quality of DNA, and to the fact that many samples belonging to the 
first DNA bank were no longer available, subsequent experiments have been performed 
solely on the second DNA bank. Thus analysis on Lactoferrin, MBL2 and LL37 genes 
has been performed on these samples collected in 2006. 
 
Mitochondrial D-loop sequencing. 
Brazilians form one of the most heterogeneous populations in the world, as a result of 
colonization and immigration waves from Europe and 5 centuries of interethnic crosses 
between peoples from three continents: the European colonizers (represented mainly by 
the Portugueses), African slaves and the autochthonous Amerindians. (Alves-Silva et 
al., 2000)  
It’s widely recognised that allelic frequency can vary significantly among ethnicity. 
Since the effect of colonization and immigration have had a differential impact in dif-
ferent regions of Brazil and the different ethnic groups of origin can actually contribute 
to the gene pool of present-day Brazilians in different percentages, polymorphisms fre-
quencies could vary greatly among populations coming from different areas of the 
country. Moreover, due to historical reasons, a quite tight correlation between ethnical 
origin and actual social condition can be evidenced also within the same geographical 
region. 
Thus it is possible, at least theoretically, that differences of allelic and genotypic 
frequencies are not indicative of disease association but are the results of stratification 
of the studied population. 
In addiction to enroll samples that all come from poor areas of the Recife metropolitan 
region, to further ensure genetical homogeneity among the three different groups in 
which was subdivided the DNA bank we decided to perform an analysis of the hyper-
variable D-loop mitochondrial sequence. 
The D-loop region is important for phylogeographic studies. Because the region does 
not code for any genes, it is free to vary with only a few selective limitations on size 
and heavy/light strand factors. The mutation rate is among the fastest of anywhere in 
either the nuclear or mitochondrial genomes in animals. Mutations in the D-loop can 
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effectively track recent and rapid evolutionary changes such as within species and 
among very closely related species.  The characteristics of the D-loop region have been 
exploited to measure the genetic contributions of African, European and Native Ameri-
can pools to the genetic background of today’s Brazilian population.  
 
 
Figure 14 Organization of mitochondrial genome. A red arrow indicates the D-loop. 
 
Alves-Silva et al. (2000) employed a restriction fragment length polymorphism (RFLP) 
approach to mitochondrial DNA to identify DNA ancestry in different continents. They 
analyzed 247 samples from different areas of Brazil and demonstrated that the total 
sample showed nearly equal amounts of Native American, African, and European mat-
rilineal genetic contribution but with regional differences within Brazil. They concluded 
that mitochondrial DNA pool of present-day Brazilians evidently reflects the imprints 
of the early Portuguese colonization process involving directional mating, as well as the 
recent immigrant waves from Europe of the last century. 
In particular the Recife’s population’s genetic background was derived from an admix-
ture of African, Caucasian and native American populations with a proportional weight 
estimated, respectively, at 44, 34 and 22%. 
Starting from this available data we decided to perform the same test of Alves-Silva 
(2000) in order to observe if there was any difference in the mtDNA pool among our 
studied groups.Results are summarized in table 1 
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Table 2 genetic contributions of African, European and Native American pools to 
the genetic background of Brazilian HIV-1 positive children, exposed-uninfected 
children and healthy controls. 
 Healthy Controls Exposed-Uninfected HIV Positive 
Continental fraction    
Native American 22.45% 20,19% 23,86% 
African 46.15% 47,12% 45,33% 
European 31.40% 32.69% 30.81% 
 
The three groups do not significantly differ one from another; nevertheless we found a 
slightly higher African contribution than reported (Alves-Silva et al., 2000). This fact 
could be due to the reason that in the study by Alves-Silva et al. there was probably a 
bias due to selection of the sample, that was especially drawn among people working or 
studying at university, therefore belonging to the upper-high class that’s historically 
more prone to receive European genetic contribution 
 
DEFB1 polymorphisms in HIV-1 vertical transmission and infection 
Literature on the influence of antimicrobial peptides on vertical transmission is scarce, 
but, on the contrary, there is more than enough literature on the anti-HIV-1 activity of 
many of those peptides to let us to be confident on a role for these molecules in influ-
encing susceptibility to be infected at the moment of the delivery. 
Given the peculiar genetic background of Brazilians, we decided to begin our work by 
trying to replicate in this population the data that were previously obtained in our lab 
about the influence of three SNPs of the DEFB1 gene on vertical transmission in Italian 
children (Braida et al., 2004).  
The 5’ UTR of the DEFB1 gene has been then sequenced in our cohort of 303 Brazilian 
subjects in order to study the influence of the -52 (G/A) -44 (C/G) and -20 (G/A) poly-
morphisms (NCBI accession numbers, respectively: rs1799946, rs1800972, rs11362) on 
HIV-1 infection and vertical transmission. 
Results are reported on table 3. 
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Table 3 Alleles and genotypes count (and frequency) of polymorphisms in the 
5’UTR of the DEFB1 gene in HIV-1 positive children, exposed-uninfected children 
and healthy controls. 
 Healthy Controls Exposed-Uninfected HIV Positive 
SNP  -52 (G/A)    
G 125 (0.54) 65 (0.54) 171 (0.67) 
A 105 (0.46) 55 (0.46) 85 (0.33) 
G/G 34 (0.30) 60 (0.32) 53 (0.41) 
G/A 57 (0.50) 27 (0.45) 65 (0.51) 
A/A 24 (0.21) 14 (0.23) 10 (0.08) 
SNP  -44 (C/G)    
C 197 (0.86) 104 (0.87) 237 (0.93) 
G 33 (0.14) 16 (0.13) 19 (0.07) 
C/C 84 (0.73) 44 (0.73) 109 (0.85) 
C/G 29 (0.25) 16 (0.27) 19 (0.15) 
G/G 2 (0.02) 0 (0.00) 0 (0.00) 
SNP  -20 (G/A)    
G 145 (0.63) 70 (0.58) 124 (0.48) 
A 85 (0.37) 50 (0.42) 132 (0.52) 
G/G  42 (0.36) 20 (0.33) 15 (0.12) 
G/A 61 (0.53) 30 (0.50) 94 (0.73) 
A/A 12 (0.10) 10 (0.17) 19 (0.15) 
 
The genotype frequencies obtained are in accordance with the Hardy-Weinberg equilib-
rium for all the SNPs studied in the three populations with the exception of the poly-
morphism -20 (G/A) in the HIV-1 infected children. (p<0.001) 
Escaping from the Hardy Weinberg equilibrium by the -20 (G/A) polymorphism de-
serve a particular consideration: in fact, while the allelic frequencies in the healthy con-
trols group do correspond to the frequencies reported in the NCBI public database 
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(http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=11362), in the remaining two groups, 
and in particular in the infected children group we observed a markedly increased fre-
quency of the -20 A allele that drove the genotype frequencies out of the equilibrium. 
We can exclude the hypothesis of experimental errors since the technique we used; di-
rect sequencing is, so far, the most reliable and precise SNP genotyping technique. 
Moreover all genotypes have been double checked in this group by repeating sequences.  
We thus believe that the detected anomaly in the Hardy-Weinberg equilibrium could be 
explained taking into account the fact that the infected children group could be enriched 
in subjects coming from a poorer environment, and thus the Caucasoid pool of genes 
could be under-represented in this group. Another hypothesis we can alternatively pro-
pose is that the -20A allele has a detrimental effect on protection from HIV-1 infection 
even when present in heterozygosis. 
It’s actually not possible, with the data we have and without performing deeper popula-
tion studies, to discriminate from the two proposed possible causes and it’s neither pos-
sible to exclude that the real rationale could be substantially different. 
In both the proposed cases departure from Hardy-Weinberg equilibrium would be 
caused by endo-stratification of the group and therefore was not possible to eliminate 
this bias factor. Nevertheless the fact that all the groups were in Hardy Weinberg equi-
librium for all the other polymorphisms make us quite confident about the correctness 
of patients selection. 
When confronting the genotype and allelic frequencies of the different groups we found 
that the -44C allele was over-represented in the HIV-1 infected group, with a frequency 
of 93%, versus 86% in the exposed non-infected group and 87% in the healthy control 
group thus pointing toward a protective effect for the -44G allele both in vertical trans-
mission and in infection by HIV-1 virus.  
These differences in allelic frequencies resulted in an increased frequency of the -44C/C 
genotype at the expenses of the -44C/G genotype as well. The -44G/G  is very rare and 
it has been found only in two healthy control subjects. 
This correlation for the -44(C/G) DEFB1 polymorphism appears quite weak and, in-
deed, when genotype frequencies are tested with a chi-square test the detected differ-
ence reaches statistical significance, but it is not able to retain the above mentioned sig-
nificance after multiple test correction with the Bonferroni method (HIV-1 infected vs. 
healthy controls gave a corrected p-value=0.052). 
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As said before, allelic frequencies of the –44G allele were similar between healthy con-
trols and HIV-1 exposed uninfected children while a lower frequency of the -44G allele 
has been found in HIV-1 infected children. In this case the difference didn’t reach sta-
tistical significance. 
Notably the frequency of this polymorphism was very low in the Brazilian population 
we studied when compared to the reported frequencies in other populations (Jurevic et 
al., 2002); the fact that genotype frequencies are so much more skewed toward the pres-
ence of the -44C allele and the G allele is so under-represented could account for the 
difficulties we have to reach statistical significance for this polymorphism. 
On the other hand, we were able to demonstrate that the DEFB1 -52A/A genotype was 
significantly less frequent in HIV-1 perinatally infected children when compared to 
healthy controls and exposed uninfected children and that this variation, contrarily to 
the -44(C/G) case, is statistically significant even after Bonferroni correction for multi-
ple testing (corrected p-values are equal to 0.023 and 0.025 respectively when confront-
ing the HIV-1 infected group with the healthy controls and the exposed non-infected 
children), while frequencies didn’t vary significantly between HIV-1 exposed unin-
fected children and healthy controls. 
Allelic frequencies of the -52(G/A) SNP in infected children varied significantly when 
compared to those of healthy controls (corrected p-value equal to 0.030), with a 13% 
increase in the -52G allele in the HIV-1 infected patients. The variation wasn’t statisti-
cally significant when infected children were compared to exposed uninfected children 
(corrected p-value equal to 0.055). This is probably due to the fact that the HIV-1 ex-
posed uninfected children group is much smaller than the healthy control group; never-
theless we were able to show that a trend exists even in this case and that the -52G allele 
gives increased susceptibility to vertical transmission and infection by HIV-1 virus (odd 
ratios 1.688, 95% confidence limits 1.151-2.482). 
Finally, the stronger and more striking association has been observed considering the -
20(G/A) polymorphism, where the frequency of -20G/G genotype was significantly 
lower in HIV-1 positive children (12%) than in exposed uninfected children (33%) and 
healthy control (36%) (corrected p-values were both less than 0.005).  
Allelic frequencies of the -20(G/A) SNP were significantly different between HIV-1 
positive children and healthy controls (corrected p-value=0.015) while the significance 
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wasn’t achieved between HIV-1 infected and exposed uninfected children due to multi-
ple test correction, similarly to the -44(C/G) case. 
The results obtained show that carrying the -20G allele infers protection from vertical 
transmission of HIV-1, while a greater susceptibility was observed in patients carrying 
the -20A allele (odd ratios 1.814, 95% confidence limits 1.243-2.655). 
As we did not find any significant difference between the exposed uninfected children 
and the healthy controls, we decided to improve our statistical analysis by pooling the 
two groups and performing single polymorphism association tests. We were basically 
able to confirm the conclusions obtained with the chi-square test on the three different 
groups, with -52G and -20A alleles increasing susceptibility to infection and vertical 
transmission. 
 
We then estimated haplotype frequency and Linkage Disequilibrium. Despite the physi-
cal proximity of the three studied polymorphisms, that stretch in less than 30 base pairs 
of the DEFB1 5’UTR, and regardless of a co-segregation rate of 93% between the -
20(G/A) and -44(C/G) polymorphisms, we didn’t find evidence of the presence of any 
haploblock that gives particular inclination to HIV-1 infection or vertical transmission 
of the virus. 
We then performed a multiple regression analysis of our data with the R software 
(www.r-project.org); the analysis was designed to highlight any potential interaction 
between the studied polymorphisms, but we were not able to show any significant syn-
ergistic effect of the different mutations. 
The data collected in this study demonstrate that significant correlation exists between 
polymorphisms in the 5’ UTR of the DEFB1 gene and the risk of being perinatally in-
fected with the HIV-1 virus in Brazilian children. 
Moreover our study presented novel data when confronted to the work of Braida et al. 
(2004) that initially inspired our work. In fact, differently from the work of Braida et al., 
in which only infected children and healthy controls were considered, the inclusion in 
the study of a group of children that where perinatally exposed to HIV-1 but didn’t con-
tract the infection gave us the opportunity to assess the role of the analyzed SNPs in 
mother to child transmission of the virus. Genotypical frequencies between infected and 
exposed uninfected children were significantly different in the case of the -52(G/A) and 
-20(G/A) polymorphisms, suggesting a role for these SNPs in vertical transmission, in 
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particular with a disadvantageous effect of the -52 G and -20 A alleles (odd ratios re-
spectively equal to 1.688 and 1.814, with 95% confidence intervals equal to 1.151-
2.482 and 1.243-2.655). 
Notwithstanding the fact that our results are statistically significant, we can’t be totally 
sure about a direct effect of DEFB1 5’ UTR polymorphisms on vertical transmission. 
In fact, the group of HIV-1-positive children studied here were likely infected during 
delivery by contact with HIV-1-infected maternal blood or mucus in the birth canal; if 
women carrying the polymorphisms in the 5’ UTR of the DEFB1 gene are more 
susceptible to HIV-1 infection or more likely to have higher viral loads during infection, 
thus their children may be expected to have a higher frequency of this polymorphism 
beside being possibly exposed to higher viral levels during delivery, even if there is not 
a direct effect on vertical transmission of the polymorphism itself. Unfortunately, as 
said before, biological samples from the mothers of HIV-1-infected children or in-
formation on their viral load at the time of delivery were not available and a direct 
confrontation was not possible at all. 
Nonetheless, evidencing a correlation between DEFB1 5’ UTR polymorphisms and 
susceptibility to HIV-1 infection and vertical transmission led us to conclude that those 
polymorphisms could be used as biological markers to determine how prone to viral in-
fection a subject is. 
 
Transcriptional effect of DEFB1 gene 5’ UTR polymorphisms 
Although we demonstrated that the polymorphisms located in the 5’ untranslated region 
of the DEFB1 gene could be employed as marker of risk in vertical transmission and 
infection of HIV-1, there wasn’t a recognized biological rationale for this fact and the 
role of these polymorphisms was unknown.  
Since the studied polymorphism fall out of the coding sequence and the peptide se-
quence is not altered, they clearly can’t have any implication in differential antiviral ac-
tivity. 
Nevertheless we hypothesized that the previously studied polymorphisms could have a 
functional effect on hBD-1 expression; in particular, given that they lie in the 5’ UTR of 
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therefore to a diminished expression of hBD-1 leading to an impaired response of the 
innate immunity system to the pathogen. 
The most straightforward way to assess if a functional effect existed was to measure 
hBD-1 levels from protein samples extracted from patients biological specimens and 
already genotyped for the DEFB1 5’ UTR polymorphisms and trying to correlate geno-
types and hBD-1 levels. Protein samples have been obtained with the BioRad’s 
ReadyPrep Protein Extraction Kit following manufacturer’s instruction from vaginal 
biopsies coming from the gynecological service of the IRCCS Burlo Garofolo. 
Unfortunately a great problem mined our tentative in this direction: the almost complete 
lack of recombinant antibodies targeted against hBD-1. In fact, while it’s possible to 
obtain anti-hBD1 antibodies from a number of suppliers, most of them are targeted to-
ward the same epitope, making them useless to design a sandwich ELISA (Enzyme 
Linked ImmunoSorbant Assay). 
The only supplier we found that had anti-hBD1 antibodies targeted toward different epi-
topes of the peptide was Immunodiagnostik AG Bensheim, that give us three mono-
clonal antibodies, targeted respectively to amino acid residues 1-5, 18-26 and 28-34. 
We tried to develop an ELISA with any of the three antibodies linked to the plate and 
any of the other two for detection without good results. In fact we had no detectable 
signal when adsorbing the 18-24 antibody to the plate, while the best results where ob-
tained by adsorbing the antibody targeted toward residues 1-5 to the plate and using the 
antibody against residues 28-34 for detection. With this setup we were able to correctly 
draw a standard curve with the reduced reference peptide given by Immunodiagnostik 
AG Bensheim. Unluckily this setup wasn’t able to recognize hBD1 when present in the 
native form with the presence of three disulfide bonds and we obtained no signal when 
testing our samples. 
We then tried to reduce the disulfide bonds adding Tris-(carboxyethyl) phosphine 
(TCEP) to a final concentration of 25mM and repeating the experiment, but results were 
inconclusive and we could not draw a standard curve with serial dilutions of protein ex-
tracts. We then concluded that the ELISA technique didn’t suit well our needs to quan-
tify hBD1 in complex protein mixtures, as we hypothesized that some interfering com-
pound was present in our samples. 
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Repeating the experiments with protein extracted with a simple “boil-and-go” proce-
dure, thereby avoiding to include any external compound in the protein extract, did 
show the same inconclusive results. 
The difficulty to correctly set an ELISA assay for antimicrobial peptides is confirmed 
by the fact that there’s no commercial kit available for any defensin and the only re-
ported developed ELISA test in literature is for hBD2 and it has been used only once 
from its first introduction in 2000 (Ortega et al., 2000). 
Thus we decided to perform an in vitro assays, more precisely a Dual-Luciferase assay, 
to study protein expression. 
The Dual-Luciferase Reporter (DLR) Assay System by Promega has been designed to 
provide an efficient means of performing two reporter assays. In the DLR Assay, the 
activities of firefly (Photinus pyralis) and Renilla (Renilla reniformis or sea pansy) lu-
ciferases are measured sequentially in a single sample. The firefly luciferase reporter is 
measured first by adding Luciferase Assay Reagent II (LAR II) to generate a lumines-
cent signal lasting at least one minute. After quantifying the firefly luminescence, this 
reaction is quenched, and the Renilla luciferase reaction is initiated simultaneously by 
adding the so-called Stop & Glo Reagent to the same sample. Both assays can be com-
pleted in about 4 seconds using a luminometer with reagent auto-injectors. In the DLR 
Assay System, both reporters yield linear assays with attomole (<10–18) sensitivities 
and no endogenous activity in the experimental host cells. Furthermore, the integrated 
format of the DLR Assay provides rapid quantification of both reporters either in trans-
fected cells or in cell-free transcription/translation reactions. 
The pGL4 and phRL series of synthetic Renilla Luciferase Reporter Vectors are de-
signed for use with the DLR Assay Systems. A Renilla luciferase vector with constitu-
tive expression may be used in combination with any experimental firefly luciferase 
vector to co-transfect mammalian cells. 
This technology, while suffering from all the limitations of an in vitro test, offered us 
the opportunity to rapidly and cheaply compare differences in protein expression due to 
5’UTR polymorphisms and therefore we decided to use it before investing on an in vivo 
assay, considering the difficulties that mined our efforts to develop an ELISA test. 
After generation of plasmids as described in the material and methods section, we 
moved on testing the functional influence of the studied SNPs on the activity of the 
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DEFB1 gene 5’UTR when cloned upstream the Firefly luciferase, used as a reporter 
gene. 
The cell strain we used to perform the assay was a Caco2 cell line and the decision was 
driven by the fact that those cells are a carcinoma-derived line and therefore come from 
a tissue, the skin, which is naturally able to express defensin genes. By using this ap-
proach we wanted to be sure that the cell line used was able to process the 5’UTR in the 
most similar way to a normal epithelial cell. 
Essentially, starting from a wild-type DEFB1 5’UTR, as assessed by direct sequencing, 
fragments have been cloned in which a site-specific mutagenesis have been performed 
to obtain fragments with mutations corresponding to the -52 (G/A) -44 (C/G) and -20 
(G/A) polymorphisms. 
The PCR-obtained fragments have been then digested with restriction enzymes and then 
cloned into the pGL3 promoter vector by Promega. In this way we cloned the wild type 
DEFB1 5’UTR with its three major variants just upstream the firefly luciferase gene, 
fundamentally creating a 5’UTR for this gene. 
The aim was to detect functional variations in gene expression due to mutations in the 
5’UTR by measuring luciferase activity. 
To avoid biases due to differences in transfection, normalization of data was performed 
by cotransfecting the cells with a plasmid containing the Renilla luciferase gene. To en-
sure the reproducibility of the results all tests have been performed in quadruplicate and 
repeated at a later time to confirm the obtained results. Inter-assay variability showed to 
be 4%, while intra-assay variability was around 10%. 
Our results show that all the studied polymorphisms have a functional effect on the ex-
pression of the downstream firefly luciferase gene. In particular, expression levels of 
firefly luciferase were sensibly reduced in all cases, as indicated by the subsequent re-
duction of the ratio between the activity of firefly luciferase and the activity of Renilla 
control luciferase.  
Statistical analysis has been performed using standard Student t test: a choice justified 
by the fact that the distributions of the observed ratios appeared to be normal after test-
ing with Shapiro-Wilk normality test. 
Notwithstanding the fact that all polymorphisms were diminishing the firefly luciferase 
expression, only the -44 G allele was able to reduce the expression of the reporter gene 
to statistically significant levels, with a calculated p-value of 0.003. The latter p-value 
  
87 
was significant enough to retain his significance (p= 0.009) even after an appropriate 
adjustment for multiple observations with the Bonferroni method. 
 
 
Figure 15 Expression levels of firefly luciferase (expressed as Renilla/firefly ratio) 
for different 5’UTR- DEFB1 gene polymorphisms 
 
Therefore we can state that this 5’ UTR polymorphism has a sensible functional effect 
one expression of the downstream gene in our model, suggesting that a similar effect 
could be also true in vivo. 
The effect of -52A and -20A polymorphisms has proved to be lower in the magnitude of 
action when compared to the effect of the -44 G allele and they didn’t reduce the lu-
ciferase expression to an extent at which it could be statistically significant; neverthe-
less the p-values calculated for these alleles suggest a functional role for these polymor-
phisms too, being equal to 0.086 and 0.060 for the -52A allele and for the -20A allele, 
respectively. 
Our in vitro results suggest that all the studied polymorphisms can be able to hamper an 
effective production of hBD-1 in vivo and, therefore, they can be related to a lack of 
proper response from the innate immune system, thus indicating that they should be 
studied in inflammatory pathologies to seek for linkage disequilibrium with the illness. 
The fact that, although not significantly, the -20 A allele is associated to a decreased 
transcriptional activity of DEFB1 gene, fits quite well with the results we obtain on pa-
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tients genotype. The -20A allele, indeed, was over-represented in HIV positive subject 
and associated to an increased risk of infection; these finding, taken together, let us sug-
gest that reduction in the protein expression rate can be a risk factor for HIV infection.  
Conversely, the results concerning -52 (G/A) -44 (C/G) SNPs are not so easy to be in-
terpreted. In fact we were expected to find that the alleles we reported to be associated 
to HIV infection susceptibility (namely – 52G and -44C) correspond to lower transcrip-
tional levels and not to increased ones, as we actually described. 
A possible explanation for this can be found considering that hBD-1 could also act as 
chemotactic agent for T cells, monocytes and immature dendritic cells. (Yang et al., 
2004). Given the fact that HIV-1 virus specifically infects T cells and monocytes, hav-
ing an increased production of hBD-1 protein (associated for example with the presence 
of  – 52G or  -44C alleles) can be detrimental, since its action in recruiting cells that are 
prone to be infected would therefore facilitate virus spreading. 
Our results aren’t in accordance to the results published by Sun et al. (2006) and ob-
tained with the same dual-luciferase report assay. 
In the above mentioned study two polymorphisms have been studied: a polymorphisms 
in the DEFB1 gene promoter, located 688 bases upstream to the ATG start codon and 
the -44 (C/G) polymorphism in the 5’ UTR. 
While they concluded that the mutant allele in position -688 was able to cut the lu-
ciferase expression to a half, they reported that the -44G allele had the capacity to en-
hance luciferase expression by a factor of 2.3. 
The data presented by Sun et al. are quite strange, as the significant decrease in lu-
ciferase expression due to the -688C allele was measured in a construct that also con-
tained the -44G mutant allele. Therefore one should assume that the -688C allele has a 
dramatic influence on expression, able to overwhelm the presumed positive effect of the 
-44G. While this is clearly possible the enhancement of expression due to the -44G al-
lele doesn’t fit either with our previous data showing a detrimental role of all three 5’ 
UTR polymorphisms on susceptibility to HIV-1 infection, or with the data previously 
published by Braida et al. (2004). 
Moreover the enhancement observed by Sun et al. and reportedly due to the -44G allele 
is based on experiments on a construct that, by admission of the authors, also contained 
the -20G mutation (Petros, 2007) and was therefore confronted with constructs that only 
contained the -20G mutation. 
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Since we showed a functional effect also for the -20(G/A) polymorphisms we think that 
the experimental protocol of Sun et al. takes into no account the bias that such mutation 
could have introduced in the experiment. 
Another parameter that could also account for the observed differences is the fact that 
different cell lines were used, with our laboratory using Caco2 cells, while Sun used 
TSU-Pr1 and DU-145 cell lines. 
Despite the fact that all three cell lines are derived from carcinoma tissue, since we dealt 
with highly mutated tumor cells, their inherent differences could lead to variations in 
dual luciferase assay results. 
Our study and the one by Sun et al. are the only ones available on functional effects of 
DEFB1 gene polymorphisms and the experimental differences could account for the 
discrepancies in observed results. 
Therefore we should conclude that, while the studied polymorphisms have always been 
correlated to modifications in gene expression no conclusive results have been obtained 
so far and a more comprehensive study is required, possibly in vivo, to elucidate a topic 
that, in face of its potential clinical importance, deserves a deeper knowledge. 
 
Defensins gene copy-number polymorphisms in vertical transmission 
and infection 
Many defensins map in the genome in a gene cluster in position 8p23.1. Most notably 
genes as DEFA3, DEFA5, DEFA7, DEFB4, DEFB103A, DEFB104, DEFB105, 
DEFB106, DEFB107B, and DEFB108 does present a copy-number polymorphism that 
impairs a correct genotyping of single nucleotide polymorphisms. In fact the presence 
of multiple copies of a gene makes difficult the discovery of new single nucleotide po-
lymorphisms by direct sequencing in this gene, since the base mutation in one copy 
could be masked by the correct sequences of the other alleles. Besides, presence of an 
unknown number of alleles deeply compromises the assessment of polymorphisms’ al-
lelic distribution in various ethnic populations for disease association studies. 
As a matter of fact, most individuals have a number of copies per diploid genome that 
ranges from 2 to 7, whereas carriers of the euchromatic variant show even greater vari-
ability, with 9 to 12 present copies (Hollox et al., 2003). 
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One interesting thing is that copy-number polymorphisms have been shown, in certain 
cases, to influence the total amount of expressed protein: Hollox et al. (2003) demon-
strated a direct correlation between number of copies of the DEFB104 gene and its tran-
script mRNA levels in a line of lymphoblastoid cells, while Linzmeier and Ganz 
(Linzmeier and Ganz, 2006) used the western blot technology to correlate between the 
total amount of HNP-1, HNP-2 and HNP-3 with the total number of DEFA1 and 
DEFB3 genes. 
The published evidences are obviously not enough to affirm that copy-number poly-
morphisms always influence protein expression, but are sufficient to sketch a picture in 
which variations in the 8p23.1 cluster are able to modify the host’s innate immunity en-
vironment. 
This, added to the previous results that show an influence of defensins on HIV-1 infec-
tion and vertical transmission, drove us to look for a feasible way to study copy-number 
polymorphisms in a number of defensin genes. 
In fact deletions and amplifications of a gene will usually not be detected by sequence 
analysis of PCR amplified gene fragments, as a normal copy is still present. An ap-
proach based on southern blot analysis could reveal many aberrations but will not al-
ways detect small deletions and is not a simple to perform routine technique, especially 
in our case, in which we wanted to analyze a considerable number of gene polymor-
phisms. 
Well-characterized deletions and amplifications can be detected by specially designed 
PCR. However, the exact breakpoint sites of most deletions of the defensin cluster have 
not been determined yet. Furthermore the number of possible different deletions in this 
region is becoming prohibitively big. 
Chen et al. (2006) have proposed an alternative approach that employed quantitative 
real-time PCR to detect copy number polymorphisms of human b-defensin genes.  
To avoid the possibility that single nucleotide polymorphism within the primer region 
may affect PCR amplification, primers were designed in region that show complete se-
quence identity between published sequences of the same target gene.  
The method was also based on the Second Derivative Maximum Method; in fact, minor 
deviations in the PCR amplification and the fluorescence detection within the logarith-
mic phase can lead to significant variation in the Cp value, that, in turn, may lead to 
gross misinterpretation of the gene copy number. On the contrary, with the Second De-
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rivative Maximum Method, Cp determination is only defined by curve shape, not by 
fluorescence background or a manually defined threshold value, which avoids manual 
arbitrary setting in each experiment and makes the results more precise and reproduci-
ble. 
We were able to test the method proposed by Chen et al. in a small subset of our cohort 
using the primers reported in his work. Since we were using an Applied Biosystems 
7900 real-time apparatus instead of the LightCycler machinery used in the original arti-
cle we had to arrange the experimental conditions to obtain consistent and reproducible 
amplification. 
The method proved to be quite strong, with copy-number determination bound to mani-
fold reproduction of experimental data and robust mathematical analysis. Unfortunately, 
due to constitutive variations in PCR amplification, to obtain consistent results all sam-
ples needed to be performed at least in triplicate, otherwise, if doing the assay in dupli-
cate or without sample replication, we observed that copy number determination was 
not accurate and that intra-assay variability was largely increased. We measured the in-
tra-assay variability in the different conditions and we obtained that when doing the 
procedure with triplicate samples the mean variability value 2.67% and was comparable 
to the one reported by Chen et al. This value grows to 6.23% when doing the assay in 
duplicate and to 15.1% when we weren’t using sample replication in the same plate. 
Due to that and to the extensive number of required internal controls, only few samples 
could be genotyped contemporarily on a 96 wells plate and only for 3 different defensin 
genes: DEFB4, DEFB3 and DEFB104. 
We concluded that this methodology, while technically trustworthy, was not suitable to 
perform a quite large case-control association study; therefore we didn’t proceed in de-
signing the probes for the other defensin genes present at multiple copies in the 8p23.1 
cluster. We still retained the assay as an internal control for the subsequent analysis. 
We found that a viable and suitable alternative we could use to perform case-control 
association with a large number of multiple copy genes was Multiple Ligation-
dependent Probe Amplification (MLPA): a technology developed by the Dutch com-
pany NRC-Holland.  
MLPA is a method to establish the copy number of up to 45 nucleic acid sequences in 
one single reaction. Its versatility makes it applicable on genomic DNA as well as on 
mRNA. 
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With this technique it is possible to perform multiplex PCR reactions in which up to 45 
specific sequences are simultaneously quantified. Amplification products are then sepa-
rated by capillary electrophoresis in an automatic sequencer, using the same protocols 
employed in microsatellite separation. As only one pair of PCR primers is used, MLPA 
reactions result in a very reproducible gel pattern with fragments ranging from 130 to 
490 bp. Comparison of this gel pattern to that obtained with a control sample indicates 
which sequences show the presence of gene copy number.  
MLPA probes are able to discriminate between sequences that differ in only one nu-
cleotide. Moreover, MLPA reactions don’t require a large amount of DNA to give con-
sistent results, with the minimum constraint, declared by MRC-Holland of 20ng of hu-
man DNA per reaction. In contrast to FISH and BAC-arrays, for example, the se-
quences detected are much smaller, typically being around 60 nucleotides long, thus 
providing an effective way to reduce the effect of eventual mutations. Moreover, one of 
the advantages of the MLPA technique is that the required equipment, a thermal cycler 
with heated lid and sequence type electrophoresis equipment, was already present in our 
laboratories. 
To perform a case-control study on multiple defensin genes we employed the SALSA 
P139 Defensin kit developed by MRC-Holland. This kit contained 44 different probes 
for defensins present in multiple copy number, defensins present in single copy per ap-
loid genome, other genes present at the 8p23 locus and control probes. 
The genes we were interested in studying were particularly those that are present in 
multiple copy number, namely: DEFA3, DEFA5, DEFA7, DEFB103A, DEFB104, 
DEFB105, DEFB106, DEFB107B, and DEFB108. In the cases of DEFA7, DEFB103A 
and DEFB104 each gene was targeted by two different probes designed to hybridize on 
different exons; this approach increased sensibility of the method for this genes and im-
proved overall copy-number assessment. 
By choosing the MLPA technique we had to face a difficulty related to the design of the 
experiment. In fact MLPA is especially suitable to study gross deletions or insertions 
like deletions in tumor tissues or trisomy of the chromosome 21. In those cases the 
technique takes advantage from the fact that a normal control to make a direct compari-
son is always available without significant aberrations. Therefore the data analysis 
software is able to easily discriminate between a normal sample, that is comparable to 
the control, and an affected individual in which the electrophoretic profile is signifi-
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cantly different from the control one. Moreover in most cases the quantitative differ-
ences between the healthy subject and the affected patient are in the 50% range, mean-
ing a loss of heterozygosity or a gene duplication, while discriminating, for example, 
between a sample with 9 copies of a gene and one with 10 copies means that the tech-
nique should be able to discriminate a 10% difference in normalized peak height. 
The case of the defensin cluster is dramatically different since that a “normal individ-
ual” does not exist and that copy number polymorphisms are so polymorphic that 
grouping different samples from the same group leads to exaggerated deviations form 
the average value. 
As a matter of fact, since the Coffalyzer software we used to perform analysis of ex-
perimental data (available for free download at the www.mlpa.com site) requires a con-
trol group and a case group to complete its analysis, our first approach was to perform 
pairwise comparisons using the three groups our cohort was divided into. 
Unfortunately such approach soon showed its statistical limits: elevated deviations from 
the mean value made all statistical approaches virtually fruitless. 
One direct solution would have be to find a subject that had only two copies per diploid 
genome of most of the studied genes and four copies per diploid genome of those genes 
that are usually duplicated. (Several defensin genes probes gave an unusually high sig-
nal when tested by MRC-Holland. Therefore, in order to have similar peak height for 
most of the probes when analyzing a mixture of DNA samples from healthy controls, 
they deliberately reduced the probe signal for some of these defensin probes by addic-
tion of competitor oligomers). In this case this subject’s DNA would have served as the 
control group and all others subjects would have been compared to it. 
While such a subject, although rare, could exist –and we effectively found one of them 
later in the study- the great difficulty was to find it without actually having the possibil-
ity to check it with MLPA, since no analysis could be done on the Coffalyzer software 
without a control group of at least five runs and that final copy-number estimation 
largely depends on the quality of the control group itself. 
Direct visual analysis of the electropherogram profile, as suggested by the kit producer, 
was even not an option. In fact this method could effectively work in the case of large 
deletions or duplications, but was unsuitable to discriminate such a fine copy-number 
polymorphisms as the ones we were interested to. Besides, automatic data analysis with 
the Coffalyzer software gave the opportunity to normalize the peak heights in order to 
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minimize the bias due to the fact that shorter fragments are preferentially amplified in a 
multiplex reaction. Moreover it gave the opportunity to do a strict quality check based 
on the control probes and the ligation-indipendent probes included in the assay. 
The only viable solution was to literally create a normal DNA similar to the one de-
tailed above. Our idea has been to create one recombinant plasmide for each probe pre-
sent in the SALSA P-139 Defensin kit. A precious help in this direction come directly 
from the MRC-Holland support that supplied us the complete sequences that are recog-
nized by the probes for each gene included in the kit. 
As a matter of fact inserting only the ligation site was enough for the probes to detect 
the gene, undergo ligation and be amplified in the following PCR step. 
Our first idea has been to introduce all the sequences in a single vector, but such an ap-
proach would have revealed largely impractical in a lab, like ours, that doesn’t have 
much experience in creating recombinant organisms. 
Therefore the way we followed has been to create 44 different plasmids, each contain-
ing one specific target sequence. To do so we employed specially designed primers, 
with whom we were able to amplify, for each target sequence, a fragment of about 150 
base pairs, flanked on each side by an XhoI restriction site. We then inserted this frag-
ment in a common pGL3 vector and selected the plasmids with only one inserted target 
sequence. Sequence determination has been done with an ABI 3130XL automatic se-
quencer. 
Plasmids were selected to match the probes for genes that are located in single copy 
outside of chromosome 8 and used as controls (IL4, FBN1, PRKCE, CDKN2A, RB1, 
FANCL, RTN4, LMO2 and RENT2), genes located in the 8p23 region and not belonging 
to the defensin family (MFHAS1,CSMD1, ANGPT2, BLK, GATA4, MSRA, TNKS, 
PPP1R3B and four different probes for MSR) defensins genes that occur in two copies 
per diploid genome: (DEFA4, DEFA6, DEFB1, and SPAG11 each with two probes di-
rected to different exons, and DEFB4 with only one probe) and finally defensin genes 
that normally present copy-number polymorphism (one plasmid for each of the two 
DEFB103A, DEFFB104 and DEFA7 probes, and one plasmid for each of the probes 
targeted to the DEFA3, DEFA5, DEFB105, DEFB106, DEFB107 and DEFB108 genes. 
An E. Coli strain has been transfected with the different plasmids and, after one night of 
growth at 37°C, amplified plasmid has been purified with a Millipore Plasmid Miniprep 
and the resulting DNA has been spectrophotometrically quantified. 
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Then, equals amounts of DNA for each different plasmid have been pooled to generate 
our standard DNA mix. 
In silico analysis of the pGL3 plasmid sequence showed that none of the target se-
quences were present before recombination. 
To confirm the functionality of our synthetic control we performed a standard MLPA 
reaction on each selected recombinant plasmid, on the resulting pool and on the native 
pGL3 plasmid and visually examined the resulting chromatograms. As expected, each 
plasmid gave a single peak at different positions, while the mix with pooled plasmids 
contained all the characteristic peaks and the native pGL3 only showed the ligation-
indipendent peaks usually used as an internal control during the Coffalyzer data analy-
sis. 
Notwithstanding the fact that our synthetic mixture proved to be quite reliable, as soon 
as we found an individual that had only two copies of each defensin gene we turned to 
use this individual as the standard control and we repeated the analysis that had been 
done with the synthetic control DNA. 
Estimation of copy-number for each gene has been performed by rounding the ratio cal-
culated by the Coffalyzer software to the nearest integer. Data obtained this way were 
then employed to perform comparison of the copy number distributions among the dif-
ferent studied groups. 
To do so we could not rely on standard t-test, since statistical distributions of copy-
number polymorphisms are inherently non-normal. Indeed, due to the fact that lower 
values were limited to 0, distributions were, at best, skewed to the right and, in the 
worst cases, not complying any common distribution descriptions. 
That was the case, for example of the distributions of the copy numbers of the DEFA3 
that was lacking, as described (Linzmeier et al., 1999, Gene, 233, 205-11), in about 
10% of the population. 
We therefore employed a non-parametrical approach to the problem, using Wilcoxon 
rank-sum test. The Wilcoxon rank-sum test is a non-parametric test for assessing 
whether two samples of observations come from the same distribution. The null hy-
pothesis is that the two samples are drawn from a single population, and therefore that 
their probability distributions are equal. It requires the two samples to be independent, 
and the observations to be ordinal or continuous measurements. More generally, the 
Wilcoxon rank-sum test may be thought of as testing the null hypothesis that the prob-
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ability of an observation from one population exceeding an observation from the second 
population is equal to 0.05. 
Following this approach we have been able to contemporarily analyze the number of 
genes present for diploid genome of the following defensin genes: DEFA3, DEFA4, 
DEFA5, DEFA6, DEFA7, DEFB1, DEFB4, DEFB103A, DEFB104, DEFB105, 
DEFB106, DEFB107B, DEFB108 and SPAG11, in order to investigate the correlation 
between gene copy number and HIV vertical transmission. 
In our results the genes DEFA4, DEFA5, DEFA6, DEFB1, DEFB4, DEFB107B, 
DEFB108 and SPAG11 are always present in two copies per diploid genome in healthy 
control, HIV-1 positive subjects and exposed uninfected children. 
This subset of the collected data confirms the evidence drawn so far about the fact that 
those genes are present in single copy per haploid genome in the human race and there-
fore have not being further analyzed in this experiment. 
The other studied genes, namely DEFA3, DEFA7, DEFB1, DEFB4, DEFB103A, 
DEFB104, DEFB105, DEFB106, and DEFB107B, on the contrary, were found to be 
present in multiple copy number in the three examined groups and the number of copies 
varied significantly among different individuals, thus justifying our hypothesis that dif-
ferences on the number of copies of the defensin genes present in the genome could be 
responsible for differential response to HIV-1 infection and vertical transmission. 
Data on the average number of copies present and the range of copies at which each 
gene appear are reported on table 4. 
We were able to show that the average number of copies of the DEFB104 gene, coding 
for the protein hBD-4, was significantly lower in HIV positive children when compared 
with exposed uninfected children (corrected p-value 0.006), with an average number of 
copies of 3.54 and 4.49 per diploid genome, respectively, with comparable range. Con-
fronting HIV-1 positive children with healthy controls evidenced a similar trend (3.54 
vs. 4.28 copies per diploid genome) that however didn’t reach statistical significance 
after Bonferroni correction. 
No significant differences could be evidenced among the studied groups for any of the 
other studied genes. 
Copy-number assessment for the DEFB104 gene was then repeated with a method 
based on quantitative real-time PCR, as reported by Chen et al. (Chen et al., 2006) and 
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we found that results were comparable to the ones obtained with MLPA (data not 
shown), confirming the reported differences. 
 
Table 4 Average (and range) of gene copy number of HIV positive children, ex-
posed-uninfected children and healthy controls 
 Healthy Controls Exposed-Uninfected HIV Positive 
DEFA3 2.44±2.38 (0-8) 3.3±2.77 (0-9) 3.94±3.67 (0-10) 
DEFA7 3.78±1.25 (2-6) 3.67±1.13 (3-5) 3.58±1.20 (2-6) 
DEFB4 3.78±1.1 (2-6) 4.87±1.56 (2-7) 4.14±2.13 (1-9) 
DEFB103A 4.62±1.04 (3-7) 4.48±1.07 (4-8) 4.55±1.57 (2-9) 
DEFB104 4.28±0.71 (2-5) 4.49±0.72 (4-7) 3.54±1.07 (2-7) 
DEFB105 6.05±1.52 (3-9) 5.78±1.29 (2-4) 5.44±1.53 (2-9) 
DEFB106 3.78±0.79 (2-6) 3.67±0.56 (3-5) 3.58±1.13 (2-6) 
 
Our results showed that the DEFB104 gene is present with reduced number of copies in 
children that were infected during delivery, when confronted with healthy controls and 
children that were exposed to the virus but didn’t contract infection. While the role of 
some #-defensin (like hBD1, 2 and 3) in HIV infection has been quite widely investi-
gated (Klotman and Chang, 2006), only few data concerning hBD-4 are available. 
Interestingly, DEFB104 expression has already been reported in the female reproductive 
tract (King et al., 2003); we can hypothesize that hBD-4 could directly interact with vi-
ral membranes destabilizing them in a way similar to that reported for hBD-2 and hBD-
3 (Quinones-Mateu et al., 2003), and that the expression of hBD-4 directly correlates to 
the number of gene repetition as reported for DEFA1 and DEFA3 (Linzmeier and Ganz, 
2005) and DEFB4 (Hollox et al., 2003); our results, that the copy number of the 
DEFB104 gene are lower in HIV positive children when compared with exposed unin-
fected children and healthy controls, suggest that  this gene is involved in protecting 
from HIV infection and that concentration of hBD4 in the female reproductive tract 
may influence HIV-1 susceptibility to infection, possibly by direct interaction with 
HIV-1. 
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 In our studied model, of course, genotype of the mothers, that is partly reflected on the 
child genotype that we studied, will be the real marker of susceptibility. 
Unfortunately, clinical follow-up of the mothers couldn’t be performed as most of the 
patients didn’t return to the hospital after the first consult for medical treatment. There-
fore we lack mothers’ biological sample to perform a comparative study. 
Although we weren’t able to evidence any correlation between HIV-1 infection and ver-
tical transmission with any other studied gene, and despite the limited number of ana-
lyzed samples, we were able to evidence that copy-number polymorphisms of defensin 
genes at the 8p23 locus can influence susceptibility in mother to child transmission of 
HIV-1. 
 
Lactoferrin gene (LTF) polymorphisms in HIV-1 vertical transmission 
and infection 
Because of the biological functions of lactoferrin, polymorphisms in the lactoferrin gene 
could be an important factor in genetic susceptibility to environmental insults and dis-
eases.  
More than 60 SNPs have been identified in the lactoferrin gene, either in the promoter 
region, exons or introns (Teng and Gladwell, 2006). 
A single-point A/G nucleotide variation causing a non-conservative threonine/alanine 
substitution at position 11 (T11A) of the secreted lactoferrin protein has been associated 
with aggressive periodontitis (Jordan et al., 2005). 
A Lysine/Arginine polymorphism at position 29 (R29K) in the N-terminal region of 
human lactoferrin that results from a single nucleotide polymorphism in exon 2 of the 
human lactoferrin gene has been associated with juvenile periodontitis, suggesting that 
lactoferrin R29K allelic variants are functionally different and that these differences 
may contribute to the pathogenesis of localized juvenile periodontitis (Velliyagounder 
et al., 2003). 
Thus we decided to genotype T11A and R29K SNPs in our HIV samples, to asses if 
they may play a role in susceptibility to HIV infection or not. Genotyping results are 
reported in table 5; all groups were in Hardy-Weinberg equilibrium for both the investi-
gated SNPs. Our results show no significant differences in allelic or genotype frequency 
for the T11A polymorphism. 
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Conversely, our results show that the frequencies of the R29K polymorphism are sig-
nificantly different when comparing the HIV-1 infected children group with the healthy 
controls group. 
 
Table 5 Alleles and genotypes count (and frequency) of the T11A and R29K poly-
morphisms in the LTF gene in HIV-1 positive children, exposed-uninfected children 
and healthy controls. 
 Healthy Controls Exposed-Uninfected HIV Positive 
SNP  T11A 
   
A 110 (0.57) 90 (0.63) 251 (0.65) 
G 82 (0.43) 54 (0.37) 133 (0.35) 
A/A 30 (0.31) 27 (0.37) 84 (0.44) 
A/G 50 (0.52) 36 (0.50) 83 (0.43) 
G/G 16 (0.17) 9 (0.13) 25 (0.13) 
SNP  R29K 
   
G 120 (0.63) 92 (0.64) 289 (0.75) 
A 72 (0.37) 52 (0.36) 95 (0.25) 
G/G 36 (0.37) 25 (0.35) 105 (0.55) 
G/A 48 (0.50) 42 (0.58) 79 (0.41) 
A/A 12 (0.13) 5 (0.07) 8 (0.04) 
 
The R29K GG genotype was significantly more frequent in HIV positive subjects 
(55%) when compared to healthy controls (37%) with a p-value, corrected for multiple 
comparisons with the Bonferroni method, equal to 0.0216. 
Allelic frequencies were also significantly different (corrected p-value equal to 0.0108) 
being the G allele present in 75% of HIV infected children and only in 63% of healthy 
controls. The presence of the G allele is associated to an increased susceptibility to HIV 
infection (O.R. = 1.8233, with a 95% confidence interval of 1.23-2.69. 
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Differences between HIV-1 positive children and exposed uninfected children, albeit 
not significant, are nevertheless evident, with the frequencies of the latter group more 
resembling the ones of the healthy control group. 
We then performed haplotype analysis, employing the Arlequin software; haplotypes 
frequencies are reported on table 6. 
 
Table 6 Haplotypes frequency of the T11A/ R29K polymorphisms in HIV-1 posi-
tive children, exposed-uninfected children and healthy controls. 
 Healthy Controls Exposed-Uninfected HIV Positive 
Haplotype    
AG 0.393 0.501 0.589 
GG 0.232 0.138 0.164 
AA 0.180 0.124 0.065 
GA 0.195 0.237 0.182 
    
L.D. 0.16 0.44 0.59 
 
Our results evidence that the AG haplotype is strongly associated to increased suscepti-
bility to HIV-1 infection, being significantly more frequent in HIV positive children 
(59%) than in healthy controls (39%) (corrected p-value 0.0048).  
This fact, coupled to the evidence that the linkage disequilibrium value was greater for 
the HIV-1 positive group, indicates that the two SNPs probably cooperate in determin-
ing mature lactoferrin influence on susceptibility to HIV-1 infection. 
Lactoferrin has been demonstrated to have a direct antiviral effect and it has also been 
reported to be active against HIV-1 (Harmsen et al., 1995). Moreover interactions be-
tween lactoferrin and HIV-1 particles have been reported, with regions of the protein 
containing a cluster of negative charges between residues 210-240 that have been 
shown to interact with the positively charged domains in the V3 loop of the viral enve-
lope protein gp12 (Swart et al., 1998).  
  
101 
Thus, lactoferrin seems to exert its effect in the early phase of infection, inhibiting viral 
replication at the level of virus adsorption and penetration, probably during virus-cell 
fusion. 
The antiviral activity of lactoferrin in HIV infection has already been tested (Berkhout 
et al., 2002): bovine lactoferrin was able to completely impede infection spreading at a 
concentration of 10 µM and a considerable inhibition of virus replication was observed 
at concentration as low as 0.1 µM. Since it was suggested that lactoferrin, apart from its 
interaction with the V3 loop, could possibly inhibit virus-cell interaction through com-
petitive binding to the CXCR4 and CCR5 coreceptors, the antiviral activity of lactofer-
rin against HIV-1 variants with different V3 domains and co-receptor usage was tested. 
Bovine lactoferrin was able to inhibit various HIV-1 strains that use the CXCR4 and 
CCR5 co-receptor, confirming the broad activity spectrum of lactoferrin (Moriuchi and 
Moriuchi, 2001). Therefore is plausible to suppose that polymorphisms that can influ-
ence both protein expression and activity could influence susceptibility to HIV-1 infec-
tion. 
Moreover, Lactoferrin has been known for a long time to be expressed in the female 
reproductive tract; thus, its antiviral activity against HIV can be exerted at this level as 
well, suggesting that lactoferrin can be implicated in mother-to-child transmission of 
infection.  
In our work we have evidenced that the G allele (and GG genotype) of the R29K poly-
morphism is more frequent in HIV positive children than healthy controls, suggesting 
that the presence of the G allele increases the susceptibility to be infected by the HIV-1 
virus during delivery. This association between R29K G allele and augmented suscepti-
bility to HIV-1 infection was also confirmed by Haplotype analysis. 
The A allele of the R29K polymorphism (corresponding to the Lysine) has been previ-
ously described to increase lactoferrin’s activity against a number of Gram-positive and 
Gram-negative microorganisms (Velliyagounder et al., 2003). Furthermore, in the same 
study, the A allele has been observed to be transcribed more efficiently than the G al-
lele, leading to increased protein expression.  
In our case, differences in both protein expression and functional activity as conse-
quence of the presence of different allelic variants, could modify the way in which the 
lactoferrin protein is able to contrast HIV-1 infection and thus promote or demote host 
infection. More in details, the increased frequency of the G allele in HIV positive sub-
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ject can account for a less effective lactoferrin in facing HIV infection thus explaning 
why carrying this SNP is associated to an increased risk of being  infected. 
Concluding, in this work we presented, for the first time, evidences that functional po-
lymorphisms of the LTF gene are able to influence the receptiveness to HIV-1 infection. 
 
hCAP-18 gene analysis 
On the second cohort we performed a screening on the entire hCAP-18 gene, coding for 
the LL37 human cathelicidin. 
The hCAP-18 is located on chromosome 3 and is composed of 4 exons that span a re-
gion of about 2 kb. We amplified all the four exons with specific PCR reactions and 
then search for mutations in hCAP-18 gene by direct sequencing with the ABI3130XL 
automatic sequencer.  
Our approach was based on the fact that, so far, no polymorphisms have been described 
in the hCAP-18 coding sequence, therefore impeding us to use more direct techniques. 
We genotyped 96 random samples and we found no mutations, except for a single syn-
onymous mutation in one of the healthy controls sample: a G to C transversion in posi-
tion 78 of the translated sequence. However, due to the rarity of the mutation we didn’t 
investigate it further. 
To improve the study on the hCAP-18 sequence we further designed two pairs of prim-
ers to detect mutations in the promoter and 5’UTR region of the gene. That allowed us 
to study 700 base pairs of promoter region and the full 140 base pairs of 5’ UTR region. 
The two resulting overlapping amplicons were screened by direct sequencing in 96 ran-
dom samples extracted from our second collection. 
We were able to identify two undescribed mutations: a T to A transversion in position -
491 and a G to A transition in position -350. 
The -491(T/A) mutation was detected in a sample drawn from the HIV-1 positive 
group, while the -350(G/A) mutation was observed in a sample belonging to the healthy 
controls group. 
In both cases the frequency of the mutation was so low that further studied would have 
been statistically irrelevant unless a much larger number of samples could be studied. 
Therefore we decided not to go on with the investigation on the cathelicidin gene. 
  
103 
Such a strict conservation that we observed both in the coding sequence and in the pro-
moter region, impaired all our efforts to perform a case-control study based on poly-
morphisms but nonetheless suggest an important role for LL37 in humans. 
It should be noted that our negative results don’t necessarily imply that variations of 
LL37 expression are not involved in the event of HIV-1 infection and vertical transmis-
sion as a direct effect on lentiviral infection has already been proved (Steinstraesser et 
al., 2005). 
MBL2 and MASP-2 polymorphisms in HIV-1 vertical transmission 
and infection 
In order to further increase our knowledge about the role of innate immunity on HIV-1 
infection we decided to genotype functional polymorphisms of the MBL2 gene. 
MBL deficiency, largely explained by three single point mutations in codons 52, 54 and 
57 of exon 1 in the MBL2 gene (Turner, 1996) could, in fact, greatly impair the activity 
of innate immunity. 
Since these three polymorphisms share a common functional effect, therefore we em-
ployed the melting temperature assay technique to contemporarily genotype them. Our 
methodology has the drawback of not permitting to discern which mutation is actually 
present in a sample, giving us only the possibility to know if there is one present. How-
ever the methodology is cheap and fast and is able to correctly pinpoint any functional 
impairment of MBL. On the basis of the melting temperature assay results we were able 
to tell if a sample was wild-type for the three polymorphisms of the first exon (A/A 
genotype), if there were any mutation in heterozygous form (A/0 genotype) or if there 
was any of the three mutation in homozygous form (0/0 genotype). 
Composite heterozygous samples, presenting two alleles with distinct polymorphisms, 
could also be detected and, due to the functional effect of this genotype, were treated as 
0/0 samples in the analysis. 
Furthermore, three polymorphisms in the promoter region of MBL2 are also responsible 
for reduced expression of the MBL protein: the H/L, X/Y and P/Q allele at positions 
$550, $221 and +4 of the MBL gene.  
These promoter polymorphisms combine to form haplotypes that are in strong linkage 
disequilibrium with the exon 1 mutations, resulting in seven common extended haplo-
types, namely HYPA, LYPA, LYQA, LXPA, HYPD, LYPB and LYQC. 
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Table 7 Alleles and genotypes count (and frequency) of polymorphisms in the first 
exon and in the promoter of the MBL2 gene in HIV-1 positive children, exposed-
uninfected children and healthy controls. 
 Healthy Controls Exposed-Uninfected HIV Positive 
Exon-1 A/0 SNP 
   
A 155 (0.81) 118 (0.82) 305 (0.79) 
0 37 (0.19) 26 (0.18) 79 (0.21) 
A/A 62 (0.65) 48 (0.67) 120 (0.62) 
A/0 31 (0.32) 23 (0.32) 65 (0.34) 
0/0 3 (0.03) 1 (0.01) 7 (0.04) 
Prom. X/Y SNP 
   
X 62 (0.32) 36 (0.25) 107 (0.28) 
Y 130 (0.68) 108 (0.75) 277 (0.72) 
X/X 14 (0.15) 3 (0.04) 14 (0.07) 
X/Y 34 (0.35) 31 (0.43) 79 (0.41) 
Y/Y 48 (0.50) 38 (0.53) 99 (0.52) 
Prom. H/L SNP 
   
H 54 (0.28) 46 (0.32) 116 (0.30) 
L 138 (0.72) 98 (0.68) 268 (0.70) 
H/H 9 (0.09) 3 (0.04) 19 (0.10) 
H/L 36 (0.38) 40 (0.56) 78 (0.41) 
L/L 51 (0.53) 39 (0.40) 95 (0.49) 
 
We studied the H/L and the X/Y variants by the means of real-time detected allele spe-
cific PCR, while we decided not to study the P/Q variant due to the scarce functional 
effect of this polymorphism. Results of MBL2 genotyping are summarized in table 7. 
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No statistical differences could be evidenced by the means of Fisher exact test when 
confronting genomic and allelic frequencies in the different groups, thus essentially 
confirming negative results already reported in literature and pointing on the absence of 
correlation between MBL polymorphisms and HIV-1 infection (Malik et al., 2003; 
McBride et al., 1998; Senaldi et al., 1995). 
Nevertheless there’s a small but noticeable trend pointing that exposed-uninfected chil-
dren are characterized by lower frequencies of the X/X and L/L genotypes, both marked 
by reduced expression of MBL. This effect could be biased by the fact that the exposed-
uninfected group is not very large, but notwithstanding this it could suggest that im-
paired levels of plasma MBL favors HIV-1 infection. 
It should however be noted that the negative results of Malik (2003) and McBride 
(McBride et al., 1998) were obtaind on groups that are considerably smaller than the 
one we studied, besides being performed on populations characterized by distinct ge-
netic background from the Brazilian population we studied. 
Therefore we couldn’t exclude that a study on larger populations or a meta-analysis of 
data could confirm the negative effect of the L and X alleles on HIV-1 infection. How-
ever this putative effect, that was already described (Boniotto et al., 2000), would 
clearly be too faint to cover any clinical relevance. 
Furthermore, none of the previous studies took into consideration the fact that MBL, 
even in high plasma concentrations, could not be totally functional if mutations on its 
associated serine proteases are present. 
 We therefore genotyped two functional polymorphisms in one of the most important 
Mannose Associated Serine Proteases: MASP2. 
The D105G mutation wasn’t detected in any but three samples and was no further con-
siderated.  
 
Rs12711521 (D371Y) SNP genotyping results are reported in table 8.  
Once again we weren’t able to detect any significant difference among the groups and 
we only found a weak trend (uncorrected p-value equal to 0.062) when confronting the 
allele frequencies of HIV-1 patients whit exposed-uninfected children, suggesting a 
feeble protective effect for the C allele. 
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Table 8 Alleles and genotypes count (and frequency) of D371Y polymorphisms in 
the MASP2 gene in HIV-1 positive children, exposed-uninfected children and 
healthy controls. 
 Healthy Controls HIV-1 positive Exposed-Uninfected 
D371Y  SNP 
   
A 103 (0.54) 227 (0.59) 72 (0.50) 
C 89 (0.46) 157 (0.41) 72 (0.50) 
A/A 26 (0.27) 69 (0.36) 18 (0.25) 
A/C 51 (0.53) 89 (0.46) 36 (0.50) 
C/C 19 (0.20) 34 (0.18) 18 (0.25) 
 
We then moved to perform haplotype analysis of the polymorphisms we found in the 
MBL2 genes 
We found that only 5 out of 8 possible haplotypes were significantly managed by the 
Arlequin software: LYA, HYA, LXA, LY0 and HY0; haplotypic frequencies for the 
various group are evidenced in figure 18; haplotype distributions are quite dissimilar 
between the analyzed groups. 
If we group together the LYA and HYA haplotypes, associated to higher production of 
MBL and the LXA, LY0 and HY0 haplotypes, associated to low or medium-low protein 
expression we could find, via a 2X2 contingency table treated with Fisher test that the 
haplotypes with high expression are significantly more present in the exposed unin-
fected children when compared to the healthy controls and HIV-1 infected childred 
(Bonferroni corrected p-value <0.001 in both cases), while the percentages of high pro-
ducers and low producers are similar between healthy controls and HIV-1 positive chil-
dren. 
This data virtually confirms the trends we observed in genotype frequencies about the 
H/L and the X/Y variants and points toward a role for high levels of plasma MBL in 
protecting from HIV-1 vertical transmission in Brazilian children. 
Moreover, in order to better clarify the role played by polymorphisms in the MBL gene, 
and to have a general picture of the phenomenon we then computed MBL combined 
genotypes considering both exon-1 and promoter variants.  
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Figure 16 Haplotype frequency of MBL2 gene promoter and exon-1 polymor-
phisms in HIV-1 positive children, exposed-uninfected children and healthy con-
trols. 
 
Resulting genotypes were than ranked in three classes according to MBL production as 
High (HP), Low (LP) and Deficient (DP).  
MBL HP genotype was significantly more frequent in Exposed uninfected children than 
in healthy controls and HIV-1 patients (p.value <0.001)  
HIV positive children present the higher frequency of Deficient producer genotypes 
(18,5% vs. 10% and 14% in healthy controls and exposed-uninfected children respec-
tively.) 
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Table 9 Frequency of MBL2 promoter and exon-1 combined genotype ranked ac-
cording to MBL production in HIV-1 positive children, exposed-uninfected children 
and healthy controls. 
 
Healthy 
Controls 
Exposed-
Uninfected 
HIV  
Positive 
 MBL2 promoter and exon- 1 combined genotypes  
 
 
High producer  
(HP) 
HYA/HYA 
HYA/LYA 
HYA/LXA 
LYA/LXA 
0.49 0.63 0.555 
Low producer  
(LP) 
X
HYA/0 
LYA/0 
0.41 0.23 0.26 
 
 
 
defective 
Deficient producer  
(DP) 
 
LXA/0 
0/0 
 
0.10 0.14 0.185 
  
Our data shows that, even if single polymorphisms in the MBL2 gene don’t affect di-
rectly HIV infection, acting synergistically they can influence protein expression levels 
and account for HIV susceptibility. Higher levels of the protein (as expected as a result 
of the presence of high producer combined genotypes) are associated to  protection 
against HIV infections, while low levels confer susceptibility.  
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CONCLUSIONS 
 
 
 
 
 
 
 
 
This study has been performed in order to characterize genetic factors implicated in the 
susceptibility to HIV infection and vertical transmission. 
Different genes involved in the innate immune system have been analyzed in Brazilian 
pediatric population constituted by three groups: HIV infected children, children who 
didn’t contract the infection but were exposed to the same risk conditions of the infected 
ones, and healthy controls that were nor infected nor exposed. 
For several of the investigated genes, an involvement in disease susceptibility has been 
found. 
The first gene of the innate immunity found to be associated to HIV infection was 
DEFB1, a gene encoding for hBD-1, a human ß-defensin constitutively expressed by 
many epithelia.  
We identified three polymorphism in the 5’UTR of the gene at position -52, -44 and -
20, that display different frequencies within the three groups analyzed. 
The -44 C allele and CC genotype were over-represented in the HIV-1 infected group, 
thus pointing toward a protective effect for the -44 G allele both in vertical transmission 
and in infection by HIV-1 virus. However this correlation for the -44(C/G) DEFB1 
polymorphism appeared quite weak.   
On the other hand, we were able to demonstrate that the DEFB1 -52A/A genotype was 
significantly less frequent in HIV-1 perinatally infected children when compared to 
healthy controls and exposed uninfected children. 
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Finally, the stronger and more striking association has been observed considering the -
20 (G/A) polymorphism, where allelic and genotype frequency were significantly dif-
ferent between HIV-1 positive children, healthy controls and exposed uninfected chil-
dren. The results obtained show that carrying the -20 G allele infers protection from 
vertical transmission of HIV-1, while a greater susceptibility was observed in patients 
carrying the -20 A allele.  
Our results thus evidenced how DEFB1 gene could be employed as a marker of risk in 
infection and vertical transmission of HIV-1. 
Since the functional role of these polymorphisms was unknown, we performed a dual 
luciferase assay with the aim of to verifying if different alleles may have distinctive 
translational effects.  
Our results showed that all the studied polymorphisms do have a functional effect. Ex-
pression levels of the reporter gene were sensibly reduced in all cases where a SNP was 
present.   
Notwithstanding the fact that all polymorphisms were diminishing the luciferase ex-
pression, only the -44 G alleles was able to reduce the expression of the reporter gene to 
statistically significant levels.  
Our in vitro results suggest that all the studied polymorphisms can be able to hamper an 
effective production of hBD-1 in vivo and, therefore, they can be related to a lack of 
proper response from the innate immunity, thus pinpointing the important role of this 
defense system in HIV infection. 
In addition to their role in this particular viral infection, our results indicate that these 
SNPs should be analyzed in other infectious and inflammatory pathologies as well to 
seek for linkage disequilibrium with the illness. 
In our work we also investigated for the first time if gene copy number polymorphisms 
of defensins genes could be related to HIV infection. 
Interestingly, we were able to show that the average number of copies of the DEFB104 
gene, coding for the protein hBD-4, was significantly lower in HIV positive children 
when compared with exposed uninfected subjects. Confronting HIV-1 positive children 
with healthy controls we evidenced a similar trend.  
Hypothesizing that hBD-4 could directly interact with viral membranes similarly to 
hBD-2 and hBD-3 and that its expression correlates to the number of gene repetition as 
reported for DEFA1, DEFA3 and DEFB4, our results suggest that DEFB104 gene copy 
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number polymorphisms are involved in protecting from HIV infection and that concen-
tration of hBD4 in the female reproductive tract may influence HIV-1 susceptibility to 
infection. 
Lactoferrin is a molecule that has already been demonstrated to have a direct antiviral 
effect and to be active against HIV. When analyzing its coding gene, we found a poly-
morphism (namely R29K) that reveals a possible involvement in HIV infection. In fact 
we evidenced that the G allele (and GG genotype) of the R29K polymorphism is more 
frequent in HIV positive children than healthy controls, suggesting that the presence of 
the G allele increases the susceptibility to be infected by the HIV virus during delivery. 
This association between R29K G allele and augmented susceptibility to HIV infection 
was also confirmed by Haplotype analysis. Since the presence of this SNP can influence 
both protein expression and functionality and since lactoferrin has been known for a 
long time to be expressed in the female reproductive tract, we hypothesize that lactofer-
rin can be implicated in mother-to-child transmission of infection.  
Analyzing all the coding region and the promoter of the gene coding for LL37, allowed 
us to recognize strong nucleotide conservation. Indeed only a couple of SNPs were 
identified in a very restricted number of samples, thus precluding their suitability for 
association studies. The strong conservation we observed both in the coding sequence 
and in the promoter region suggest an important role for LL37 in host defense.  
MBL is an important molecule of the innate immune system; the understanding of its 
function has grown rapidly over the past three decades. It is now recognized to have a 
role in different processes, as complement activation, promotion of complement-
independent opsonophagocytosis, modulation of inflammation, recognition of altered 
self-structures and apoptotic cell clearance. 
We analyzed polymorphisms in the promoter region and in the first exon of the gene 
that are known to affect protein expression levels and that has already been associated 
to many diseases. While we found no significant data considering the single polymor-
phisms, when we compute combined genotype and ranked them in three classes accord-
ing to MBL resulting production as High (HP), Low (LP) and Deficient (DP), we found 
that MBL HP genotypes were significantly more frequent in exposed uninfected chil-
dren than in healthy controls and HIV-1 patients, whereas HIV positive children present 
the greatest frequency of DP genotypes. 
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Our data show that, even if single polymorphisms in the MBL2 gene don’t affect di-
rectly HIV infection, acting synergistically they can influence protein expression levels 
and account for HIV susceptibility. Higher levels of the protein (as expected as a result 
of the presence of high producer combined genotypes) are associated to protection 
against HIV infections, while low levels confer susceptibility. 
 
Identifying the genetic factors involved in such a complex disease as HIV infection is 
quite a troublesome challenge and association studies have some well known limita-
tions. One of the major drawback of this entire thesis work has been, of course, the lack 
of mothers biological samples and, as a consequence, their genetic data. In fact, it’s 
plausible that vertical transmission could be also influenced by mother’s genetical back-
ground.  
Despite all, with our work we have been able to highlight the role of innate immunity 
and many host defense genes in conferring susceptibility or protection towards HIV in-
fection, thus stressing up, once again, the pivotal function of this branch of the immune 
system.  
  
113 
ACKNOWLEDGMENTS 
 
 
 
 
 
 
Fare un dottorato non è una cosa che si può fare da soli. E non lo si può fare a cuor leg-
gero. I tre anni appena trascorsi sono stati molto intensi, sia dal punto di vista scientifico 
che, soprattutto, dal punto di vista umano. 
E’ pertanto inevitabile che i miei ringraziamenti vadano a tutti quelli che in questo pe-
riodo mi sono stati vicino e che han capito quando era meglio non farlo. 
Innanzitutto ringrazio Sergio, che mi ha insegnato molto più di quello che era tenuto ad 
insegnarmi. 
Poi Valentina, Ludovica e Camilla che, chi meglio e chi peggio, son riuscite a soppor-
tarmi nei miei alterni umori. E che se non hanno capito hanno almeno fatto finta di stare 
ad ascoltarmi. 
Marco, perché lui sì che ha capito tutto, e Üalter per non averci neppure provato; en-
trambi sono molto più che impagabili compagni di bevute. 
Non sarò mai troppo grato al Brasile per le persone che mi ha fatto incontrare e per a-
vermi fatto assaporare la loro visione del mondo: Lula, Zé Luis, Lucas e Raphael, tutti 
gli abitanti della Pousada Alquimia ed il cameriere taciturno della San Francisco. 
Loris per i giri in moto, e tutti gli amici motociclisti lasciati a Trieste mentre la Eva 
dorme in garage. 
Grazie anche alla mia famiglia, per esserci sempre: grazie ai miei genitori, ai miei zii, a 
mio cugino e alla sua famiglia. 
 
Avervi vicino ha reso questi anni un vero spettacolo. 
 
  
114 
 
REFERENCES 
 
 
 
 
 
 
 
Agerberth, B, et al. (1995), 'FALL-39, a putative human peptide antibiotic, is cysteine-
free and expressed in bone marrow and testis.', Proc Natl Acad Sci U S A, 92 (1), 
195-99. 
Agerberth, B, et al. (2000), 'The human antimicrobial and chemotactic peptides LL-37 
and alpha-defensins are expressed by specific lymphocyte and monocyte popula-
tions.', Blood, 96 (9), 3086-93. 
Ahmad, R, et al. (2002), 'Elevated levels of circulating interleukin-18 in human immu-
nodeficiency virus-infected individuals: role of peripheral blood mononuclear 
cells and implications for AIDS pathogenesis.', J Virol, 76 (24), 12448-56. 
Aldred, PM, EJ Hollox, and JA Armour (2005), 'Copy number polymorphism and 
expression level variation of the human alpha-defensin genes DEFA1 and 
DEFA3.', Hum Mol Genet, 14 (14), 2045-52. 
Alkhatib, G, et al. (1996), 'CC CKR5: a RANTES, MIP-1alpha, MIP-1beta receptor as a 
fusion cofactor for macrophage-tropic HIV-1.', Science, 272 (5270), 1955-58. 
Alison, AC (1954), 'Protection afforded by sickle-cell trait against subtertian malareal 
infection.', Br Med J, 1 (4857), 290-94. 
Alves-Silva, J, et al. (2000), 'The ancestry of Brazilian mtDNA lineages.', Am J Hum 
Genet, 67 (2), 444-61. 
Amoroso, A, et al. (1999), 'Polymorphism at codon 54 of mannose-binding protein gene 
influences AIDS progression but not HIV infection in exposed children.', AIDS, 
13 (7), 863-64. 
An, P, et al. (2002), 'Modulating influence on HIV/AIDS by interacting RANTES gene 
variants.', Proc Natl Acad Sci U S A, 99 (15), 10002-07. 
  
115 
Appelmelk, BJ, et al. (1994), 'Lactoferrin is a lipid A-binding protein.', Infect Immun, 
62 (6), 2628-32. 
Arai, T, P Tabona, and JA Summerfield (1993), 'Human mannose-binding protein gene 
is regulated by interleukins, dexamethasone and heat shock.', Q J Med, 86 (9), 
575-82. 
Arnold, RR, MF Cole, and JR McGhee (1977), 'A bactericidal effect for human lac-
toferrin.', Science, 197 (4300), 263-65. 
Arnold, RR, M Brewer, and JJ Gauthier (1980), 'Bactericidal activity of human lactofer-
rin: sensitivity of a variety of microorganisms.', Infect Immun, 28 (3), 893-98. 
Arnold, RR, et al. (1981), 'Bactericidal activity of human lactoferrin: influence of 
physical conditions and metabolic state of the target microorganism.', Infect Im-
mun, 32 (2), 655-60. 
Axen, A, et al. (1997), 'Gloverin, an antibacterial protein from the immune hemolymph 
of Hyalophora pupae.', Eur J Biochem, 247 (2), 614-19. 
Bals, R, et al. (1998), 'The peptide antibiotic LL-37/hCAP-18 is expressed in epithelia 
of the human lung where it has broad antimicrobial activity at the airway surface.', 
Proc Natl Acad Sci U S A, 95 (16), 9541-46. 
Bals, R, et al. (1999), 'Augmentation of innate host defense by expression of a 
cathelicidin antimicrobial peptide.', Infect Immun, 67 (11), 6084-89. 
Bals, R (2000), 'Epithelial antimicrobial peptides in host defense against infection.', 
Respir Res, 1 (3), 141-50. 
Barber, JC, et al. (1998), 'Duplication of 8p23.1: a cytogenetic anomaly with no estab-
lished clinical significance.', J Med Genet, 35 (6), 491-96. 
Bateman, A, et al. (1991), 'The effect of HP-1 and related neutrophil granule peptides 
on DNA synthesis in HL60 cells.', Regul Pept, 35 (2), 135-43. 
Bauer, F, et al. (2001), 'Structure determination of human and murine beta-defensins 
reveals structural conservation in the absence of significant sequence similarity.', 
Protein Sci, 10 (12), 2470-79. 
Bellamy, W, et al. (1992), 'Antibacterial spectrum of lactoferricin B, a potent bacteri-
cidal peptide derived from the N-terminal region of bovine lactoferrin.', J Appl 
Bacteriol, 73 (6), 472-79. 
Bellamy, W, et al. (1992), 'Identification of the bactericidal domain of lactoferrin.', Bio-
chim Biophys Acta, 1121 (1-2), 130-36. 
  
116 
Bellamy, WR, et al. (1993), 'Role of cell-binding in the antibacterial mechanism of lac-
toferricin B.', J Appl Bacteriol, 75 (5), 478-84. 
Benjamini, Y and Y Hochberg (1995), 'Controlling the false discovery rate: a practical 
and powerful approach to multiple testing', J R Stat Soc, 57 289-300. 
Bensch, KW, et al. (1995), 'hBD-1: a novel beta-defensin from human plasma.', FEBS 
Lett, 368 (2), 331-35. 
Bergman, P, et al. (2007), 'The antimicrobial peptide LL-37 inhibits HIV-1 replication.', 
Curr HIV Res, 5 (4), 410-15. 
Berkhout, B, et al. (1997), 'Structural and functional analysis of negatively charged milk 
proteins with anti-HIV activity.', AIDS Res Hum Retroviruses, 13 (13), 1101-07. 
Berkhout, B, et al. (2002), 'Characterization of the anti-HIV effects of native lactoferrin 
and other milk proteins and protein-derived peptides.', Antiviral Res, 55 (2), 341-
55. 
Biragyn, A, et al. (2002), 'Toll-like receptor 4-dependent activation of dendritic cells by 
beta-defensin 2.', Science, 298 (5595), 1025-29. 
Bleul, CC, et al. (1996), 'The lymphocyte chemoattractant SDF-1 is a ligand for 
LESTR/fusin and blocks HIV-1 entry.', Nature, 382 (6594), 829-33. 
Boldt, AB and ML Petzl-Erler (2002), 'A new strategy for mannose-binding lectin gene 
haplotyping.', Hum Mutat, 19 (3), 296-306. 
Boman, HG, B Agerberth, and A Boman (1993), 'Mechanisms of action on Escherichia 
coli of cecropin P1 and PR-39, two antibacterial peptides from pig intestine.', In-
fect Immun, 61 (7), 2978-84. 
Boniotto, M, et al. (2000), 'Polymorphisms in the MBL2 promoter correlated with risk 
of HIV-1 vertical transmission and AIDS progression.', Genes Immun, 1 (5), 346-
48. 
Boniotto, M, et al. (2005), 'Evidence of a correlation between mannose binding lectin 
and celiac disease: a model for other autoimmune diseases.', J Mol Med, 83 (4), 
308-15. 
Bortner, CA, RD Miller, and RR Arnold (1986), 'Bactericidal effect of lactoferrin on 
Legionella pneumophila.', Infect Immun, 51 (2), 373-77. 
Bowdish, DM, et al. (2004), 'The human cationic peptide LL-37 induces activation of 
the extracellular signal-regulated kinase and p38 kinase pathways in primary hu-
man monocytes.', J Immunol, 172 (6), 3758-65. 
  
117 
Braida, L, et al. (2004), 'A single-nucleotide polymorphism in the human beta-defensin 
1 gene is associated with HIV-1 infection in Italian children.', AIDS, 18 (11), 
1598-600. 
Brambilla, A, et al. (2000), 'Shorter survival of SDF1-3'A/3'A homozygotes linked to 
CD4+ T cell decrease in advanced human immunodeficiency virus type 1 infec-
tion.', J Infect Dis, 182 (1), 311-15. 
Chaka, W, et al. (1997), 'Induction of TNF-alpha in human peripheral blood mononu-
clear cells by the mannoprotein of Cryptococcus neoformans involves human 
mannose binding protein.', J Immunol, 159 (6), 2979-85. 
Chaly, YV, et al. (2000), 'Neutrophil alpha-defensin human neutrophil peptide modu-
lates cytokine production in human monocytes and adhesion molecule expression 
in endothelial cells.', Eur Cytokine Netw, 11 (2), 257-66. 
Chang, TL, et al. (2003), 'CAF-mediated human immunodeficiency virus (HIV) type 1 
transcriptional inhibition is distinct from alpha-defensin-1 HIV inhibition.', J Vi-
rol, 77 (12), 6777-84. 
Chang, TL, et al. (2005), 'Dual role of alpha-defensin-1 in anti-HIV-1 innate immu-
nity.', J Clin Invest, 115 (3), 765-73. 
Charp, PA, et al. (1988), 'Inhibition of protein kinase C by defensins, antibiotic peptides 
from human neutrophils.', Biochem Pharmacol, 37 (5), 951-56. 
Chen, CB and R Wallis (2004), 'Two mechanisms for mannose-binding protein modula-
tion of the activity of its associated serine proteases.', J Biol Chem, 279 (25), 
26058-65. 
Chen, Q, et al. (2006), 'Screening of copy number polymorphisms in human beta-
defensin genes using modified real-time quantitative PCR.', J Immunol Methods, 
308 (1-2), 231-40. 
Chertov, O, et al. (1996), 'Identification of defensin-1, defensin-2, and 
CAP37/azurocidin as T-cell chemoattractant proteins released from interleukin-8-
stimulated neutrophils.', J Biol Chem, 271 (6), 2935-40. 
Chitnis, SN, DB Kameswari, and KS Prasad (1993), 'Induction of autolysis in starved 
Escherichia coli cells by seminalplasmin, an antimicrobial protein from bovine 
seminal plasma.', FEMS Microbiol Lett, 112 (2), 147-50. 
  
118 
Cowland, JB, AH Johnsen, and N Borregaard (1995), 'hCAP-18, a cathelin/pro-
bactenecin-like protein of human neutrophil specific granules.', FEBS Lett, 368 
(1), 173-76. 
Crouch, SP, KJ Slater, and J Fletcher (1992), 'Regulation of cytokine release from 
mononuclear cells by the iron-binding protein lactoferrin.', Blood, 80 (1), 235-40. 
Daher, KA, ME Selsted, and RI Lehrer (1986), 'Direct inactivation of viruses by human 
granulocyte defensins.', J Virol, 60 (3), 1068-74. 
Davies, EJ, et al. (1997), 'A dysfunctional allele of the mannose binding protein gene 
associates with systemic lupus erythematosus in a Spanish population.', J Rheu-
matol, 24 (3), 485-88. 
Deacon, NJ, et al. (1995), 'Genomic structure of an attenuated quasi species of HIV-1 
from a blood transfusion donor and recipients.', Science, 270 (5238), 988-91. 
Dean, M, et al. (1996), 'Genetic restriction of HIV-1 infection and progression to AIDS 
by a deletion allele of the CKR5 structural gene. Hemophilia Growth and Devel-
opment Study, Multicenter AIDS Cohort Study, Multicenter Hemophilia Cohort 
Study, San Francisco City Cohort, ALIVE Study.', Science, 273 (5283), 1856-62. 
Deng, H, et al. (1996), 'Identification of a major co-receptor for primary isolates of 
HIV-1.', Nature, 381 (6584), 661-66. 
Dork, T and M Stuhrmann (1998), 'Polymorphisms of the human beta-defensin-1 gene.', 
Mol Cell Probes, 12 (3), 171-73. 
Dragic, T, et al. (1996), 'HIV-1 entry into CD4+ cells is mediated by the chemokine re-
ceptor CC-CKR-5.', Nature, 381 (6584), 667-73. 
Eisen, DP and RM Minchinton (2003), 'Impact of mannose-binding lectin on suscepti-
bility to infectious diseases.', Clin Infect Dis, 37 (11), 1496-505. 
Elass-Rochard, E, et al. (1995), 'Lactoferrin-lipopolysaccharide interaction: involve-
ment of the 28-34 loop region of human lactoferrin in the high-affinity binding to 
Escherichia coli 055B5 lipopolysaccharide.', Biochem J, 312 (Pt 3), 839-45. 
Ellison, RT 3rd, TJ Giehl, and FM LaForce (1988), 'Damage of the outer membrane of 
enteric gram-negative bacteria by lactoferrin and transferrin.', Infect Immun, 56 
(11), 2774-81. 
Ellison, RT 3rd, et al. (1990), 'Lactoferrin and transferrin damage of the gram-negative 
outer membrane is modulated by Ca2+ and Mg2+.', J Gen Microbiol, 136 (7), 
1437-46. 
  
119 
Ellison, RT 3rd and TJ Giehl (1991), 'Killing of gram-negative bacteria by lactoferrin 
and lysozyme.', J Clin Invest, 88 (4), 1080-91. 
Engstrom, P, et al. (1984), 'The antibacterial effect of attacins from the silk moth 
Hyalophora cecropia is directed against the outer membrane of Escherichia coli.', 
EMBO J, 3 (13), 3347-51. 
Esposito, JJ and JF Obljeski (1976), 'Enterovirus type 70 virion and intracellular pro-
teins.', J Virol, 18 (3), 1160-62. 
Ezekowitz, RA, LE Day, and GA Herman (1988), 'A human mannose-binding protein is 
an acute-phase reactant that shares sequence homology with other vertebrate lect-
ins.', J Exp Med, 167 (3), 1034-46. 
Ezekowitz, RA, et al. (1989), 'A human serum mannose-binding protein inhibits in vitro 
infection by the human immunodeficiency virus.', J Exp Med, 169 (1), 185-96. 
Faure, S, et al. (2000), 'Rapid progression to AIDS in HIV+ individuals with a structural 
variant of the chemokine receptor CX3CR1.', Science, 287 (5461), 2274-77. 
Fernandez de Caleya, R, et al. (1972), 'Susceptibility of phytopathogenic bacteria to 
wheat purothionins in vitro.', Appl Microbiol, 23 (5), 998-1000. 
Frohm, M, et al. (1997), 'The expression of the gene coding for the antibacterial peptide 
LL-37 is induced in human keratinocytes during inflammatory disorders.', J Biol 
Chem, 272 (24), 15258-63. 
Ganz, T, ME Selsted, and RI Lehrer (1990), 'Defensins.', Eur J Haematol, 44 (1), 1-8. 
Ganz, T and RI Lehrer (1994), 'Defensins.', Curr Opin Immunol, 6 (4), 584-89. 
Ganz, T (2000), 'Paneth cells--guardians of the gut cell hatchery.', Nat Immunol, 1 (2), 
99-100. 
Ganz, T.(2005), 'Defensins and other antimicrobial peptides: a historical perspective 
and an update.', Comb Chem High Throughput Screen, 8 (3), 209-17. 
Garcia, JR, et al. (2001), 'Human beta-defensin 4: a novel inducible peptide with a spe-
cific salt-sensitive spectrum of antimicrobial activity.', FASEB J, 15 (10), 1819-
21. 
Garred, P, et al. (1994), 'Dual role of mannan-binding protein in infections: another case 
of heterosis?', Eur J Immunogenet, 21 (2), 125-31. 
Garred, P, et al. (1997), 'Mannan-binding lectin in the sub-Saharan HIV and tuberculo-
sis epidemics.', Scand J Immunol, 46 (2), 204-08. 
  
120 
Garred, P, et al. (1997), 'Susceptibility to HIV infection and progression of AIDS in re-
lation to variant alleles of mannose-binding lectin.', Lancet, 349 (9047), 236-40. 
Garred, P, et al. (2000), 'Two edged role of mannose binding lectin in rheumatoid arthri-
tis: a cross sectional study.', J Rheumatol, 27 (1), 26-34. 
Giglio, S, et al. (2001), 'Olfactory receptor-gene clusters, genomic-inversion polymor-
phisms, and common chromosome rearrangements.', Am J Hum Genet, 68 (4), 
874-83. 
Giglio, S, et al. (2002), 'Heterozygous submicroscopic inversions involving olfactory 
receptor-gene clusters mediate the recurrent t(4;8)(p16;p23) translocation.', Am J 
Hum Genet, 71 (2), 276-85. 
Gonzalez, E, et al. (2002), 'HIV-1 infection and AIDS dementia are influenced by a mu-
tant MCP-1 allele linked to increased monocyte infiltration of tissues and MCP-1 
levels.', Proc Natl Acad Sci U S A, 99 (21), 13795-800. 
Gonzalez, E, et al. (2005), 'The influence of CCL3L1 gene-containing segmental 
duplications on HIV-1/AIDS susceptibility.', Science, 307 (5714), 1434-40. 
Gonzalez, GC, DL Caamano, and AB Schryvers (1990), 'Identification and characteri-
zation of a porcine-specific transferrin receptor in Actinobacillus pleuropneumo-
niae.', Mol Microbiol, 4 (7), 1173-79. 
Gould, SJ, AM Booth, and JE Hildreth (2003), 'The Trojan exosome hypothesis.', Proc 
Natl Acad Sci U S A, 100 (19), 10592-97. 
Groisman, EA (1996), 'Bacterial responses to host-defense peptides.', Trends Microbiol, 
4 (4), 127-8; discussion 128-9. 
Guo, CJ, et al. (2004), 'Alpha-defensins inhibit HIV infection of macrophages through 
upregulation of CC-chemokines.', AIDS, 18 (8), 1217-18. 
Hakomori, S (2001), 'Tumor-associated carbohydrate antigens defining tumor malig-
nancy: basis for development of anti-cancer vaccines.', Adv Exp Med Biol, 491 
369-402. 
Hancock, RE and G Diamond (2000), 'The role of cationic antimicrobial peptides in in-
nate host defences.', Trends Microbiol, 8 (9), 402-10. 
Harder, J, et al. (1997), 'A peptide antibiotic from human skin.', Nature, 387(6636) 
(6636), 861. 
Harder, J, et al. (2001), 'Isolation and characterization of human beta -defensin-3, a 
novel human inducible peptide antibiotic.', J Biol Chem, 276 (8), 5707-13. 
  
121 
Harmsen, MC, et al. (1995), 'Antiviral effects of plasma and milk proteins: lactoferrin 
shows potent activity against both human immunodeficiency virus and human cy-
tomegalovirus replication in vitro.', J Infect Dis, 172 (2), 380-88. 
Heggelund, L, et al. (2005), 'Modulatory effect of mannose-binding lectin on cytokine 
responses: possible roles in HIV infection.', Eur J Clin Invest, 35 (12), 765-70. 
Henzler Wildman, KA, DK Lee, and A Ramamoorthy (2003), 'Mechanism of lipid bi-
layer disruption by the human antimicrobial peptide, LL-37.', Biochemistry, 42 
(21), 6545-58. 
Herrington, DA and PF Sparling (1985), 'Haemophilus influenzae can use human trans-
ferrin as a sole source for required iron.', Infect Immun, 48 (1), 248-51. 
Higazi, AA, et al. (1996), 'Defensin modulates tissue-type plasminogen activator and 
plasminogen binding to fibrin and endothelial cells.', J Biol Chem, 271 (30), 
17650-55. 
Higazi, AA, et al. (2000), 'The alpha-defensins stimulate proteoglycan-dependent ca-
tabolism of low-density lipoprotein by vascular cells: a new class of inflammatory 
apolipoprotein and a possible contributor to atherogenesis.', Blood, 96 (4), 1393-
98. 
Hill, AV (1996), 'Genetic susceptibility to malaria and other infectious diseases: from 
the MHC to the whole genome.', Parasitology, 112 Suppl S75-84. 
Hill, CP, et al. (1991), 'Crystal structure of defensin HNP-3, an amphiphilic dimer: 
mechanisms of membrane permeabilization.', Science, 251 (5000), 1481-85. 
Hogan, CM and SM Hammer (2001), 'Host determinants in HIV infection and disease. 
Part 2: genetic factors and implications for antiretroviral therapeutics.', Ann Intern 
Med, 134 (10), 978-96. 
Hollox, EJ, JA Armour, and JC Barber (2003), 'Extensive normal copy number varia-
tion of a beta-defensin antimicrobial-gene cluster.', Am J Hum Genet, 73 (3), 591-
600. 
Hollox, EJ, et al. (2005), 'Beta-defensin genomic copy number is not a modifier locus 
for cystic fibrosis.', J Negat Results Biomed, 4 9. 
Howell, MD, et al. (2004), 'Selective killing of vaccinia virus by LL-37: implications 
for eczema vaccinatum.', J Immunol, 172 (3), 1763-67. 
  
122 
Hristova, K, ME Selsted, and SH White (1997), 'Critical role of lipid composition in 
membrane permeabilization by rabbit neutrophil defensins.', J Biol Chem, 272 
(39), 24224-33. 
Huang, YF, et al. (2003), 'Increased frequency of the mannose-binding lectin LX haplo-
type in Chinese systemic lupus erythematosus patients.', Eur J Immunogenet, 30 
(2), 121-24. 
Hundt, M, H Heiken, and RE Schmidt (2000), 'Low mannose-binding lectin serum con-
centrations in HIV long-term nonprogressors?', AIDS Res Hum Retroviruses, 
16(17) (17), 1927. 
Huttner, KM and CL Bevins (1999), 'Antimicrobial peptides as mediators of epithelial 
host defense.', Pediatr Res, 45 (6), 785-94. 
Hwang, PM, et al. (1998), 'Three-dimensional solution structure of lactoferricin B, an 
antimicrobial peptide derived from bovine lactoferrin.', Biochemistry, 37 (12), 
4288-98. 
Ikeda, K, et al. (1987), 'Serum lectin with known structure activates complement 
through the classical pathway.', J Biol Chem, 262 (16), 7451-54. 
Ioannidis, JP, et al. (2001), 'Effects of CCR5-Delta32, CCR2-64I, and SDF-1 3'A alleles 
on HIV-1 disease progression: An international meta-analysis of individual-
patient data.', Ann Intern Med, 135 (9), 782-95. 
Iobst, ST, et al. (1994), 'Binding of sugar ligands to Ca(2+)-dependent animal lectins. I. 
Analysis of mannose binding by site-directed mutagenesis and NMR.', J Biol 
Chem, 269 (22), 15505-11. 
Jan, MS, et al. (2006), 'CC chemokines induce neutrophils to chemotaxis, degranula-
tion, and alpha-defensin release.', J Acquir Immune Defic Syndr, 41 (1), 6-16. 
John, GC, et al. (2000), 'Maternal SDF1 3'A polymorphism is associated with increased 
perinatal human immunodeficiency virus type 1 transmission.', J Virol, 74 (12), 
5736-39. 
Jones, DE and CL Bevins (1993), 'Defensin-6 mRNA in human Paneth cells: implica-
tions for antimicrobial peptides in host defense of the human bowel.', FEBS Lett, 
315 (2), 187-92. 
Jordan, WJ, et al. (2005), 'A non-conservative, coding single-nucleotide polymorphism 
in the N-terminal region of lactoferrin is associated with aggressive periodontitis 
  
123 
in an African-American, but not a Caucasian population.', Genes Immun, 6 (7), 
632-35. 
Jurevic, RJ, et al. (2002), 'Single-nucleotide polymorphisms and haplotype analysis in 
beta-defensin genes in different ethnic populations.', Genet Test, 6 (4), 261-69. 
Kalmar, JR and RR Arnold (1988), 'Killing of Actinobacillus actinomycetemcomitans 
by human lactoferrin.', Infect Immun, 56 (10), 2552-57. 
Kamysz, W, M Okroj, and J Lukasiak (2003), 'Novel properties of antimicrobial pep-
tides.', Acta Biochim Pol, 50 (2), 461-69. 
Kaslow, RA, T Dorak, and JJ Tang (2005), 'Influence of host genetic variation on sus-
ceptibility to HIV type 1 infection.', J Infect Dis, 191 Suppl 1 S68-77. 
Kaul, R, et al. (2000), 'HIV-1-specific mucosal CD8+ lymphocyte responses in the cer-
vix of HIV-1-resistant prostitutes in Nairobi.', J Immunol, 164 (3), 1602-11. 
Kerr, MA (1980), 'The human complement system: assembly of the classical pathway 
C3 convertase.', Biochem J, 189 (1), 173-81. 
Kim, SJ, et al. (1998), 'Structure of the human lactoferrin gene and its chromosomal lo-
calization.', Mol Cells, 8 (6), 663-68. 
King, AE, et al. (2003), 'Differential expression of the natural antimicrobials, beta-
defensins 3 and 4, in human endometrium.', J Reprod Immunol, 59 (1), 1-16. 
Klickstein, LB, et al. (1997), 'Complement receptor type 1 (CR1, CD35) is a receptor 
for C1q.', Immunity, 7 (3), 345-55. 
Klotman, ME and TL Chang (2006), 'Defensins in innate antiviral immunity.', Nat Rev 
Immunol, 6 (6), 447-56. 
Kougias, P, et al. (2005), 'Defensins and cathelicidins: neutrophil peptides with roles in 
inflammation, hyperlipidemia and atherosclerosis.', J Cell Mol Med, 9 (1), 3-10. 
Kuhlman, M, K Joiner, and RA Ezekowitz (1989), 'The human mannose-binding pro-
tein functions as an opsonin.', J Exp Med, 169 (5), 1733-45. 
Laquerre, S, et al. (1998), 'Heparan sulfate proteoglycan binding by herpes simplex vi-
rus type 1 glycoproteins B and C, which differ in their contributions to virus at-
tachment, penetration, and cell-to-cell spread.', J Virol, 72 (7), 6119-30. 
Larrick, JW, et al. (1996), 'Structural, functional analysis and localization of the human 
CAP18 gene.', FEBS Lett, 398 (1), 74-80. 
  
124 
Larsen, F, et al. (2004), 'Disease-associated mutations in human mannose-binding lectin 
compromise oligomerization and activity of the final protein.', J Biol Chem, 279 
(20), 21302-11. 
Leem, JY, et al. (1996), 'Purification and characterization of N-beta-alanyl-5-S-
glutathionyl-3,4-dihydroxyphenylalanine, a novel antibacterial substance of Sar-
cophaga peregrina (flesh fly).', J Biol Chem, 271 (23), 13573-77. 
Lehrer, RI, AK Lichtenstein, and T Ganz (1993), 'Defensins: antimicrobial and cyto-
toxic peptides of mammalian cells.', Annu Rev Immunol, 11 105-28. 
Lehrer, RI (2004), 'Primate defensins.', Nat Rev Microbiol, 2 (9), 727-38. 
Leikina, E, et al. (2005), 'Carbohydrate-binding molecules inhibit viral fusion and entry 
by crosslinking membrane glycoproteins.', Nat Immunol, 6 (10), 995-1001. 
Levay, PF and M Viljoen (1995), 'Lactoferrin: a general review.', Haematologica, 80 
(3), 252-67. 
Levy, H, et al. (2005), 'Association of defensin beta-1 gene polymorphisms with 
asthma.', J Allergy Clin Immunol, 115 (2), 252-58. 
Lichtenstein, A, et al. (1986), 'In vitro tumor cell cytolysis mediated by peptide defens-
ins of human and rabbit granulocytes.', Blood, 68 (6), 1407-10. 
Linzmeier, R, et al. (1999), 'A 450-kb contig of defensin genes on human chromosome 
8p23.', Gene, 233 (1-2), 205-11. 
Linzmeier, RM and T Ganz (2005), 'Human defensin gene copy number polymor-
phisms: comprehensive analysis of independent variation in alpha- and beta-
defensin regions at 8p22-p23.', Genomics, 86 (4), 423-30. 
Linzmeier, RM and T Ganz (2006), 'Copy number polymorphisms are not a common 
feature of innate immune genes.', Genomics, 88 (1), 122-26. 
Lipscombe, RJ, et al. (1992), 'High frequencies in African and non-African populations 
of independent mutations in the mannose binding protein gene.', Hum Mol Genet, 
1 (9), 709-15. 
Liu, H, et al. (1999), 'Polymorphism in RANTES chemokine promoter affects HIV-1 
disease progression.', Proc Natl Acad Sci U S A, 96 (8), 4581-85. 
Lu, W, et al. (2004), 'Therapeutic dendritic-cell vaccine for chronic HIV-1 infection.', 
Nat Med, 10 (12), 1359-65. 
  
125 
Ma, Y, et al. (1999), 'Antitumor activity of mannan-binding protein in vivo as revealed 
by a virus expression system: mannan-binding proteindependent cell-mediated cy-
totoxicity.', Proc Natl Acad Sci U S A, 96 (2), 371-75. 
Maas, J, et al. (1998), 'Presence of the variant mannose-binding lectin alleles associated 
with slower progression to AIDS. Amsterdam Cohort Study.', AIDS, 12 (17), 
2275-80. 
MacDonald, KS, et al. (1998), 'Mother-child class I HLA concordance increases perina-
tal human immunodeficiency virus type 1 transmission.', J Infect Dis, 177 (3), 
551-56. 
MacDonald, KS, et al. (2000), 'Influence of HLA supertypes on susceptibility and resis-
tance to human immunodeficiency virus type 1 infection.', J Infect Dis, 181 (5), 
1581-89. 
Mackewicz, CE, et al. (2003), 'alpha-Defensins can have anti-HIV activity but are not 
CD8 cell anti-HIV factors.', AIDS, 17 (14), F23-32. 
Madsen, HO, et al. (1994), 'A new frequent allele is the missing link in the structural 
polymorphism of the human mannan-binding protein.', Immunogenetics, 40 (1), 
37-44. 
Madsen, HO, et al. (1995), 'Interplay between promoter and structural gene variants 
control basal serum level of mannan-binding protein.', J Immunol, 155 (6), 3013-
20. 
Malhotra, R, et al. (1990), 'Human leukocyte C1q receptor binds other soluble proteins 
with collagen domains.', J Exp Med, 172 (3), 955-59. 
Malik, S, et al. (2003), 'Absence of association between mannose-binding lectin gene 
polymorphisms and HIV-1 infection in a Colombian population.', Immunogenet-
ics, 55 (1), 49-52. 
Mars, WM, et al. (1995), 'Inheritance of unequal numbers of the genes encoding the 
human neutrophil defensins HP-1 and HP-3.', J Biol Chem, 270 (51), 30371-76. 
Martin, MP, et al. (1998), 'Genetic acceleration of AIDS progression by a promoter 
variant of CCR5.', Science, 282 (5395), 1907-11. 
Martin, MP, et al. (2002), 'Epistatic interaction between KIR3DS1 and HLA-B delays 
the progression to AIDS.', Nat Genet, 31 (4), 429-34. 
Masson, PL and JF Heremans (1971), 'Lactoferrin in milk from different species.', 
Comp Biochem Physiol B, 39 (1), 119-29. 
  
126 
Matsushita, I, et al. (2002), 'Genetic variants of human beta-defensin-1 and chronic ob-
structive pulmonary disease.', Biochem Biophys Res Commun, 291 (1), 17-22. 
Matsushita, M, et al. (1998), 'Hepatitis C virus infection and mutations of mannose-
binding lectin gene MBL.', Arch Virol, 143 (4), 645-51. 
McBride, MO, et al. (1998), 'Mannose-binding protein in HIV-seropositive patients 
does not contribute to disease progression or bacterial infections.', Int J STD 
AIDS, 9 (11), 683-88. 
McDermott, DH, et al. (1998), 'CCR5 promoter polymorphism and HIV-1 disease pro-
gression. Multicenter AIDS Cohort Study (MACS).', Lancet, 352 (9131), 866-70. 
McDermott, DH, et al. (2000), 'Chemokine RANTES promoter polymorphism affects 
risk of both HIV infection and disease progression in the Multicenter AIDS Co-
hort Study.', AIDS, 14 (17), 2671-78. 
McDermott, DH, et al. (2000), 'Genetic polymorphism in CX3CR1 and risk of HIV dis-
ease.', Science, 290 (5499), 2031. 
Message, SD and SL Johnston (2004), 'Host defense function of the airway epithelium 
in health and disease: clinical background.', J Leukoc Biol, 75 (1), 5-17. 
Metz-Boutigue, MH, et al. (1984), 'Human lactotransferrin: amino acid sequence and 
structural comparisons with other transferrins.', Eur J Biochem, 145 (3), 659-76. 
Meyer, L, et al. (1997), 'Early protective effect of CCR-5 delta 32 heterozygosity on 
HIV-1 disease progression: relationship with viral load. The SEROCO Study 
Group.', AIDS, 11 (11), F73-8. 
Misrahi, M, et al. (1998), 'CCR5 chemokine receptor variant in HIV-1 mother-to-child 
transmission and disease progression in children. French Pediatric HIV Infection 
Study Group.', JAMA, 279 (4), 277-80. 
Mohamed, JA, et al. (2007), 'A novel single-nucleotide polymorphism in the lactoferrin 
gene is associated with susceptibility to diarrhea in North American travelers to 
Mexico.', Clin Infect Dis, 44 (7), 945-52. 
Moore, CB, et al. (2002), 'Evidence of HIV-1 adaptation to HLA-restricted immune re-
sponses at a population level.', Science, 296 (5572), 1439-43. 
Moriuchi, M and H Moriuchi (2001), 'A milk protein lactoferrin enhances human T cell 
leukemia virus type I and suppresses HIV-1 infection.', J Immunol, 166 (6), 4231-
36. 
  
127 
Mummidi, S, et al. (1998), 'Genealogy of the CCR5 locus and chemokine system gene 
variants associated with altered rates of HIV-1 disease progression.', Nat Med, 4 
(7), 786-93. 
Murphy, CJ, et al. (1993), 'Defensins are mitogenic for epithelial cells and fibroblasts.', 
J Cell Physiol, 155 (2), 408-13. 
Murphy, PM (1996), 'Chemokine receptors: structure, function and role in microbial 
pathogenesis.', Cytokine Growth Factor Rev, 7 (1), 47-64. 
Naidu, SS, et al. (1993), 'Relationship between antibacterial activity and porin binding 
of lactoferrin in Escherichia coli and Salmonella typhimurium.', Antimicrob 
Agents Chemother, 37 (2), 240-45. 
Nakagawa, T, et al. (2003), 'Antitumor activity of mannan-binding protein.', Methods 
Enzymol, 363 26-33. 
Nakashima, H, et al. (1993), 'Defensins inhibit HIV replication in vitro.', AIDS, 7(8) (8), 
1129. 
Nakayama, EE, et al. (2000), 'Polymorphism in the interleukin-4 promoter affects ac-
quisition of human immunodeficiency virus type 1 syncytium-inducing pheno-
type.', J Virol, 74 (12), 5452-59. 
Nakayama, EE, et al. (2002), 'Protective effect of interleukin-4 -589T polymorphism on 
human immunodeficiency virus type 1 disease progression: relationship with virus 
load.', J Infect Dis, 185 (8), 1183-86. 
Nassar, T, et al. (2002), 'Human alpha-defensin regulates smooth muscle cell contrac-
tion: a role for low-density lipoprotein receptor-related protein/alpha 2-
macroglobulin receptor.', Blood, 100 (12), 4026-32. 
Ng, TB, et al. (2001), 'Inhibition of human immunodeficiency virus type 1 reverse tran-
scriptase, protease and integrase by bovine milk proteins.', Life Sci, 69 (19), 2217-
23. 
Nielsen, SL, et al. (1995), 'The level of the serum opsonin, mannan-binding protein in 
HIV-1 antibody-positive patients.', Clin Exp Immunol, 100 (2), 219-22. 
Niyonsaba, F, et al. (2003), 'Epithelial cell-derived antibacterial peptides human beta-
defensins and cathelicidin: multifunctional activities on mast cells.', Curr Drug 
Targets Inflamm Allergy, 2 (3), 224-31. 
  
128 
O'Malley, DP and PD Storto (1999), 'Confirmation of the chromosome 8p23.1 euchro-
matic duplication as a variant with no clinical manifestations.', Prenat Diagn, 19 
(2), 183-84. 
Odell, EW, et al. (1996), 'Antibacterial activity of peptides homologous to a loop region 
in human lactoferrin.', FEBS Lett, 382 (1-2), 175-78. 
Ogden, CA, et al. (2001), 'C1q and mannose binding lectin engagement of cell surface 
calreticulin and CD91 initiates macropinocytosis and uptake of apoptotic cells.', J 
Exp Med, 194 (6), 781-95. 
Okrent, DG, AK Lichtenstein, and T Ganz (1990), 'Direct cytotoxicity of polymor-
phonuclear leukocyte granule proteins to human lung-derived cells and endothe-
lial cells.', Am Rev Respir Dis, 141 (1), 179-85. 
Okumura, K, et al. (2004), 'C-terminal domain of human CAP18 antimicrobial peptide 
induces apoptosis in oral squamous cell carcinoma SAS-H1 cells.', Cancer Lett, 
212 (2), 185-94. 
Olesen, HV, et al. (2006), 'The mannan-binding lectin pathway and lung disease in cys-
tic fibrosis--disfunction of mannan-binding lectin-associated serine protease 2 
(MASP-2) may be a major modifier.', Clin Immunol, 121 (3), 324-31. 
Oppenheim, JJ, et al. (2003), 'Roles of antimicrobial peptides such as defensins in in-
nate and adaptive immunity.', Ann Rheum Dis, 62 Suppl 2 ii17-21. 
Ortega, MR, T Ganz, and SM Milner (2000), 'Human beta defensin is absent in burn 
blister fluid.', Burns, 26 (8), 724-26. 
Pareja, E, et al. (1997), 'The tetramer model: a new view of class II MHC molecules in 
antigenic presentation to T cells.', Tissue Antigens, 50 (5), 421-28. 
Park, CB, HS Kim, and SC Kim (1998), 'Mechanism of action of the antimicrobial pep-
tide buforin II: buforin II kills microorganisms by penetrating the cell membrane 
and inhibiting cellular functions.', Biochem Biophys Res Commun, 244 (1), 253-
57. 
Petros, J (2007), 'Transcriptional Effect of DEFB1 Gene 5' Untranslated Region 
Polymorphisms.', Cancer Res, 67 (12), 5997. 
Pirhonen, J, et al. (1999), 'Virus infection activates IL-1 beta and IL-18 production in 
human macrophages by a caspase-1-dependent pathway.', J Immunol, 162 (12), 
7322-29. 
  
129 
Polycarpou, A, et al. (2002), 'Association between maternal and infant class I and II 
HLA alleles and of their concordance with the risk of perinatal HIV type 1 trans-
mission.', AIDS Res Hum Retroviruses, 18 (11), 741-46. 
Prohaszka, Z, et al. (1997), 'Mannan-binding lectin serum concentrations in HIV-
infected patients are influenced by the stage of disease.', Immunol Lett, 58 (3), 
171-75. 
Quinones-Mateu, ME, et al. (2003), 'Human epithelial beta-defensins 2 and 3 inhibit 
HIV-1 replication.', AIDS, 17 (16), F39-48. 
Reddy, KV, RD Yedery, and C Aranha (2004), 'Antimicrobial peptides: premises and 
promises.', Int J Antimicrob Agents, 24 (6), 536-47. 
Rigopoulos, D, et al. (2007), 'AIDS in pregnancy, part II: Treatment in the era of highly 
active antiretroviral therapy and management of obstetric, anesthetic, and pediat-
ric issues.', Skinmed, 6 (2), 79-84. 
Robinson, D, NC Phillips, and B Winchester (1975), 'Affinity chromatography of hu-
man liver alpha-D-mannosidase.', FEBS Lett, 53 (1), 110-12. 
Saito, H, et al. (1991), 'Potent bactericidal activity of bovine lactoferrin hydrolysate pro-
duced by heat treatment at acidic pH.', J Dairy Sci, 74 (11), 3724-30. 
Salvatore, F, O Scudiero, and G Castaldo (2002), 'Genotype-phenotype correlation in 
cystic fibrosis: the role of modifier genes.', Am J Med Genet, 111 (1), 88-95. 
Samson, M, et al. (1996), 'Resistance to HIV-1 infection in caucasian individuals bear-
ing mutant alleles of the CCR-5 chemokine receptor gene.', Nature, 382 (6593), 
722-25. 
Santos, IK, et al. (2001), 'Mannan-binding lectin enhances susceptibility to visceral 
leishmaniasis.', Infect Immun, 69 (8), 5212-15. 
Schibli, DJ, PM Hwang, and HJ Vogel (1999), 'The structure of the antimicrobial active 
center of lactoferricin B bound to sodium dodecyl sulfate micelles.', FEBS Lett, 
446 (2-3), 213-17. 
Schouten, JP, et al. (2002), 'Relative quantification of 40 nucleic acid sequences by 
multiplex ligation-dependent probe amplification.', Nucleic Acids Res, 30 (12), 
e57. 
Schutte, BC and PB Jr McCray (2002), '(beta)-defensins in lung host defense.', Annu 
Rev Physiol, 64 709-48. 
  
130 
Schwaeble, W, et al. (2002), 'The mannan-binding lectin-associated serine proteases 
(MASPs) and MAp19: four components of the lectin pathway activation complex 
encoded by two genes.', Immunobiology, 205 (4-5), 455-66. 
Segat, L, et al. (2006), 'IL-18 gene promoter polymorphism is involved in HIV-1 infec-
tion in a Brazilian pediatric population.', Immunogenetics, 58 (5-6), 471-73. 
Sei, S, et al. (2001), 'Protective effect of CCR5 delta 32 heterozygosity is restricted by 
SDF-1 genotype in children with HIV-1 infection.', AIDS, 15 (11), 1343-52. 
Senaldi, G, et al. (1995), 'Circulating levels of mannose binding protein in human im-
munodeficiency virus infection.', J Infect, 31 (2), 145-48. 
Seyfarth, J, P Garred, and HO Madsen (2006), 'Extra-hepatic transcription of the human 
mannose-binding lectin gene (mbl2) and the MBL-associated serine protease 1-3 
genes.', Mol Immunol, 43 (7), 962-71. 
Shimokawa, O, et al. (2004), 'Molecular characterization of inv dup del(8p): analysis of 
five cases.', Am J Med Genet A, 128 (2), 133-37. 
Shin, HD, et al. (2000), 'Genetic restriction of HIV-1 pathogenesis to AIDS by promoter 
alleles of IL10.', Proc Natl Acad Sci U S A, 97 (26), 14467-72. 
Singh, A, et al. (1988), 'Structure of a novel human granulocyte peptide with anti-
ACTH activity.', Biochem Biophys Res Commun, 155 (1), 524-29. 
Soell, M, et al. (1995), 'Activation of human monocytes by streptococcal rhamnose glu-
cose polymers is mediated by CD14 antigen, and mannan binding protein inhibits 
TNF-alpha release.', J Immunol, 154 (2), 851-60. 
Sorensen, R, S Thiel, and JC Jensenius (2005), 'Mannan-binding-lectin-associated ser-
ine proteases, characteristics and disease associations.', Springer Semin Im-
munopathol, 27 (3), 299-319. 
Steinstraesser, L, et al. (2005), 'Inhibition of early steps in the lentiviral replication cy-
cle by cathelicidin host defense peptides.', Retrovirology, 2 2. 
Stephens, JC, et al. (1998), 'Dating the origin of the CCR5-Delta32 AIDS-resistance 
allele by the coalescence of haplotypes.', Am J Hum Genet, 62 (6), 1507-15. 
Stover, CM, et al. (1999), 'Two constituents of the initiation complex of the mannan-
binding lectin activation pathway of complement are encoded by a single struc-
tural gene.', J Immunol, 162 (6), 3481-90. 
  
131 
Stylianou, E, et al. (2003), 'Raised serum levels of interleukin-18 is associated with dis-
ease progression and may contribute to virological treatment failure in HIV-1-
infected patients.', Clin Exp Immunol, 132 (3), 462-66. 
Sugawara, H, et al. (2003), 'Complex low-copy repeats associated with a common po-
lymorphic inversion at human chromosome 8p23.', Genomics, 82 (2), 238-44. 
Sumiya, M, et al. (1991), 'Molecular basis of opsonic defect in immunodeficient chil-
dren.', Lancet, 337 (8757), 1569-70. 
Summerfield, JA, et al. (1995), 'Mannose binding protein gene mutations associated 
with unusual and severe infections in adults.', Lancet, 345 (8954), 886-89. 
Sun, CQ, et al. (2006), 'Human {beta}-Defensin-1, a Potential Chromosome 8p Tumor 
Suppressor: Control of Transcription and Induction of Apoptosis in Renal Cell 
Carcinoma.', Cancer Res, 66 (17), 8542-49. 
Sun, L, et al. (2005), 'Human beta-defensins suppress human immunodeficiency virus 
infection: potential role in mucosal protection.', J Virol, 79 (22), 14318-29. 
Super, M, et al. (1989), 'Association of low levels of mannan-binding protein with a 
common defect of opsonisation.', Lancet, 2 (8674), 1236-39. 
Swart, PJ, et al. (1998), 'Lactoferrin. Antiviral activity of lactoferrin.', Adv Exp Med 
Biol, 443 205-13. 
Takahashi, M, et al. (1999), 'A truncated form of mannose-binding lectin-associated ser-
ine protease (MASP)-2 expressed by alternative polyadenylation is a component 
of the lectin complement pathway.', Int Immunol, 11 (5), 859-63. 
Tanabe, H, et al. (2004), 'Differential effects on human immunodeficiency virus type 1 
replication by alpha-defensins with comparable bactericidal activities.', J Virol, 78 
(21), 11622-31. 
Tanaka-Kataoka, M, et al. (1999), 'In vivo antiviral effect of interleukin 18 in a mouse 
model of vaccinia virus infection.', Cytokine, 11 (8), 593-99. 
Taudien, S, et al. (2004), 'Polymorphic segmental duplications at 8p23.1 challenge the 
determination of individual defensin gene repertoires and the assembly of a con-
tiguous human reference sequence.', BMC Genomics, 5 (1), 92. 
Teng, CT and W Gladwell (2006), 'Single nucleotide polymorphisms (SNPs) in human 
lactoferrin gene.', Biochem Cell Biol, 84 (3), 381-84. 
  
132 
Tenner, AJ, SL Robinson, and RA Ezekowitz (1995), 'Mannose binding protein (MBP) 
enhances mononuclear phagocyte function via a receptor that contains the 
126,000 M(r) component of the C1q receptor.', Immunity, 3 (4), 485-93. 
Territo, MC, et al. (1989), 'Monocyte-chemotactic activity of defensins from human 
neutrophils.', J Clin Invest, 84 (6), 2017-20. 
Theodorou, I, et al. (1997), 'HIV-1 infection in an individual homozygous for CCR5 
delta 32. Seroco Study Group.', Lancet, 349(9060) (9060), 1219-20. 
Thiel, S, et al. (1992), 'The concentration of the C-type lectin, mannan-binding protein, 
in human plasma increases during an acute phase response.', Clin Exp Immunol, 
90 (1), 31-35.  
Thiel, S, et al. (1997), 'A second serine protease associated with mannan-binding lectin 
that activates complement.', Nature, 386 (6624), 506-10. 
Thiel, S, et al. (2007), 'Deficiency of mannan-binding lectin associated serine protease-2 
due to missense polymorphisms.', Genes Immun, 8 (2), 154-63. 
Turner, J, et al. (1998), 'Activities of LL-37, a cathelin-associated antimicrobial peptide 
of human neutrophils.', Antimicrob Agents Chemother, 42 (9), 2206-14. 
Turner, MW (1996), 'Mannose-binding lectin: the pluripotent molecule of the innate 
immune system.', Immunol Today, 17 (11), 532-40. 
Turner, MW and RM Hamvas (2000), 'Mannose-binding lectin: structure, function, ge-
netics and disease associations.', Rev Immunogenet, 2 (3), 305-22. 
Turner, MW (2003), 'The role of mannose-binding lectin in health and disease.', Mol 
Immunol, 40 (7), 423-29. 
Van Wetering, S, et al. (1997), 'Effect of neutrophil serine proteinases and defensins on 
lung epithelial cells: modulation of cytotoxicity and IL-8 production.', J Leukoc 
Biol, 62 (2), 217-26. 
Vankeerberghen, A, et al. (2005), 'Distribution of human beta-defensin polymorphisms 
in various control and cystic fibrosis populations.', Genomics, 85 (5), 574-81. 
Velasco, M, et al. (1997), 'Macrophage triggering with cecropin A and melittin-derived 
peptides induces type II nitric oxide synthase expression.', J Immunol, 158 (9), 
4437-43. 
Velliyagounder, K, et al. (2003), 'One of two human lactoferrin variants exhibits in-
creased antibacterial and transcriptional activation activities and is associated with 
localized juvenile periodontitis.', Infect Immun, 71 (11), 6141-47. 
  
133 
Wallis, R and JY Cheng (1999), 'Molecular defects in variant forms of mannose-binding 
protein associated with immunodeficiency.', J Immunol, 163 (9), 4953-59. 
Wang, H, X Ye, and TB Ng (2000), 'First demonstration of an inhibitory activity of 
milk proteins against human immunodeficiency virus-1 reverse transcriptase and 
the effect of succinylation.', Life Sci, 67 (22), 2745-52. 
Wang, W, et al. (2004), 'Activity of alpha- and theta-defensins against primary isolates 
of HIV-1.', J Immunol, 173 (1), 515-20. 
Wang, Z and G Wang (2004), 'APD: the Antimicrobial Peptide Database.', Nucleic Ac-
ids Res, 32 (Database issue), D590-2. 
Weiss, G, HO Madsen, and P Garred (2007), 'A novel mannose-binding lectin-
associated serine protease 1/3 gene variant.', Scand J Immunol, 65 (5), 430-34. 
Wiercinska-Drapalo, A, et al. (2004), 'Plasma interleukin-18 is associated with viral 
load and disease progression in HIV-1-infected patients.', Microbes Infect, 6 (14), 
1273-77. 
Wild, J, D Robinson, and B Winchester (1983), 'Isolation of mannose-binding proteins 
from human and rat liver.', Biochem J, 210 (1), 167-74. 
Williams, A, CA Peh, and T Elliott (2002), 'The cell biology of MHC class I antigen 
presentation.', Tissue Antigens, 59 (1), 3-17. 
Wu, Z, et al. (2005), 'Human neutrophil alpha-defensin 4 inhibits HIV-1 infection in 
vitro.', FEBS Lett, 579 (1), 162-66. 
Yamaguchi, Y, et al. (2002), 'Identification of multiple novel epididymis-specific beta-
defensin isoforms in humans and mice.', J Immunol, 169 (5), 2516-23. 
Yamauchi, K, et al. (1993), 'Antibacterial activity of lactoferrin and a pepsin-derived 
lactoferrin peptide fragment.', Infect Immun, 61 (2), 719-28. 
Yang, D, et al. (1999), 'Beta-defensins: linking innate and adaptive immunity through 
dendritic and T cell CCR6.', Science, 286 (5439), 525-28. 
Yang, D, et al. (2000), 'Human neutrophil defensins selectively chemoattract naive T 
and immature dendritic cells.', J Leukoc Biol, 68 (1), 9-14. 
Yang, D, et al. (2004), 'Multiple roles of antimicrobial defensins, cathelicidins, and 
eosinophil-derived neurotoxin in host defense.', Annu Rev Immunol, 22 181-215. 
Yenugu, S, et al. (2004), 'The androgen-regulated epididymal sperm-binding protein, 
human beta-defensin 118 (DEFB118) (formerly ESC42), is an antimicrobial beta-
defensin.', Endocrinology, 145 (7), 3165-73. 
  
134 
Yi, M, et al. (1997), 'Hepatitis C virus envelope proteins bind lactoferrin.', J Virol, 71 
(8), 5997-6002. 
Ying, H, et al. (2004), 'Interaction of mannose-binding lectin with HIV type 1 is suffi-
cient for virus opsonization but not neutralization.', AIDS Res Hum Retroviruses, 
20 (3), 327-35. 
Yoo, YC, et al. (1997), 'Apoptosis in human leukemic cells induced by lactoferricin, a 
bovine milk protein-derived peptide: involvement of reactive oxygen species.', 
Biochem Biophys Res Commun, 237 (3), 624-28. 
Zanetti, M (2004), 'Cathelicidins, multifunctional peptides of the innate immunity.', J 
Leukoc Biol, 75 (1), 39-48. 
Zhang, L, et al. (2002), 'Contribution of human alpha-defensin 1, 2, and 3 to the anti-
HIV-1 activity of CD8 antiviral factor.', Science, 298 (5595), 995-1000. 
Zimmerman, PA, et al. (1997), 'Inherited resistance to HIV-1 conferred by an inactivat-
ing mutation in CC chemokine receptor 5: studies in populations with contrasting 
clinical phenotypes, defined racial background, and quantified risk.', Mol Med, 3 
(1), 23-36. 
Zimmermann, GR, et al. (1995), 'Solution structure of bovine neutrophil beta-defensin-
12: the peptide fold of the beta-defensins is identical to that of the classical de-
fensins.', Biochemistry, 34 (41), 13663-71. 
Zlotnik, A and O Yoshie (2000), 'Chemokines: a new classification system and their 
role in immunity.', Immunity, 12 (2), 121-27. 
Zuccotti, GV, et al. (2006), 'Oral lactoferrin in HIV-1 vertically infected children: an 
observational follow-up of plasma viral load and immune parameters.', J Int Med 
Res, 34 (1), 88-94. 
Zundel, S, et al. (2004), 'Characterization of recombinant mannan-binding lectin-
associated serine protease (MASP)-3 suggests an activation mechanism different 
from that of MASP-1 and MASP-2.', J Immunol, 172 (7), 4342-50. 
 
  
135 
REPRINTS OF PAPERS INCLUDES IN THE THESIS 
Copyright © Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.
serum creatinine alone [8], serum potassium and phos-
phate levels, and a urinalysis to detect proteinuria and
glucosuria [6,7]. Assessment for increased urinary
frequency may be helpful in detecting treated patients
who may be at risk. The associated consequences of
tenofovir-related nephrotoxicity and hypokalemia may
be profound and life threatening.
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DEFB1 gene polymorphisms and increased risk of
HIV-1 infection in Brazilian children
Michele Milanesea, Ludovica Segata, Alessandra
Pontilloa, Luiz Claudio Arraesb,c, Jose´ Luiz de Lima
Filhoc and Sergio Crovellaa,c
In our study we analysed three single nucleotide
polymorphisms (SNPs) in the 50 untranslated region
(UTR) of the DEFB1 gene, namely S52(G/A)
S44(C/G) andS20(G/A), in three groups of north-
eastern Brazilian children in order to assess their
role in HIV-1 infection. Our results allowed us to
hypothesize that the SNPs located in the 50 UTR of
theDEFB1 gene can be employed as amarker of risk
for HIV-1 infection.
Beta defensins are small secreted antimicrobial peptides
that are components of innate immunity [1]. A role for
beta defensins in contrasting infection from HIV-1 has
been reported by Quin˜ones-Mateu et al. [2], who
suggested that human beta defensin (hBD) 2 and hBD-3
are able to protect GHOST X4/R5 cells from being
infected, by directly binding to the viral envelope. A
similar effect, in which beta defensins interact with
surface carbohydrates, has been shown by Leikina et al.
[3]. Moreover Sun et al. [4] hypothesized an involvement
of beta-defensins in HIV-1 oral transmission, emphasizing
their protective role in the oral mucosa.
Despite the fact that Quin˜ones-Mateu et al. [2] were not
able to prove a role for hBD-1 in protecting cells from
infection by HIV-1, Braida et al. [5] recently reported
an association between the !44(C/G) single nucleotide
polymorphism (SNP) in the 50 untranslated region (UTR)
of the DEFB1 gene, encoding for the hBD-1 peptide, and
HIV-1 infection in Italian children.
In our study we analysed the same SNPs in the 50 UTR of
the DEFB1 gene, !52(G/A), !44(C/G) and !20(G/A)
(rs1799946, rs1800972, and rs11362, respectively), as
reported by Braida et al. [5] in three groups of north-
eastern Brazilian children in order to assess the role of
these polymorphisms in HIV-1 infection when looking at
ethnic groups other that the Caucasians studied by Braida
et al. [5].
We enrolled 128 HIV-1 perinatally infected children
(average age 4 years, range 0–13) and 60 exposed
uninfected children (average age 7 years, range 0–15)
born to HIV-1-positive mothers who did not receive
antiretroviral therapy during gestation, and did not
undergo caesarean section to prevent vertical transmission.
We also recruited 115 uninfected and unexposed children
(average age 8 years, range 0–19) from the same population
as the healthy controls. All children came from the Instituto
Materno Infantil do Pernambuco (Recife, Brazil), and
informed consent was obtained from their parents.
DNA extraction and DEFB1 SNP genotyping were
performed according to Braida et al. [5].
The significance of differences in allelic and genotype
frequencies was calculated by chi-square test. Yates’ con-
tinuity correction and Fisher’s exact test were employed
when appropriate. The correction of P values for multiple
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tests was performed automatically using the R software
(www.r-project.org) according to Benjamini and Hoch-
berg [6] in order to keep the false discovery rate under 5%.
The allelic and genotype frequencies for 50 UTRDEFB1
SNPs in the three groups studied are shown in Table 1.
The genotype frequencies follow the Hardy–Weinberg
equilibrium in the three populations, with the excep-
tion of the polymorphism !20(G/A) in HIV-1-infected
children.
DEFB1 genotype!52 A/Awas significantly less frequent
in HIV-1 perinatally infected children when compared
with healthy controls and exposed uninfected children
(corrected P values are 0.023 and 0.025, respectively),
whereas frequencies did not vary between HIV-1-
exposed uninfected children and healthy controls. The
allelic frequencies of the !52(G/A) SNP in infected
children varied significantly when compared with those
of healthy controls (corrected P value 0.030), but when
compared with exposed uninfected children were not
statistically significant (corrected P value 0.055). Never-
theless, the odd ratios calculated comparing HIV-positive
children with exposed uninfected children and healthy
controls were not statistically different when tested using
bootstrapping techniques, suggesting that the !52 A
allele has a similar protective effect in the two groups.
A weaker correlation was found for the !44(C/G) poly-
morphism in which the P values for genotype frequencies
did not remain statistically significant after multiple test
correction. Allelic frequencies of the !44 G allele were
similar between healthy controls and HIV-1-exposed
uninfected children, and although a lower frequency of
the !44 G allele was found in HIV-1-infected children,
the difference was not statistically significant. A stronger
association was observed in the!20(G/A) SNP, in which
the frequency of the!20 G/G genotype was significantly
lower in HIV-1-positive children than in exposed
uninfected children and healthy controls (corrected
P values both < 0.005). Allelic frequencies of the
!20 G/A SNP were significantly different between
HIV-1-positive children and healthy controls (corrected
P value 0.015), whereas the significance was not achieved
between HIV-1-infected and exposed uninfected chil-
dren as a result of multiple test correction.
As we did not find any significant difference between the
exposed uninfected children and the healthy controls, we
pooled the two groups to perform a more powerful
analysis using the Haploview software [7], built to
perform single SNP and haplotype association tests. We
confirmed the results found with the chi-square test,
but despite the proximity of the three SNPs and a
co-segregation rate of 93% between the !20(G/A) and
!44(C/G) SNPs, we did not find evidence of the
presence of any haploblock. Multiple regression analysis
performed with the R software on the new dataset did
not show any significant interaction between the different
SNPs.
We have demonstrated that significant correlation exists
between SNPs in the 50 UTR of the DEFB1 gene and the
risk of being infected with HIV-1 in Brazilian children.
We found a significant increase of the !52 A/A and
!20 G/G genotypes among HIV-1-infected children,
when compared with healthy controls, and the odd ratios
of carrying the !52 A or !20 G allele were, respectively,
1.688 (95% confidence limits 1.151–2.482) and 1.814
(95% confidence limits 1.243–2.655), suggesting a role
for these polymorphisms in increasing the susceptibility
to infection. We also found a sensible, even if not sig-
nificant, reduction of the frequency of the !44 G allele:
the frequency of this polymorphism was very low in the
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Table 1. Frequencies of DEFB1 polymorphisms in children perinatally exposed to HIV-1 (infected and uninfected) and healthy controls.
SNP
HIV-1-infected
children (n ¼ 128)
HIV-1-exposed uninfected
children (n ¼ 60)
Healthy controls
(n ¼ 115)
!52 (G/A)
G 0.67 (171/256) 0.54 (65/120) 0.54 (125/230)
A 0.33 (85/256) 0.46 (55/120) 0.46 (105/230)
G/G 0.41 (53/128) 0.32 (19/60) 0.30 (34/115)
G/A 0.51 (65/128) 0.45 (27/60) 0.50 (57/115)
A/A 0.08 (10/128) 0.23 (14/60) 0.21 (24/115)
!44 (C/G)
C 0.93 (237/256) 0.87 (104/120) 0.86 (197/230)
G 0.07 (19/256) 0.13 (16/120) 0.14 (33/230)
C/C 0.85 (109/128) 0.73 (44/60) 0.73 (84/115)
C/G 0.15 (19/128) 0.27 (16/60) 0.25 (29/115)
G/G 0.00 (0/128) 0.00 (0/60) 0.02 (2/115)
!20 (G/A)
G 0.48 (124/256) 0.58 (70/120) 0.63 (145/230)
A 0.52 (132/256) 0.42 (50/120) 0.37 (85/230)
G/G 0.12 (15/128) 0.33 (20/60) 0.36 (42/115)
G/A 0.73 (94/128) 0.50 (30/60) 0.53 (61/115)
A/A 0.15 (19/128) 0.17 (10/60) 0.10 (12/115)
SNP, Single nucleotide polymorphism.
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Brazilian population when compared with other popu-
lations [8], and this fact could account for the lack of
statistical significance.
Finally, a particular consideration is deserved for the
departure of the !20 G/A allele from the Hardy–
Weinberg equilibrium. The excess of G/A heterozygous
subjects in the exposed-infected children could possibly
be explained by hypothesizing a dominant effect for the
A allele, able to increase the susceptibility to HIV-1
infection even if present in a single dose.
In conclusion, our results obtained on Brazilian children
confirm that the SNPs located in the 50 UTR of the
DEFB1 gene can be employed as a marker of risk for
HIV-1 infection.
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Ezetimibe effectively decreases LDL-cholesterol in
HIV-infected patients
Blai Colla,b, Gerard Aragone´sa, Sandra Parrab, Carlos
Alonso-Villaverdeb and Lluis Masanab
We tested the security and efficacy of ezetimibe
in the treatment of HIV-associated dyslipemia.
Twenty HIV-infected patients were randomly
assigned to receive ezetimibe 10 mg/day or fluvas-
tatin 80 mg/day. Patients receiving ezetimibe
experienced a statistically significant (P ¼ 0.003)
20% reduction in the concentration of LDL-cho-
lesterol, similar to that observed with fluvastatin
(24%, P between groups 0.70). We concluded that
ezetimibe monotherapy effectively decreases LDL-
cholesterol in HIV-infected patients.
The control of cardiovascular risk factors in HIV-infected
patients is relevant because the incidence of myocardial
infarction [1] and other atherosclerosis-related events [2]
are increasing. Lipid abnormalities are commonly present
in this clinical setting [3], but the majority of 3-hydroxy-
3-methylglutaryl coenzyme A reductase inhibitors, with
the exception of pravastatin and fluvastatin, are meta-
bolized by the cytochrome P450 3A4, which in turn is also
themetabolic pathway of many of the antiretroviral agents,
especially the protease inhibitors (PI) [4]. Recent evidence
supports theuseof ezetimibe in combinationwith statins to
add a powerful lipid-lowering effect [5]. However, the
metabolism of ezetimibe, which is P450 independent, and
the low incidence of drug interactions and side-effects,
make this drug suitable to be tested in monotherapy in
HIV-infected patients.
Patientswere enrolled during the 3months of the inclusion
period if they fulfilled the eligibility criteria: more than
6months on stableHAART,more than 18 years of age, and
a fasting LDL-cholesterol concentration of 3.30 mmol/l or
greater. Classic cardiovascular risk factors were recorded,
and fasting total cholesterol, HDL-cholesterol, triglycer-
ides, and glucosewere determined. LDL-cholesterol values
were obtained using the Friedewald formula. CD4 and
CD8 lymphocyte counts and HIV-1 viral load were
determined using standard techniques.
Endothelial function was analysed using peripheral
arterial tonometry [6]. Briefly, this system (Itamar
Medical Ltd., Caesarea, Israel) utilizes a finger probe to
assess digital volume changes accompanying pulse waves.
The peripheral arterial tonometry data were analysed by a
computer in an operator-independent manner. A ratio of
less than 1.6 was considered to be a marker for endothelial
dysfunction [6].
Patients were then randomly assigned (according to the
HAART regime: boosted PI or non-nucleoside
analogues) to receive ezetimibe 10 mg/day or fluvastatin
extended release 80 mg/day in a 1 : 1 ratio. Patients were
evaluated 2–3 weeks after the initiation of lipid-lowering
agents to assess tolerability and adherence, and at 6 weeks,
the baseline protocol was re-applied.
Results are expressed as mean (SEM) or in percentages.
Univariate analyses, using non-parametric tests, were
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Transcriptional Effect of DEFB1
Gene 5' Untranslated Region
Polymorphisms
To the Edltor:
Hurnan p-defensin-l (J1BD-l)hus b~en shown to be a candldute
tU010r supprC5sor gelle by Suo ct al (1) who reported that single
nucleotlde po1ymorphjsms (SNP) in tJle DEFBl gene oce able to
modlfy the trllnscriptional activity of hBD.l promoter. In
particular, the -44C/(} SNP wns described tu enbance transcrip-
tion up to 2.3 times more tban the wild-type sequence in DUl45 or
TSU-Prl celllines.
RecentJy, we showed that signifiCll11tcorre1ation exlsts between
SNPs in the t5 untransJated region (UTR) of the DEFBl gene und
tbe risk of bein~ infected with lOV.l in ltalian and Brazllian
chiJdren (2, 3).
With the aim of verifying nn evp.ntllal transc:riptional
functionaJ cffret or tbc SNPs in the s'UTR region of DEPBl S0ne,
we employcd a dualluciferase 8888Y,tbe same techniquc uscd by
Sun ct al. (I).
Starting from the wild-typc DEFBl s'UTR region. we generated
t.hrec mutatc:d inserts using prlmen designed to inlrodure the
desired mutanDo into the wild-type sequence. The four dlfferent
hagmenu (wild-type, -5211, -44G, and -2M) have been cloned
int.u pGI.3 promot.er vector (Promega~ and Caco2 cells were
transfectcd for 48 Il~ith I flg of the reporter plasmids and 20 ng oi
control ReniUa lucifemse expression plasmid (phRG-TK, Promega)
using 5 flL of GenePORTER transfection reagent: Il dualluciferll5e
(lSsay (promega) was done accordlng to tbc manufucturer's
il1struction, To ensure tbc reproducibillty of the results, alJ testa
have been done in quadruplicate and repeated at f1later time tu
confinn the obtained results.
Dur resuJts show that tbe three SNPs do possess a functional
activity.leading to an Impaired produttion of the gene downstream
t Mo.., dotan"" IDlormation ÙI.""ùlnbl.. at http;//www.bbatLllnlv.ldUll.JI/N!Jbcrn{
delb i{unct./.
to the mutated promoter" 80th the -52.1 and the -2OA nIIeles
cause a 25%mean redllct-inn of expression. Although <luantit.ntively
relevant. t.his reduction was not. stntisticaJly significant. The -44G
murotion. oontrary to tbc data presented by Sun ct al. (I). drng to Il
mockedJy redUCEdexprcssion of ubout 53% in our experirncntal
sctup.
Bascd on our results (2, 3) and becuu8e ull the studied SNPs
could hamper an effel.tive production of hBD-1 in VIvo, we
hypot.hesized that they could be relnt.ed to reduced response from
the Innate Immune system
Desplte the tact that DU145, TSU-Prl, and Cuco2 are ali
carcinoma-derived ccl1lines, their inherent differences could lend
to variations in dunlluciferase assay result.!!:we bclieve that the
functional effcct ofthc DEf'Bl S'UTRSNPs is stiUcontroversiaJ and
deserves a more comprehensive study.
Michele MUaneae
LudovIca Segat
Set1Jio Crovella
Gonctic Scrvice.
btituto di IUcovero e CUl'a a Caral.tere Scientifico
Burlo Garofolo, Tl'jcsle, ltaly
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